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ABSTRACT
Gaucher's disease is characterised by a malfunction 
of the enzyme glucocerebrosidase which hydrolyses the 
glycolipid glucocerebroside. Mammalian tissues contain at 
least two p-glucosidases capable of releasing glucose from 
the synthetic substrate 4--niethylumbelliferyl-p-D- 
glucopyranoside (^.MUGlc). One of these enzymes, a 
membrane bound 'acid' form, also hydrolyses glucocerebroside 
and is deficient in patients with Gaucher's disease. The 
synthetic substrate is used to measure this latter enzyme 
in the routine diagnosis of Gaucher's disease. Diverse 
conditions have been used by different workers to assay 
this enzyme in various animal and tissue sources. An 
appropriate and reliable assay system to measure 
selectively the activity of the particulate p-glucosidase 
in crude mouse liver homogenate was developed. This 
revealed the possible existence of a hitherto unreported 
isoenzyme of glucocerebrosidase in mouse liver. Conduritol- 
B-epoxide (CBE) is a specific inhibitor of non-mammalian 
and mammalian p-glucosidase. When injected into mice it 
produces some biochemical and certain pathological 
characteristics of Gaucher's disease which are very short­
lived. Much of the injected dose is cleared rapidly via 
the kidneys. Liposomes are known to localise preferentially 
in the tissues of the reticuloendothelial system. It was 
established that administering liposomally-entrapped CBE 
greatly increased its localisation in the liver and spleen
3and reduced loss through the kidneys. Evaluation of the 
liposomal lipid composition which combined high entrapment 
with optimum stability revealed that liposomes composed of 
sphingomyelin/cholesterol (1 :1 , molar ratio) were the 
most suitable. The extent of inhibition as well as the 
rate of recovery of endogenous tissue f-glucosidase was 
also investigated. Chronic administration of inhibitor 
entrapped within these liposomes produced the biochemical 
parameters of decreased enzyme activity and increased 
tissue glucocerebroside levels together with the tissue 
enlargement associated with Gaucher's disease. It was 
found that a toxicity effect of the liposomal lipid was 
responsible for the increased tissue size. Histological 
examination of the tissues revealed the presence of a 
widespread granulomatous inflammation incited by the 
administered lipid.
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1CHAPTER 1
GENERAL INTRODUCTION
1 c
1,1. Introduction.
In 1892, Phillips E Gaucher published a description 
of a clinical syndrome which was characterised by chronic 
enlargement of liver and spleen. Today, a century later, 
a rather more detailed description of this disorder which 
became known as Gaucher's disease is available.
Gaucher's disease is an inborn error of sphingolipid 
metabolism which is characterised by the lack or malfunction 
of the enzyme glucocerebrosidase (EC 3.2.1.45). Inborn 
errors of metabolism are a group of disorders, each caused 
by a block in one of the metabolic pathways.
"Just as when the film of a biograph is brought 
to a standstill, the moving figures are left
foot in air ....."
In this way, Sir Archibald Garrod introduced the concept of 
inborn errors of metabolism in the Croonian lectures in 
1906. These are now defined as genetically determined 
biochemical disorders due to specific defects in the structure 
and function of protein molecules. We owe the current state 
of understanding of these disorders to the pioneering work 
of Garrod in the early part of this century. Based on his 
observations of accumulation and increased excretion of 
homogenistic acid in Alcaptonuria and cystine, in Cystinuria, 
Garrod developed the concept of blocks in normal metabolic 
pathways. He further concluded that these diseases arose 
because an enzyme governing a single step was reduced in 
activity or missing altogether (Garrod, 1908). It was not 
until half a century later that Garrod's hypothesis was 
vindicated by the demonstration of an absence of homogenistic 
acid oxidase in the liver of a patient with Alcaptonuria
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by La Du et al. (1958). Garrod not only described a 
biochemical blockage, he also investigated its pattern of 
inheritance and its genetic occurrence. Influenced by a 
revival of Mende&an theories of inheritance, Garrod, in 
collaboration with Bateson, proposed that the factor 
responsible for these disorders was a mutant gene, and that 
this was inherited as a recessive trait. Although a direct 
relationship between genes and enzymes was implicit in his 
formulations, this was not established until 1945, when 
Beadle and Tatum working on Neurosporra Crassa and 
Drosoohilla, focussed attention on the molecular basis of 
inheritance. Mutations in the structural or regulatory 
genes which are manifested in the transcriptional or trans­
lational phases of protein synthesis (Fig. l(i)), give rise 
to the innumerable metabolic defects that exist. The 
consequences of such a genetic alteration will depend largely 
on the role normally served by the protein. The disorders 
reflected by these changes include derangements in enzymatic 
functions, control of rates of reaction and abnormalities of 
transport processes or of the function of specific membrane, 
cytoplasmic or nuclear receptors.
The presence of a metabolic block could result in a 
range of situations. The product of a defective reaction 
may be reduced in quantity or perhaps missing altogether. 
Alternatively, it could result in the accumulation of 
precursors of the defective reaction. It could also result 
in the excessive production of substances derived from 
these precursors through alternative pathways. For instance 
in Alcaptonuria, it is the immediate precursor of the
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blocked reaction, homogenistic acid, that accumulates and 
is excreted. In other circumstances where the reactions 
preceding the blocks are reversible, steady state factors 
may lead to the accumulation of a more distant metabolite.
The precursors of the blocked reaction may undergo metabolic 
transformations to give products which are normally only 
present in small amounts. In Phenylketonuria, the block 
in phenylalanine hydroxylase activity results both in the 
accumulation of phenylalanine and in the gross overproduction 
of phenylketone products. In type I Hyperoxaluria, a block 
in the metabolism of glyoxylate leads to its excessive 
conversion to oxalate. A precursor of a blocked reaction 
may accumulate in the cell if it is poorly soluble. The 
lysosomal storage diseases fall into this latter category. 
Among these are the mucopolysaccharidoses, the glycogen 
deposition diseases and the disorders of lipid metabolism. 
Gaucher's disease belongs to this category. It is a 
lysosomal storage disease of sphingolipid metabolism.
1.2. Lysosomal Storage Diseases.
Lysosomes are discrete cellular organelles that contain 
a variety of hydrolytic enzymes with acid pH optima. The 
term lysosome, meaning lytic particle, was coined by deDuve 
in 1955 to describe membrane bound organelles containing 5 
acid hydrolases. Most disorders currently classified as 
lysosomal diseases have been shown to be associated with 
the loss in activity of one of over 40 acid hydrolases now 
known to be present in lysosomes. In general this enzyme 
arsenal found in lysosomes is sufficient to degrade most 
biological macromolecules. The main function of these
20
organelles is to catabolise foreign material entering the 
cells as well as ageing cellular components (Dean and 
Barrett, 1976).
External material is interiorised into cells by the 
process of endocytosis, in vesicles formed from the plasma 
membrane, endocytotic vacuoles. When these endocytotic 
vacuoles contain particulate material, they are referred to 
as phagosomes, and the process phagocytosis. Uptake of 
external material in solution is known as pinocytosis. 
Intracellular components such as cell organelles are degraded 
by autophagy, where the organelles are enveloped in smooth 
endoplasmic reticular membrane to form autophagosomes which 
are then taken up by lysosomes. These endocytotic vesicles 
and autophagosomes, containing material to be degraded, fuse 
with primary lysosomes to form secondary lysosomes. The 
lysosomal hydrolases then digest theendocytosed material, 
and low molecular weight breakdown products diffuse out 
across the lysosomal membrane to be either re-used or 
excreted. A diagrammatic representation of this process is 
illustrated in Fig. l(ii). Indigestible or slowly digesting 
substances remain in the lysosomes and accumulate, resulting 
in aged lysosomes, in their final stage, the residual body.
The concept of inborn lysosomal diseases was first 
formulated by Hers in 1963. It was discovered that glycogen 
deposits in type II glycogen storage disease (Pompe's 
disease) were not found free in the cytoplasm as in other 
glycogenoses, but rather were localised within lysosomes.
As more examples of this class of disorders were discovered. 
Hers defined an inborn lysosomal disease as one in which.
2 1-
Fig. 1 (ii).
The Lysosomal System.
Primary
lysosomes
Secondary
lysosomes
plasma
membrane
exocytosis interactions
0 @
pinocytosis phagocytosis 
endocytosis
The general categories of primary lysosomes (L)(containing lysosomal 
enzymes); secondary lysosomes (in which internalised material is 
undergoing enzymic attack), the processes of pinocytosis (uptake of 
soluble substrates) and phagocytosis (uptake of particulate material) 
are distinguished in this scheme.
N nucleus; RE rough endoplasmic reticulum;. GA Golgi apparatus
(i) a single lysosomal enzyme is deficient, (ii) abnormal 
deposits (of substrate) lie within membrane bound vesicles, 
and (iii) several tissues are affected but to varying 
degrees. In these diseases the lysosomes containing the 
stored material are not only larger and more numerous, but 
morphologically quite distinct from normal lysosomes.
Examples of these include glycogen containing vacuoles in 
Pompe’s disease, the Gaucher bodies in Gaucher’s disease, 
the lamellar bodies in Tay-Sach’s disease and the zebra 
bodies in Hurler’s disease. Since there are an estimated 
>40 acid hydrolases in lysosomes, the list of inborn lysosomal 
diseases is equally numerous. Furthermore although some of 
the basic mechanisms are common to all these diseases, their 
clinical manifestations are highly varied, depending on the 
function normally served by the enzyme. Gaucher’s disease 
is thus a lysosomal storage disorder belonging to the 
sphingolipidosis group.
1.3. Gaucher’s Disease.
This disease is characterised by the absence or 
malfunction of the enzyme glucocerebroside;p-glucosidase, 
resulting in ihe accumulation of its substrate, the 
sphingolipid, glucocerebroside (GC), in the lysosomes of 
the organs of the reticuloendothelial system (RES), notably 
the liver and spleen. It occurs in three clinically 
distinct forms, types 1* 2 and 3. The disorder is panethnic, 
but the type 1 or ’adult’ form occurs with a frequency of 
about 1 in 2500 births among Ashkenazy Jews. Infantile 
(type 2), and juvenile (type 3) Gaucher’s disease are less 
common and type 2 Gaucher’s disease, although rare, is more
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prevalent in infants of non-Jewish extraction. Gaucher’s 
disease is transmitted as an autosomal recessive trait. 
Estimates of carrier frequency in Ashkenazic Jews range 
from 1 in 100 to as high as 1 in 20. All three types have 
the characteristic hepatosplenomegaly as well as the lipid - 
laden Gaucher cells in various organs including the bone 
marrow.
Type 1 can be distinguished from the other two types 
by the absence of central nervous system involvement. 
Although often known as adult Gaucher's disease this term is 
unsatisfactory,as the disorder has been reported in patients 
ranging from 7 months to 66 years. There is considerable 
heterogeneity even within this one category of the disease, 
where the symptoms and manifestations of the disease are 
not consistent. Whilst in most patients the disorder is 
first detected during adolescence when bouts of bone pain, 
abdominal distention, splenomegaly and easy bruising 
appear, others have enlarged livers and spleens by the third 
or fourth year. In yet another group, the disease is not 
identified until late in life when occasionally splenic 
enlargement is not evident and the diagnosis is based on the 
presence of Gaucher cells in the bone marrow or enzymatic 
assays alone.
Type 2 is an acute neuropathic form of the disease where 
as well as the involvement of the fixed organs of the RES, 
there are developmental abnormalities of the central nervous 
system (CNS). This is manifested primarily by the regression 
of motor function and spasticity. The average age of 
survival is usually 9 months and the cause of death is often 
due to anoxia and pneumonia.
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A relatively small number of cases have been described 
with enlarged liver and spleen, Gaucher cells in the bone 
marrow and neurological involvement occurring after 
infancy. This is categorised as type 3 Gaucher’s disease.
In view of the considerable heterogeneity of this 
disease it is somewhat surprising that the molecular 
abnormality appears constant. All three forms of Gaucher's 
disease are either deficient or totally lacking in the 
activity of the enzyme glucocerebroside:Ç-glucosidase.
This enzyme catalyses the hydrolysis of the sphingolipid, 
glucocerebroside, to glucose and ceramide according to the 
following reaction(* see p. 88 for structural formula.)
enzyme
Glucocerebroside + H^O -------^  cerebroside + glucose
Although the description of this disease had been established 
for some time its metabolic basis was not elucidated until 
1965 by Brady and co-workers. Originally there were three 
different hypotheses proposed to explain the source of 
accumulating excess cerebroside.
The first was the possibility of an alteration of 
carbohydrate metabolism resulting in the synthesis of an 
abnormal glycocerebroside containing glucose instead of 
galactose (galactocerebroside was believed to be the only 
physiological glycosphingolipid). This theory was disproved 
by Thannhausser in 1950 and also by Trams and Brady in I960. 
The second possibility was an increased synthesis of gluco­
cerebroside which is normally a minor tissue component.
However this again was shown to be not the case by Brady et al, 
(1965a). These results prompted the final hypothesis that a
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deficiency in one or more enzymes involved in the catabolism 
of glucocerebroside was responsible for the metabolic defect. 
This defect was narrowed down to an enzymatic deficiency at 
the site of cleavage of glucose from glucocerebroside by 
Philippart and Menkes in 1967. Brady et al. (1965b), using 
rat and human spleen, purified the enzyme responsible for 
cleaving the glucosidic bond of glucocerebroside. Using ' 
radiolabelled ^^U-glucocerebroside as substrate, they 
demonstrated that while purified spleen extracts from normal 
subjects cleaved the radiolabelled compound to glucose and 
cerebroside, spleen tissue from Gaucher patients subjected 
to the same extraction procedure were markedly less 
efficient at doing so. This enzyme deficiency has now been 
established as the basis of the metabolic abnormality of 
Gaucher’s disease. Type 2 Gaucher’s disease patients show 
no glucocerebrosidase activity and type 1 have abnormally 
low glucocerebrosidase activity in the range of 12-4-5? of 
normal. In general it appears that early onset cases of the 
disease have less enzyme activity than those which develop, 
late in life.
In view of the various clinical forms of the disease 
that exist, a different structural abnormality in the 
enzyme molecule accounting for each type would not appear 
unreasonable. However there is as yet no direct evidence 
to support this. For instance direct evidence for the 
presence of an inactive protein molecule having antigenic 
properties of the enzyme has not yet been established.
There is however evidence for a mutant gene product in 
type 1 Gaucherls disease, on the basis of an apparent 
decrease in substrate affinity and altered heat stability
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of the residual glucocerebrosidase activity present (Yaqoob and 
Carrol, 1980). Not only is it probable that several different 
mutant products occur in the different forms of Gaucher*s 
disease, but there also appears to be considerable microhetero­
geneity in the glucocerebrosidase found in normal individuals. 
For instance although enzyme activity from a single source is 
reproducible within a error with the radioactive glucocere­
broside assay, activity may range from 80-120% of the mean in 
samples- from different normal subjects. The stark differences 
in phenotype occurring in types 1 and 2 Gaucher’s disease, 
their consistency in members of the same family, and their 
quite different ethnic distribution appears to indicate the 
existence of several different mutant forms of the enzyme in 
Gaucher*s disease.
Since sphingolipids are normal components of mammalian 
cells, a probable source of the accumulating glucocerebroside 
in Gaucher’s disease is from the normal turnover of body 
tissue. While liver, kidney, muscle and brain contain variable 
quantities of glycolipids which could be precursors of gluco­
cerebroside, the various components of blood are believed to 
be a major source of the lipid which accumulates in Gaucher’s 
disease. It is estimated that the erythrocytes contain 
approximately 3.4- nMol of GO per ml of packed cells. They also 
contain other neutral sphingoglycolipids such as ceramide 
lactoside (Cer-Glc-Gal.), ceramide trihexoside (Cer-Glc-Gal-Gal) 
and globoside (Cer-Glc-Gal-Gal-Gal) all of which are precursors 
of glucocerebroside, and collectively contribute approximately 
90 nMol of GO per ml of packed erythrocytes. Several 
gangliosides or compounds containing N-acetyl neuraminic 
acid (NANA) are additional sources of GO in red cells.
These include hematosides (Cer-Glc-Gal-NANA) and the 
major red blood cell ganglioside ceramide-glucose-
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galactose-N-acetyl-glucosamine-galactose-N-acetylneuraminic 
acid (Wherrett, 1973). The main source of GC however is 
probably from the turnover of leucocytes. Ceramide-lactoside 
is the major neutral glycolipid in white blood cells and it 
has been estimated that 20-4-0 times more GC arises from 
leucocyte turnover than from erythrocytorhexis (Kattlove et 
al., 1969). Platelets also contain the sphingolipids 
present in erythrocytes and as in leukocytes, ceramide 
lactoside is the main component and thus presents a further 
source of accumulating GC (Snyder et al., 1972).
A major aspect of Gaucher's disease that remains 
unresolved is the reason for liver and spleen enlargement.
The degree of enlargement which may be as much as a kilogram 
seems disproportionate to the milligram amounts of GO per 
gram of tissue that accumulate in most patients with the 
disease. The small fraction of GC that accumulates in the 
affected organs in comparison to that which is catabolised 
each day is another unresolved point. For example it has 
been estimated that nearly 4-00 mg of glycolipid is turned 
over daily from leukocyte and erythrocyte breakdown, yet 
only a calculated 0.27 mg GC accumulates each day in the 
liver of a type 3 patient, and 0.19 mg in the liver of a 
type 1 patient (Brady et al., 1965). This represents a 
high specific ac tivity for the residual glucocerebrosidase 
activity present in the tissues of these patients. A 
tentative conclusion from this may be that the enzyme is 
present in considerable excess in normal individuals.
A third point which at present seems even harder to 
resolve is the source of GC in the brain of patients
with type 2 and type 3 Gaucher’s disease. One theory is based 
on the finding that the fatty acid composition of the cere­
broside in the cerebral grey matter of type 2 patients is 
quite distinct from that in normal individuals. Svennerholm 
(1967), demonstrated that the major fatty acid in the cere- 
brosides from these patients was stearic acid (CIS) which is 
also the predominant fatty acid in the gangliosides in brain. 
The fatty acid in normal brain is liquoceric acid (C2l). It 
was therefore postulated that GC arises from the catabolism of 
tetrahexosyl gangliosides such as GM^ (Cer-Glc-Gal-(NAM)- 
Gal-(NAc-Gal). However there are several shortcomings to this 
theory, a major one being that the principal site of GC 
accumulation is in the juxtavascular sites and not in the 
intraneuronal sites of the cerebral grey matter as the theory 
might suggest (Okada and O'Brien, 1968). Resolving these 
points would be a major breakthrough in furthering the under­
standing of the biochemical pathogenesis of Gaucher*s disease 
and would lead to a more informed approach to therapy of 
lysosomal storage diseases.
1 .4.. Methods of Treatment of Inborn Errors of Metabolism.
Depending on the nature of the defect, a variety of 
different approaches towards treatment of these diseases 
have been made. Environmental manipulation, dietary 
control, replacement of missing enzyme, depletion of stored 
substances, the use of metabolic inhibitors and induction 
of metabolising enzymes are some of the ingenious manoeuvres 
being used with these diseases. For instance, supplying 
the missing metabolite created by a metabolic block can be 
most effective; metabolic cretinism can be arrested if 
thyroxine is given sufficiently early. In phenotypically 
normal maternal phenylketonuria, the high plasma phenylalanine
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levels associated with this condition result in mentally 
retarded children. However, if the maternal environment 
of the foetus is modified prior to conception by lowering 
the dietary intake of phenylalanine, the offspring will be 
normal (Holtzman, 1970). In Gout, allopurinol is an 
effective inhibitor of xanthine oxidase and thus a 
successful agent for regulating production of uric acid 
(Frederick et al., 1962). Gout can also be alleviated by 
substances which increase the elimination of stored product.
A more novel development in this area has been as a 
potential treatment of lysosomal storage diseases by 
induced exocytosis of stored product, stimulated disgorgement 
as it were I Exocytosis is mediated by, among other things, 
the components of the cytoskeletal system, namely the 
microtubules and microfilaments (Danpure and Fyfe, 1980).
This method is based on the pharmacological disruption of 
the microfilamentous system thereby enhancing the exocytosis 
of a variety of intralysosomally stored indigestible 
macromolecules.
However, even when the biochemical abnormality can be 
corrected, clinical improvement does not necessarily follow. 
Various forms of organ transplantation have also been used 
as a method of treating a number of metabolic diseases.
The most encouraging results have involved bone marrow 
transplantation to patients with immunological deficiency 
states, bone marrow aplasia, and severe combined immuno­
deficiency disease (SCID). It is the treatment of choice 
in SCID when a histocompatible donor is available (Dupont 
et al., 1971). However, by far the greatest experience has
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involved renal transplantation in a number of diseases 
including Fabry's disease, diabetes mellitus, Gaucher's 
disease type 2 and Gout. Again, success has been limited.
In cases such as Oxalosis, the disease has recurred in the 
new organ. In other instances organ grafting has served 
a dual purpose, not only has it replaced a damaged organ, 
but in addition, the healthy one has served as the source 
of the missing enzyme or "factor" and thus corrected the 
metabolic disease itself. The use of skin fibroblasts in 
the treatment of Hurler, Hunter and San Filippo B disease 
IS another area, of organ transplantation under investigation 
(Gibbs et al., 1980). Recent advances in genetic engineering 
have also opened up several avenues of diagnostic and 
therapeutic value, but by far the most popular technique 
for treatment of inborn errors has been that of replacement 
therapy, i.e. supplying the missing or defective protein to 
correct the error in metabolism.
Lysosomal storage diseases are in theory particularly 
good candidates for enzyme replacement therapy. The 
rationale for enzyme replacement therapy is based on the 
premise that the cell is able to take up enzyme from the 
extracellular fluid by means of endocytosis, and as a 
result of the continual fusion that takes place between 
the different elements of the lysosomal system, the 
endocytosed enzyme is brought into contact with its 
accumulated substrate in the vacuoles of the lysosomal 
system (see Fig. l(ii)). However enzyme replacement 
therapy per se' has not been as effective as anticipated.
In disorders such as Pompe's (Glycogenosis Type II),
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Metachromatic leucodystrophy, Tay-Sachs or Fabry success 
has been rather limited (Brady, 1976). The main form of 
treatment with Gaucher's disease has been with enzyme 
replacement therapy. A fundamental requirement of this 
technique is sufficient quantities of the purified enzyme.
It follows too that it should be proven to be active on the 
natural storage material, and for repeated administration, 
be of relatively low antigenicity in humans.
Glucocerebrosidase is present in large quantities in 
human placenta, and this has been used as a source for 
obtaining partially purified (Braidman and Gregoriadis, 1977) 
and pure enzyme preparations (Dale and Beutler, 1976 and 
Furbish et al., 1977) for infusion in replacement therapy 
trials. Until recently these techniques were beset with 
many problems. However, more recently Dale et al. have 
overcome these, and large quantities or highly purified 
glucocerebrosidase are now relatively easily available.
Two different purification procedures have been developed 
to meet different requirements; a laboratory scale method 
utilising frozen placentae as starting material and an 
industrial scale procedure which uses a protein fraction 
commercially prepared from human placentae. This ready 
supply of glucocerebrosidase has given rise to a number of 
enzyme replacement therapy trials in Gaucher's disease.
Early trials with laboratory preparations of 
glucocerebrosidase were carried out by Bradÿ et al. (1974).
A patient with type 3 Gaucher's disease was infused with a 
large dose of glucocerebrosidase (1.5 x 10^ i.u.) 
intravenously, and a patient with type 1 infused with
approximately twice this dose. In both cases the enzyme 
was cleared from the circulation rapidly with a half life 
of 18 min. Based on the findings of previous animal 
investigations, liver biopsies were taken from both patients 
administered with exogenous enzyme. The stored glucocere­
broside content of the livers of both patients was reported 
to have decreased by 26? but this decrease was not sustained. 
These results are highly equivocal since it is known that 
stored lipid is not uniformly distributed in the liver 
(Ihler and Glew, 1977). A far more promising result was 
obtained with the glucocerebroside levels associated with 
the erythrocytes in the circulation. 72 h after the 
infusion the level of erythrocyte glucocerebroside 
decreased from an elevation of two and a half times that in 
normal subjects, to essentially normal values. This 
decrease has been sustained up to l6 months after the 
infusion. However these results were not obtained when 
highly purified enzyme was used in similar clinical trials 
(Brady et al., 1980).
In all the attempts at treating the various lysosomal 
storage diseases by enzyme replacement therapy, no lasting 
improvement was demonstrable. The main problems met in 
these trials have been immunological complications.
Enzymes for these replacement trials have been obtained 
from a variety of sources. In Pompe's disease when a crude 
preparation of glucosidase from Aspergillus niger was 
used, immune nephritis set in (Hug et al., 1968). When 
fibroblast preparations were used as a means of supplying 
the missing human enzyme as in some mucopolysaccharidoses,
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rejection was a major problem (Gibbs et al., 1979). It is 
possible that the use of highly purified human enzyme 
preparations would circumvent these problems since each extra 
component increases the chances of immunological complications. 
However, highly purified enzyme may not be as catalytically 
active as was evident by the trial by Brady et al. on 
Gaucher's disease described above. Also, the use of 
human enzyme is no guarantee that problems of compatibility 
will not arise. The mutation responsible for the enzyme 
deficiency may be such that not only catalytic activity, but 
also the enzyme protein itself is absent, so that cross­
reacting immunological material is missing. Even human 
enzyme could be antigenic under these circumstances. In 
the case of lysosomal storage diseases, the absence of 
cross-reacting immunological material has been established 
in patients with Pompe’s, Tay-Sach's and Fabry's diseases 
(Brady, 1976 and de Barsy et al., 1973).
Apart from these immunological complications, a number 
of other problems are recognised when considering replacement 
therapy. The concentration of enzyme required in the cell 
for correction can be very low. For instance, only a small 
percentage of the normal enzyme activity is required to 
achieve 70? correction in San Filippo B fibroblasts.
However, efficient uptake of administered enzyme by the 
relevant tissues remains a major problem. The constant 
hazard of inactivation of administered enzyme by circulating 
proteases as well as lack of target specifity of the drug 
are problems that prevail.
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A number of approaches have been tried to overcome 
these obstacles. It has been established that the 
oligosaccharide portion on the lysosomal enzyme determines 
efficiency of uptake. It is therefore not surprising that 
this property has been exploited by several investigators 
as a means of improving efficiency of uptake of administered 
enzyme. Much of the enzyme administered intravenously is 
taken up by hepatocytes of the liver. It is known that the 
hepatic Kupffer cells have high affinity receptors for 
N-acetylglucosamine or mannose-terminated glycoproteins 
(Schlesinger et al., 1978). Furbish et al. (1978) have 
modified the terminal oligosaccharide on the glucocerebrosidase 
enzyme to introduce these groups in the hope that these 
target-directed preparations will be more effective in 
replacement therapy. However, inactivation of the enzyme 
during the process of modification is a problem.
Concurrently with these methods of treatment, there has 
been a progression to the concept of drug encapsulation. A 
number of three-dimensional carrier systems have been 
proposed. These include nylon semipermeable spherules, 
erythrocyte ghosts, cells, viruses and liposomes. Once 
within such a carrier, the entrapped enzyme would be 
protected from the external milieu and thus remain in an 
active form for longer. The carrier however has to conform 
to certain criteria before it can be considered suitable 
for use. It has to be biodegradable and non-toxic. It 
must also be versatile in size, composition and surface 
properties, to ensure not only accommodation of a wide 
variety of active molecule regardless of their physical
characteristics but to enable specific manipulation of the 
carrier in order to confer target selectivity.
The wide availability of erythrocytes and the knowledge
of their metabolism have made these a popular choice for use
as drug carriers. They have the obvious advantage of
reducing immunological problems since the patient's own
blood can be used. Healthy red blood cells (RBC) have been
given to patients whose own erythrocytes are deficient or
lacking in a particular component. For example adenosine
deaminase (Polmar et al., 1976) and purine phosphorylase
(Staal et al., 1980) which are lacking in severe T-cell
deficiency disease may be supplied in this manner.
Erythrocytes have also been preloaded with drugs which they
then deliver to the liver and spleen (ihler, 1979).
Modified erythrocytes are phagocytosed and degraded by the
lysosomal apparatus of the reticuloendothelial system (RES).
Re-sealed erythrocytes appear therefore to be an ideal
carrier system for the delivery of therapeutic agents to
the RES lysosomes affected in lysosomal storage diseases.
Dale et al. have used highly purified glucocerebrosidase in
resealed erythrocytes to treat a patient with Gaucher's
disease. The results obtained were suggestive but not
conclusive that infusions of this sort could be effective.
Although some improvement in liver function could be seen,
together with a possible decrease in liver size and relief
of subjective symptoms, no change was observed in erythrocyte
and plasma glucocerebroside levels (Dale et al., 1979).
The use of erythrocytes as carriers is restricted to the
/
organs of the RES and although they hold potential in this 
area, they lack the possibility of direction to other
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organs. Technical difficulties such as inefficiency of 
drug encapsulation and leakage of entrapped drugs are also 
contributory problems.
Neutrophils localise spontaneously in inflammatory 
lesions and have been used for imaging lesions (McAfee et 
al., 1980). Islet implantation in the treatment of 
experimental diabetes (Andersson, 1979) and fibroblast 
transplantation in the treatment of enzyme deficiencies 
(Gibbs et al., 1980) are other areas being investigated.
However, these carriers of natural origin have fixed 
properties that allow them to localise in specific cell 
types only and are thus limited in scope. A further 
vehicle for delivering enzymes that are deficient into the 
affected organs has been liposomes (Gregoriadis, 1980).
A relatively long term study (over 5 yrs) has been made of 
the effect on a type 1 patient of repeated injections of 
a partially purified enzyme preparation entrapped within 
liposomes. However, the results obtained from this study 
have not been as successful as anticipated on the basis of 
preliminary investigations on model systems (Belchetz et 
al., 1977). This is indeed the case with all three types 
of enzyme replacement on Gaucher*s disease; viz.free, 
erythrocyte-entrapped, and liposome-entrapped glucocerebrosidase 
The change in the stored GC levels obtained by these methods 
were relatively small when one considers the most important 
parameter of the disease, organomegaly , which was not 
convincingly altered by these attempts at therapy.
The value of conducting replacement trials with highly 
purified enzyme on patients with Gaucher's disease is
questionable, especially in view of the lack of success 
reported by Brady et al. (1980), when using this enzyme.
Ho and O'Brien (1973), demonstrated that the dependence of 
this enzyme on non-physiological, extraneous factors such 
as detergents for optimal activity ini vitro, could be 
replaced by low molecular weight glycoproteins. Thus it is 
possible that the highly purified enzyme is lacking in 
cofactors necessary for its expression in. vivo.
1.5. Need for an Animal Model for Gaucher's Disease.
It is apparent that our current understanding of the 
enzymatic properties of glucocerebroside:p-glucosidase is 
inadequate. This together with the lack of knowledge about 
the physicochemical mechanisms of enzyme uptake as well as 
the general pathophysiology of the disease has hindered the 
development of a rational mode of therapy for Gaucher's 
disease in particular, and lysosomal storage diseases as a 
whole. The experiments described above have been carried 
out at most on two patients per trial. The statistical 
variations of physiological and biochemical parameters 
within any group is considerable and so larger groups must 
be studied to render any results conclusive. The 
availability of sufficient quantities of enzyme required for 
replacement therapy, as well as the limitation in, scope of 
human trials due to the ethical and medical barriers that 
exist, point to the need for a suitable animal model in 
order to investigate the features characteristic of 
lysosomal diseases.
Many attempts involving a variety of approaches have 
been made to artificially induce lysosomal storage.
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Administration of slowly digestible or inert substances 
have been used to grossly overload the lysosomes both in 
the whole animal and in different types of cell in. vitro 
(reviewed by Werb and Dingle, 1976). Also excessively 
high quantities of normal substrate have been administered 
both in vivo and in vitro resulting in lysosomal 
accumulation of the substrate. For example feeding 
cultured fibroblasts with very large amounts of polar lipids 
have resulted in cellular changes resembling those of 
certain lipidoses (Stern, 1973; Philippart and Kamensky, 
1976). Similar lipidoses like changes were produced in 
animals by local injection of polar lipids (Anzil et al., 
1973) or by intravenous injection of liposomes (Segal et 
al., 1974). Induced storage due to interference with 
lysosomal digestion can also occur as a result of 
administration of certain amphiphilic cationic drugs which 
can interact with polar lipids to render them indigestible 
(reviewed by Lullman-Rauch, 1979).
Other attempts at simulating lysosomal storage diseases 
have involved manipulation of the activity of lysosomal 
enzymes, either by direct action on these enzymes or by 
interfering with intralysosomal conditions required for their 
optimum activity. Antibodies against lysosomal enzymes 
have been applied to cells in culture resulting in vacuolar 
storage of heterogeneous material (Dingle et al., 1973).
Lipid analogues (Radin et al., 1976) and enzyme inhibitors 
have been used to inhibit specific enaymes in attempts to 
simulate certain lipidoses found in man.
A preliminary attempt at producing an animal model of 
Gaucher's disease has been made by Kanfer et al. (1975b).
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It was based on the ability of a synthetic compound,
*
conduritol-B-epoxide (CBE) to inhibit both non-mammalian 
and mammalian p-glucosidase. Administration of this 
inhibitor to mice, elevated levels of tissue (liver, spleen, 
brain) glucocerebroside and endogenous tissue p-glucosidase 
Addendum
% %
see p. 161 for structure
Presentation of conduritol-B-epoxide entrapped within 
a liposome carrier was explored with a view to improving 
efficiency of delivery of the inhibitor to the target 
organs. Whilst CBE is not known to be unstable ±n° 
aqueous solution, and no evidence for instability was 
found (as ascertained by TLC, section 2.2.(v)) in the 
present studies, any possibility of the molecule being ert 
broken down in vivo should be minimised by the use of 
a carrier.
characteristic of Gaucher's disease it is necessary to 
maintain these symptoms for longer periods of time. 
Investigations towards achieving this end are reported here.
1.6 . Liposomes.
When amphipathic molecules such as phospholipids are 
dispersed in an aqueous medium, they spontaneously arrange 
themselves to form a variety of structures which are known
as smectic mesophases or liposomes. These consist of one or
more concentric bilayers of phospholipid, intercalating 
with aqueous spaces in an arrangement which is similar to 
that which is now accepted as that of natural eukaryotic 
membranes (Fig. i(iii)). Liposomes were first described by 
Bangham in the early 1960s, and have since been used
extensively in model membrane studies.
The bilayer is a thermodynamically stable structure in 
which the hydrophobic associations of the phospholipid 
fatty acyl chains at the centre, and the hydrophilic
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interactions of the polar head groups with the aqueous 
phase at the surface, are maximised (Israelachvili et al., 
1976). When initially introduced into aqueous media, the 
phospholipid forms flat bilayer structures which on shaking 
produce a heterogeneous population of large multilamellar 
vesicles. The size of the liposomes may be varied by 
exposure to ultrasonic radiation which tends to break up 
the large particles into a homogeneous population of smaller 
unilamellar particles. The size of liposomes obtained can 
thus be regulated by the time of sonication. The limiting 
size is probably defined by the constraint of the small 
radius of curvature on the packing of the phospholipid 
molecules. The time of sonication required for complete 
conversion into small vesicles of uniform size depends on 
the type of lipid, ionic strength, temperature and volume.
Studies with various physical techniques indicate that 
the membrane bilayer can exist in two well defined physically 
distinct states, the gel phase and the liquid crystalline 
phase (Penkett et al., 1968; Rottem et al., 1973). The 
former is a more ordered state where the hydrocarbon chains 
are extended and tightly packed giving rise to a rigid 
structure. As the temperature is increased a point is 
reached at which there is a sharply defined thermotropic 
phase transition associated with a melting of the hydrocarbon 
chains which involves increased mobility of these chains. 
Above this transition temperature (Tc), the individual 
molecules are more loosely packed so that the interior of 
the bilayer is more disordered and fluid. This is the liquid 
crystalline phase. The Tc is characteristic for each
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phospholipid and is defined chiefly by the length and 
configuration of the acyl chains, the degree of hydration and 
the nature of the polar head group (Chapman, 1973; Phillips 
et al., 1972). Long saturated acyl chains allow greater 
Van der Waals interactions and hence the transition 
temperature is high. Incorporation of a cis double bond 
allows fewer Van der Waals contacts and hence a lower Tc. 
Liposomes are formed when their phospholipids are brought 
into contact with water at temperatures close to or above 
the melting point for the acyl chains.
Van Deenan et al., (1974) using vesicles composed of 
synthetic phospholipids with well defined fatty acyl chains 
have shown that permeability of vesicles generally increases 
with increasing unsaturation and decreasing chain length.
Thus factors which affect the phase transition of bilayer 
lipids also affect the nature of the membrane bilayer.
The presence of a further component such as cholesterol can 
also affect the Tc or else eliminate the phase transition 
altogether. The consequences of incorporation of cholesterol 
into the bilayer have been studied using model systems. 
Studies with monolayers have shown that incorporation of 
cholesterol into a liquid expanded film of phosphatidyl­
choline, results in the apparent reduction in the area per 
molecule, suggesting an increased intermolecular interaction. 
On the other hand addition of cholesterol to condensed mono­
layers results in -increased fluidity due to disruption of 
ordered packing of the fatty acid chains (Demel et al.,
1972). The presence of cholesterol in the bilayer 
consequently leads to a condition of intermediate fluidity 
in the phospholipid hydrocarbon chains.
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The exchange of both sterols and phospholipids within 
bilayers and the role of membrane proteins are further 
aspects of membrane structure studied with the aid of 
liposomes. Whilst such studies continue to further our 
understanding of membrane structure, liposomes have more 
recently been utilised as vehicles suitable for the delivery 
of many compounds of therapeutic interest. The criteria 
for an ideal carrier listed previously can be reproduced 
almost exclusively in liposomes. They satisfy these 
requirements by being biodegradable and non-toxic (if non­
toxic lipids are used). Diversity in the liposomal lipid 
composition allows a virtually infinite number of liposomal 
variations suited to any particular environment. A wide 
variety of substances can be entrapped in liposomes by 
passive encapsulation in the aqueous compartments in the 
case of water soluble substances or by interaction with 
the hydrophobic regions of the bilayer in the case of 
lipophilic materials. Macromolecules with hydrophobic and 
hydrophilic regions such as some proteins can accordingly 
span the bilayer. Control of permeability of the membrane 
to entrapped substances and of liposomal stability have 
also been demonstrated by the presence of sterols and 
appropriate choice of phospholipids.
The control of stability of liposomes is essential for 
their effective use as drug carriers. Liposomal stability 
may be defined as the extent to which the carrier retains 
its drug contents ini vitro and vivo. It has been shown 
that increasing the cholesterol content of small unilamellar 
or multilamellar vesicles (SUV or MLV) greatly improves
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their stability in.' vivo' and in vitro' '(Kirby et al., 1980 a; 
Gregoriadis and Davis, 1979). High density lipoproteins in 
the blood remove phospholipid from liposomes thus rendering 
the liposomes more permeable to entrapped drug (Scherphof 
et al., 1978). It is believed that cholesterol confers greater 
stability on the membrane system by reducing loss of 
phospholipids to circulating lipoproteins (Kirby et al.,
1980 b). High cholesterol content is advantageous in 
circumstances where direct delivery of liposomes and their 
contents is required, as to the lysosomal apparatus of the 
liver and*spleen in the case of Gaucher’s disease. When 
slow release of drug into the circulation is required, a 
lower cholesterol to phospholipid ratio would be more 
favourable. The size of liposomes can be controlled as 
discussed above, and has been shown to influence their half 
life in the circulation. Large MLVs are removed rapidly 
with a biphasic clearance profile, by the tissues of the 
reticuloendothelial system, mainly by the fixed macrophages 
of the liver and spleen (Juliano and Stamp, 1975).
Clearance is rapid during the first phase and slows down 
during the second phase. There is some evidence to support 
the theory that the rapid phase of clearance involves the 
macrophages, whereas liver parenchymal cells are responsible 
for the slower phase. However, this has not been fully 
substantiated. The rate of clearance also depends on the 
liposomal surface charge, negatively charged liposomes being 
cleared faster than positive or neutral ones (Tagesson et 
al., 1977). Thus judicious manipulation of these and other 
liposomal characteristics can provide a wide range of 
options in controlled drug release or direct delivery via 
stable liposomes.
4The concept that liposomes could be used as drug 
carriers was first proposed by Gregoriadis et al. (1971) and 
Sessa and Weisgmann (1969) and subsequently demonstrated by 
Gregoriadis and Ryman (l972a,b) and Gregoriadis and 
Buckland (1973). It is accepted that liposomes can 
associate with cells in a variety of different ways (Fig. 
l(iv)), and it is likely that more than one of these 
mechanisms of liposome -cell interactions can occur 
simultaneously (Kimelberg and Mayhew, 1978).
The principal mode of uptake for both MLVs and SUVs 
is believed to be endocytosis. This is a relatively well 
understood phenomenon which is energy dependent and 
relevant to a wide variety of macromolecules and particulate 
material. Uptake results in tie formation of endocytotic 
vacuoules which then fuse with primary lysosomes to form 
secondary lysosomes. In the case of endocytosed liposomes, 
lysosomal phospholipases can then disrupt the lipid bilayers 
to free the entrapped agents which can then either act 
within the lysosomes or, after diffusing out, in other 
compartments of the cell.
Gregoriadis and Buckland (1973), using an ini vitro - 
model of a lysosomal storage condition, viz. sucrose 
loaded macrophages, showed that liposomal invertase was able 
to hydrolyse the stored sucrose. This was believed to occur 
by endocytosis of the carrier, whose subsequent disruption 
within the cells, liberated the enzyme in its active form. 
Endocytotic uptake of liposomes has also been demonstrated 
in' viv'o' by Segal et al. (1974), Rahman and Wright (1975) 
and Wisse et al. (1976), and in vitro' by Weissmann et al. 
(1975) and Poste and Papahadjapoulos (1976). Liposomes
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composed of unsaturated phospholipids have been shown to be 
capable of uptake in the presence of both inhibitors and 
stimulators of active transport, indicating that endocytosis 
is not the principal mode of uptake here. In this system 
association of the liposome with the cells is believed to 
occur largely through fusion with the plasma membrane 
(Poste, 1980). In the case of unilamellar vesicles, the 
entrapped contents will be delivered into the cell 
cytoplasm, although lipophilic agents may well localise in 
the cell membrane. Whilst several theories have been put 
forward to explain the mechanism of fusion between 
liposomes and cell membranes, unequivocal evidence 
supporting the process itself has yet to be obtained.
Another mode of liposome-cell interaction involves 
adsorption of the liposome to the cell membrane without 
subsequent intériorisation.
From the pharmocological standpoint there are a number 
of situations in which lysosomes are directly involved. 
Lysosomal storage diseases are one such group. Endocytotic 
uptake is ideally suited to treatment of these diseases 
since therapeutic agents entrapped inside the liposomes will 
be delivered to the lysosomes in which the material to be 
catabolised is stored. In other situations where extra- 
lysosomal action of the therapeutic agent is needed, direct 
fusion of the liposome with the plasma membrane of the cell 
would be more desirable. Parameters such as cell type and 
liposomal lipid composition, size and surface charge will 
decide which type of uptake predominates.
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Since liposomes tend to localise in the lysosomes of 
the liver and spleen, and due to encouraging results 
obtained with ^  vitro systems (Roerdink et al., 1976 
and Colley and Ryman, 1976) attempts were made at treating 
a Gaucher disease type 1 patient with liposome-entrapped 
glucocerebroside:p-glucosidase (Belchetz et al., 1977).
This condition is ideally suited to this approach since 
the product of the metabolic block, glucocerebroside, is 
stored in the lysosomal apparatus of the liver and spleen.
The enzyme glucocerebroside:p-glucosidase deficient in 
this condition was purified from human placentae and 
entrapped in liposomes composed of egg lecithin and 
cholesterol (Braidman and Gregoriadis, 1977). Repeated 
intravenous injections of this preparation over a five 
year period of treatment however,has shown no clinical 
improvement (Gregoriadis et al., 1979).
Other conditions involving the RES have however 
vindicated the theoretical possibilities put forward by this 
approach. A variety of parasitic diseases are prevalent in 
most tropical countries, and microbes responsible for these 
diseases reside in the fixed macrophages of the RES. 
Antimicrobial agents used to combat these diseases are 
often toxic and high doses are required in order to overcome 
inefficient uptake. The liposome approach is therefore 
infinitely suitable in this area. In several trials, 
animal models of both visceral and cutaneous leischmaniasis 
have been treated successfully with liposomally entrapped 
antimicrobial drugs (New et al., 1978 and Alving et al^ 1978), 
and human trials are now in progress. These results are
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particularly encouraging since this approach can be 
extended to several other microbial diseases such as 
malaria, trypansomiasis, leprosy and brucellosis. As well 
as enzyme' replacement therapy in lysosomal storage diseases 
and antimicrobial therapy, other areas in which the use of 
liposomes as carriers of drugs are being actively explored 
include metal overload, oral administration of insulin and 
factor viii, as immunological adjuvants and in cancer 
chemotherapy.
Aims of this Project.
A variety of approaches have been made towards the 
treatment of lysosomal storage diseases. However, success 
has so far been very limited. Our current understanding of 
the pathophysiology of Gaucher’s disease is inadequate. It
follows therefore that better understanding of the disease
should lead to the development of a more rational mode of 
therapy for Gaucher*s disease and other related lysosomal 
storage diseases. A suitable animal model would facilitate 
investigations towards this end. This study addresses
itself to tie following areas in the development of a
'Gaucher' animal model: (i) the complex inter-relationship
of the enzymes involved, and the putative role on non- 
enzymatic factors in modulating the enzyme activity;
(ii) the efficacy of the inhibitor conduritol-B-epoxide 
in inhibiting endogenous glucocerebrosidase thereby creating 
the symptoms characteristic of Gaucher's disease; (iii) 
the advantages of applying a liposome delivery system with 
the inhibitor to amplify its effects within the relevant 
organs. The value of liposomes as a delivery system for 
enzyme in enzyme replacement therapy is also explored.
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CHAPTER 2 
MATERIALS AND METHODS
2,1. Mat'erial'S.'
(i) Solvent's.'
Absolute alcohol, acetone, chloroform, diethyl ether, 
formaldehyde, hexane, isopentane, isopropanol, methanol, 
petroleum ether, propylene oxide, pyridine, toluene were 
"Analar" grade (BDH Chemicals Ltd.). 0.5 N HCl in methanol, 
conc. hydrochloric acid, conc. sulphuric acid and triton
X-lOO were reagent grade (BDH Chemicals Ltd.).
(ii) Chemicals.
Chemicals used in assay procedures were "Analar".
Other chemicals were BDH reagent grade.
(iii) Special materials.
Cholesterol BDH
Bovine serum albumin
Sodium dodecyl sulphate
Mannitol
Silver carbonate
Folin Ciocalteau reagent
Sphingomyelin Sigma Chemical
Dicetyl phosphate Company
(%-methyl mannoside 
Silicic acid 
Florisil
Sodium taurocholate
l-raethylumbellif eryl-]^-D-glucopyranoside 
l-methylumbelliferyl-acetamidopyranoside 
l-methylumbelliferyl-p-D-galactopyranoside
53
(iv)
Egg phosphatidylcholine 
Phosphatidylserin.e 
Phosphatidic acid
Sepharose CL 6B 
Con-A sepharose
PPG
POPOP
Crude sodium taurocholate 
Sodium cholate
Silica gel G pre-coated plates
Hexamethyldisilazane
Trimethylchlorosilane
Radioactive chemicals'.
g
6- H-glucose (N)-cerebroside
3
4- H-conduritol-B-epoxide
Lipid products
Pharmacia
Koch-light
ICN pharmaceutical
Eastman
Anachem
Pierce and Warriner
New England Nuclear 
was obtained from 
Dr. G Legler, Univ. 
of Cologne.
(v) Buffers.
Phosphate buffered saline (PBS) consisted of 8 g NaCl, 
0.2 g KCl, 0.05 g Na2HP0^.12H20 and 0.05 g NaH2P0^.2H20 per 
litre of distilled HgO. pH was adjusted to 7.4 with dilute 
sodium hydroxide prior to making to 1 1 .
b Citrate-phosphate buffer (C/p) of constant ionic 
strengths was used in a pH range from 3.0-7.0. It 
consisted of Na2HP0^ .2H2O, citric acid and KCl in appropriate 
concentrations for 0.5 M C/P buffer (Table 2(i)). This was 
diluted to 0.25 M buffer prior to use.
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Table 2(1). Composition of citrate/phosphate buffers of constant 
ionic strength in a pH range of 3.0-7.0.
pH at 25°C
Composition 
g/L solution KCl g 
for 0.5 M solutionNa^HPO^.ZH^O Citric
acid
3.0 7.35 16.7 • 31.4
3.4 10.2 15.0 28.9
4.0 13.76 12.9 25.5
4.4 15.7 11.7 23.1
5.0 18.34 10.2 18.2
5.4 19.88 9.29 14.8
6,0 22.47 7.74 11.6
6.4 24.64 6.47 9.26
7.0 29.26 3.7 5.44
5(c) Glycine/sodium hydroxide buffer pH 9.5, was composed 
of 250 ml of 0.2 M glycine and 195 ml of 0.2 M NaOH made 
up to 1 1 with distilled H^O.
(d) Sodium citrate buffer 0.5 M was made up with 14-7.0 g 
of sodium citrate and 29.2 g sodium chloride made up to
1 1 with distilled H^O. The pH was adjusted to pH 6.0 
with dilute citric acid and the buffer was diluted to a 
concentration of 50 mM prior to use.
(é) Phosphate buffer 0.15 M pH 7.6 was made up with 880 ml 
0.15 M Na^HPO^ and 120 ml 0.15 M KH^PO^.
(vi) Scintillation fluid.
(a) Triton/toluene scintillation fluid was made up of 6 g 
of PPG and 0.5 g POPOP dissolved in 750 ml toluene. 500 ml 
triton X-100 and 250 ml of toluene was added to this.
(b) Toluene scintillant for estimation of radioactivity in 
tissues consisted of 7.06 g PPO and 88.24- mg POPOP 
dissolved in 1 1 of toluene.
(vii) Preparation of glucocerebroside (substrate).
Pure glucocerebroside was prepared from human Gaucher 
spleen according to the method of Patrick (1965). The 
spleen was obtained after splenectomy from a Gaucher 
patient from the Institute of Child Health, London.
All steps were carried out at room temperature unless 
stated otherwise.
110 g (net weight) of tissue was homogenised in 200 ml 
of acetone in a Waring blender, and the homogenate shaken 
gently overnight in a MSE mechanical shaker. The
5G
preparation was filtered using Whatman No 1 filter paper 
and the residue re-extracted in a further 200 ml acetone 
for 3 h with occasional shaking. This procedure was 
repeated on the residue using 150 ml of petroleum ether 
instead of acetone. The resultant residue was dried in a 
stream of N^ and re-extracted with 300 ml chloroform/ 
methanol (2 :1, v/v) for three hours with mechanical shaking.
The preparation was left to stand overnight and filtered.
The filtrate obtained was saved and the residue extracted 
for a further three hours in 150 ml CHCl^/MeOH (2:1, v/v), 
and filtered. The pooled filtrates were evaporated to a 
syrup at 37° C in a rotary evaporator and allowed to set to 
a waxy solid. This was dissolved in a minimal volume of 
boiling ethanol and filtered hot. The clear filtrate was 
left overnight at 4° 0 to form crystals. These were washed 
in a small volume of acetone and then dissolved in a 
minimal volume of warm pyridine. The mixture was filtered, 
and acetone was added dropwise to the resultant filtrate 
with gentle stirring until no more white fumes were seen.
This was filtered, and the precipitate was re-crystalised 
twice from methanol/acetone (2:1, v/v) under reflux. The 
final crystallised filtrate contained 95  ^ pure glucocerebroside 
Purity was ascertained by TLC against a pure standard of 
glucocerebroside.
2.2. General Methods.
(i) Preparation of liposomes,
a.' Multilamellar vesicles (MLV).
Large multilamellar vesicles containing a net neutral 
or negative surface charge, composed of phosphatidyl-
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choline (PC) and cholesterol (Choi) and a charged amphiphile 
(containing 45 ^moles total lipid per ml aqueous) were 
prepared as follows.
Appropriate quantities of the phopholipids and 
cholesterol were dissolved in chloroform and dried in a 
50 ml round bottomed flask by rotary evaporation to leave 
a thin film of lipid on the bottom of the flask. Any 
remaining traces of solvent were removed by flushing the 
lipids in a stream of oxygen free nitrogen. The dried 
lipid film was disrupted with 2 ml of PBS containing the 
material to be entrapped. In the case of conduritol-B- 
epoxide (CBE) a typical preparation contained 20 mg of
/ o
solute with 0.5 x 10 dpm ( H)-CBE as radiolabelled tracer. 
These CBE containing liposome suspensions were sonicated 
for 30 s in a MSE sonicator (150 watt; 20K) on medium power 
( 8/4, peak to peak). An ice bath was used to maintain the 
temperature at 4° 0. The resulting dispersion was left to 
anneal at room temperature for approximately 1 h. Several 
techniques were used to separate the CBE containing 
liposomes from unentrapped material. These are discussed 
fully in Chapter 4.
When the enzyme glucocerebrosidase was used for 
entrapment with these liposomes, all steps were carried out 
at 4° C in ice. 3,000 units (nMol min"^) of enzyme diluted 
in 2 ml of citrate/phosphate buffer were used in a typical 
preparation. Since sonication tended to denature these 
enzymes the lipid suspensions were vigorously hand-shaken 
instead, until the entire lipid film was dispersed in 
solution. These preparations were left to anneal at room
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temperature for a maximum of one hour. The resultant 
liposome dispersion was centrifuged at 100,000 x g for 30 min 
to pellet the enzyme containing liposomes. The supernatant 
containing unentrapped enzyme was carefully removed with a 
Pasteur pipette and the sedimented liposomes were re-suspended 
in 2 ml of PBS. The quantities of lipid used in these 
preparations are given in Table 2(ii).
b.' Large oligolamellar reverse evaporation vesicles (REV)* 
The reverse phase evaporation method of Szoka and 
Papahadjapoulos (1978), with slight modifications was 
followed for the preparation of liposomes of varying lipid 
compositions. Solutions of lipid in CHCl^/MeOH (2:1, v/v) 
were dried in 25 ml quick-fit tubes by rotary evaporation of 
the solvents. The lipids were then flushed with and 
re-dissolved in 3 ml diethyl ether, supplemented with 3 ml 
chloroform in the case of sphingomyelin (SM) liposomes.
1 ml of O.OIM PBS (pH 7.4) containing the material to be 
entrapped was then added and the resultant two-phase system 
was sonicated in a bath type sonicator until a stable 
emulsion was formed. This was usually achieved within 
5 min. A final aqueous suspension of liposomes was produced 
by removing the organic solvent present by evaporation under 
reduced pressure in a rotary evaporator rotating at 
approximately 200 rpm. During evaporation of the solvent 
the system tends to froth. As the majority of the solvent 
is removed the preparation goes through a viscous gel phase 
before becoming an aqueous suspension. Excess water or 
buffer was added at this point and the preparation 
evaporated for a further 15 min to ensure complete removal 
of solvent. The liposomes produced were allowed to anneal
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for about an hour and then either dialysed or centrifuged 
to remove non-encapsulated material. Preparations composed 
of PC were sonicated at 4° C in ice, and the rest of the 
stages carried out at room temperature. Preparation of SM 
liposomes were made entirely at 40° C. 'Empty' or buffer 
loaded liposomes were also prepared in this manner. The 
composition of the liposomes and their lipid content is 
given in Table 2(ii). 10-25 mg QBE and 0.5-2 x 10^ dpm
( H)-CBE, 25 mg glucose and 3,000 units of glucocerebrosidase 
were used with these preparations.
The liposomes containing small molecular weight 
(< 500 M.W) material were separated from any unentrapped 
material by extensive dialysis at 4° C over 36 h. 
Unencapsulated enzyme was removed in the supernatant after 
pelleting the liposomes by centrifugation at 600 x g for 
10 min.
(ii) Subcellular fractionation of mouse liver.
Mouse liver was fractionated according to the published 
procedure of Gregoriadis and Sourkes (1970). Mice were 
killed by exsanguination via the brachial vein, the livers 
removed rapidly, washed in isotonic saline at 4° 0 and 
weighed. The tissue was cut into small pieces, suspended 
in 0.3 M sucrose solution (4 ml sucrose per g tissue) and 
homogenised in a Potter Elvehjeim homogeniser for 2 min.
The homogenate was centrifuged at 600 x g for 10 min to 
precipitate the nuclear fraction. The supernatant was 
carefully removed and saved and the pellet was re-homogenised 
in an equal volume of sucrose solution and centrifuged as 
above. The resultant pellet was the nuclear fraction.
G 1
Scheme 2(1)
Subcellular fractionation of mouse liver.
Liver
0.3/Vl Sucrose 600 g _ lOmin
Nuclear Sn i
14,000 9, 30min
M&L
\
Sn 2
100,000 g, 1 h
Microsomal Sn 3 
(cytosol)
This was suspended in 10 ml of distilled water and stored.
The supernatants (Snl), were pooled and re-centrifuged at
14,000 X g for 30 min. The resultant supernatant was saved 
while the pellet was re-homogenised in more sucrose and 
centrifuged. The pellet thus obtained was suspended in 
10 ml H^O. This contained the mitochondrial and lysosomal 
(M & L) fractions of the tissue. The supernatants (Sn2) 
were centrifuged at 100,000 x g for 1 h. The resultant 
pellet was the microsomal {jx) fraction and the supernatant, 
the soluble or cytosolic fraction (C) (see Scheme 2(i)).
It was essential that the entire procedure was conducted 
rapidly with the temperature maintained at 4° 0 throughout.
The sub-cellular fractions thus obtianed were either used 
for enzyme estimations immediately or stored at -20° C 
until required.
(iii) Extraction of total tissue lipid.
Total lipid was extracted from the mouse liver and 
spleen according to the method of Folch et al. (1957).
Mouse liver and spleen homogenates were prepared in 
distilled H^O at 4° 0 using 4 parts water to 1 part by 
weight of liver, and 2 parts water to 1 part by weight of 
spleen. Each ml of homogenate was extracted with 19 ml 
of chloroform/methanol (2:1, v/v). The approximate volume 
of methanol was added dropwise with continuous mixing, and 
the chloroform was then added separately while the entire 
mixture was being shaken gently. This procedure prevented 
large masses of tissue precipitate from forming. The 
mixture was allowed to stand for several hours
(approximately 4 h) at room temperature with occasional shaking
at the end of which any precipitated protein was filtered 
through a scintered glass funnel. The precipitate was 
washed through with a further 15 ml of CHCl^/MeOH (2:1, v/v), 
and to each 20 ml of filtrate, 4 ml of glass distilled water 
was added and mixed well. The phases were clarified by 
centrifugation at 200 x g for 10 min and the upper aqueous 
phase removed by aspiration and discarded. The preparation 
was made up to the original volume by adding Folch^ 
theoretical upper phase (FUP, CHCl^/MeOH/H^O;3:48 : 47, v/v, 
containing 0.02# CaCl^ per total upper phase), and mixed 
thoroughly. The two phases were separated as before and 
the upper phase (UP) discarded. This procedure was 
repeated once more. The final lower phase was taken to 
dryness by rotary evaporation, and the total tissue lipid 
extracted in this manner was dissolved in a known volume 
of chloroform and stored under at -20° 0.
(iv) Preparation of mouse tissue for radioactive estimation.
Mouse liver, spleen and kidney were processed for 
radioactive estimation according to the method of Lindsay 
et al. (1969). This method utilises NOS tissue solubiliser 
which solubilises biological samples for liquid scintillation 
counting. Livers were homogenised to a total volume of 
4 ml and spleens and kidneys to 2 ml with distilled H^O.
To 0.4 ml of these homogenates, 2.4 ml of NCS were added, 
gently mixed and left overnight at room temperature to 
ensure total solubilisation of the tissue. 0.07 ml of 
glacial acetic acid was added in order to neutralise 
(pH 6-7) the samples which would otherwise have given high 
background readings and thus poor counting efficiency.
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0.2 ml toluene and 17 ml of toluene scintillant were then 
added and the samples allowed to dark adapt for 24 h at 
4° 0 before counting.
(v) Thin layer chromatography (TLC).
a.' TLC on total lipid and glycolipid.
Qualitative separation of crude lipid extracts as 
well as pure glucocerebroside by TLC was accomplished in a 
solvent system composed of chloroform/methanol/water 
(65:25:4, v/v). The TLC tanks were lined with filter 
paper, 120-180 ml of developing solvent added and the 
tanks allowed to equilibriate for 1 h before use in order 
to saturate the atmosphere with the developing solvent. 
Pre-coated silica gel G plates were activated overnight 
at 80° C prior to use. The sample to be analysed as well 
as the standards were applied by micropipette as small 
discrete spots about 2 cm from the lower edge of the plates. 
These spots were dried rapidly in a stream of in order 
to minimise absorption of water from the air, since this 
affects the separation of the lipids.
Once the spots were dried the chromatoplate was inserted 
into the tank and the solvent allowed to rise along the 
plate until it reached a designated distance (approximately 
15 cm) from the origin. The plate was then removed, dried 
in an oven at 100° C for 10 min and the separated lipid 
spots were visualised with vapour by placing the plate 
in a trough containing crystals of iodine.
When a permanent record of the chromatogram was 
required, the plate was sprayed lightly with a saturated 
solution of potassium dichromate in 50# (v/v) aqueous
sulphuric acid. The oxidised lipid spots were charred by 
heating the chromatogram in an oven at 180° C for 25-30 min.
b. TLC on CBE.
The small water soluble molecule CBE was chromatographed 
by TLC in a solvent system composed of chloroform/methanol/H^O 
(60:35:8, v/v) and visualised by a dichromate/sulphuric 
acid spray and subsequent heating as described above.
(vi) Preparation of purified glycosylceramides.
Glycolipids were separated from total tissue lipid 
extract by column chromatography using a slight modification 
of the method of Suomi and Agranoff (1965). Total lipid 
obtained from the Folch extraction procedure was first 
fractionated on a glass column containing florisil 
(10 cm X 1 cm). Florisil is a magnesium silicate which 
absorbs phospholipids. The lipids were loaded on to the 
column in chloroform/MeOH (2:1, v/v) and eluted with 
CHCl^/MeOH (/:1, v/v). TLC on this column eluate after 
concentration by rotary evaporation showed neutral and 
glycolipids to be present but not phospholipids as 
expected.
For further purification, this column eluate was 
re-fractionated on silicic acid. Silicic acid was previously 
activated 80° C overnight and suspended immediately in 
diethyl ether. The slurry was poured into a small all 
glass column (10 cm x 1 cm). After it had settled, the 
absorbent was washed with one column volume of CHCl^.
The florisil column eluate was concentrated to a small 
volume, and applied to the silicic acid column in CHCl^.
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Neutral lipids were eluted with 50 ml of CHCl^, after 
which total glycosylceramides were obtained by elution 
with 100 ml of acetone : methanol (9:1, v/v). TLC on this 
eluate on silica gel G plates showed mainly glucosylceramide 
present with trace amounts of neutral lipid still present.
(vii) Estimations.
a. Glucocerebrosidase activity (EC 3.2.1.45).  ^ see p. 85
The activity of this enzyme was followed using its 
natural substrate glucocerebroside. Radiolabelled 
glucocerebroside-(glucose-6- H(N))-ceramide, was diluted 
with non-radioactive glucocerebroside to a specific 
radioactivity of 5000 cpm/nMol in toluene/methanol 
(1 :1 , v/v) and the activity of glucocerebrosidase was 
estimated by incubating this substrate mixture with a 
sample of either pure or tissue bound enzyme and measuring 
the formation of water soluble radioactive product 
( H-glucose). The substrate mixtures contained 6.8 nMol 
•(34.000 cpm) substrate which were dried under a stream of 
N^ and re-suspended in 0.1 ml of 0.25 M citrate/phosphate 
buffer at pH 4 containing 0.5 mg sodium taurocholate (Tc). 
This was incubated with 25-50 p,l of enzyme (containing 
15-30 jdg protein in the case of glucocerebrosidase, and 
25-35 /ig protein with liver homogenate) at 37° 0 for 30 min. 
The reaction was stopped by adding 0.6 ml of H^O and 2.8 ml 
of chloroform/methanol (2 :1 , v/v) the phases clarified by 
centrifugation at 600 x g for 5 min. The UP was carefully 
pipetted into graduated tubes and fresh FUP was added to 
the remaining lower phase (LP) mixture with minimum 
mixing of the phases, to make up to the original volume.
This was centrifuged and the second UP mixed with the
first. After noting total volumes of each phase, 1 ml of
UP and 0.1 ml of LP were added into glass vials and
dessicated overnight in the presence of conc. H_SO. and
(L 4
NaOH pellets under reduced pressure. To the dry samples 
1 ml of water and 10 ml of triton/toluene scintillant were 
added and the samples taken for radioactive estimation. The 
counts present in the UP represented the amount of glucose 
hydrolysed by the enzyme, and this was used to calculate 
the activity of the enzyme expressed as nMol of 
glucocerebroside cleaved per min per ml enzyme.
b .' Glucocerebroside:p-glucosidase activity (EC 3.2.1.21).
Assay of p-glucosidase activity was carried out using 
the synthetic substrate 4-methylumbelliferyl-p-D-glucopyranoside 
(4-MUGlc). The product of this hydrolysis, 4-methylumbelliferone 
is fluorescent and may be quantitatively estimated 
spectroscopically. This substrate was used in routine 
assays for estimation of ’acid' p-glucosidase activity in 
both pure enzyme preparations as well as in mouse tissue 
homogenates.
A typical assay consisted of 4 mM of 4MUGlc in 0.2 ml 
of 0.25 M citrate/phosphate buffer pH 5.0 containing 0.5 mg 
Tc incubated with 50 pX of either pure placental enzyme or 
tissue homogenate (containing between 0.5-1 mg tissue) for 
10 min at 37° 0. The reaction was stopped by the addition 
of 3 ml of glycine buffer pH 9.5. The umbelliferone which 
is a product of the hydrolysis fluoresces at alkaline pH 
and was estimated fluorimetrically using excitation and
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emission wavelengths of 360 nm and 44-8 nm respectively.
_c.' Glucose oxidase assay.
The method of Bernt and Lachenicht (1974), developed 
for the determination of blood glucose was extended to 
estimate glucose entrapped in liposomes (see Chapter 4).
Principle:
( 1 ) Ç-D-glucose + H^O + 0 ^ D-gluconic acid + ^2^2
(2) H_0_ + ABTS H,0 + ABTS ^  ^ 1*00. 2 ox*
GOD - glucose oxidase 
POD - peroxidase
ABTS - Redox indicator (2,2^-azinodi-3-ethyl benzothiazoline- 
6-sulphonic acid).
Reagents were prepared as follows:
A. 7.682 g of Na^H PO^ 2H2O, 3.634 g NaH^PO^ 2H2O,
7.5 mg POD, 45 mg GOD and 250 mg ABTS were 
made in 500 ml of distilled water.
B. Standard glucose solution.
A stock solution of glucose was prepared 
by 1 g of glucose in 1 1 of saturated 
benzoic acid solution.
The working mixture consisted of 2 ml of reagent A, 
with 100 ul of sample containing 1-4 ug glucose. Colour 
was allowed to develop for 30 min and optical density read 
at 420 nm.
A typical standard curve is shown in Fig. 2(i).
6C
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d.' Protein,
Protein was estimated by a modification of the Lowry 
procedure which enables determination of membrane proteins.
Reagents were prepared as follows:
Reagent A 2% sodium carbonate, O.A# sodium hydroxide,
0.16  ^ sodium potassium tartarate and 1% 
sodium dodecyl sulphate in H^O.
Reagent B k% copper sulphate solution.
Reagent C working reagent. 100 vol. A to 1 vol. B.
Reagent D 50^ dilution of IN Folin-Ciocalteau reagent.
1 ml if the sample (containing 10-100 pg protein) was 
mixed with 3 ml C and allowed to stand at room temperature 
for 10-60 min. 0.3 ml of reagent D was then added and mixed 
rapidly. The colour was allowed to develop for 4-5 min at 
room temperature and the absorbance was then read at 700 nm 
against a reagent blank.
Human serum albumin was used to prepare a standard 
curve (Fig. 2 (ii)).
_e. Lipid.
A. Dichromate reduction technique.
The method of Amenta (1964.), was used to quantitate 
glycolipids separated by TLC. The principle of this
procedure is based on the ability of lipids to reduce acid
• 2 —  2 4"
dichromate, Cr^O,^ to Or . The technique involved
determining the reduction in absorbance of the oxidised
2 _
form of the reagent (Gr^Oy ”) at 350 mp.
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Working reagent: 2.5 g K^Cr^Oy in 1 1 of 36N H^SO^.
Mixtures containing the lipids to be separated were 
applied to a silica gel plate as discrete spots. Known 
amounts of standard glycolipid (pure glucocerebroside) were 
also applied in separate lanes and the plate developed 
according to the conditions described above. Exposure of 
the plate to iodine vapour revealed the positions of the 
isolated lipids. The areas corresponding to the glyco­
sylceramides were outlined and the plates heated at 
90-100° 0 for 30 min to evaporate the iodine and any traces 
of solvent.
The silica gel in the outlined areas was scraped and 
transferred to small (5-10 ml) stoppered tubes, to which 
the dichromate reagent had already been added (1 ml of 
reagent for 20-125 Jig lipid, 3 ml for 60-4-00 pg lipid).
The samples were mixed well and placed in a water bath at 
100° C for 4-5 min with occasional shaking. After cooling, 
the tubes were centrifuged at 1200 x g for 15 min, and 
0.5 ml of the supernatant removed and mixed with 20 ml of 
H^O. Finally, the absorbance of these samples were 
determined at 350 lyi using equimolar KCr2(S0^)2 as a blank.
B. Fluorescamine assay.
The glycosylceramides separated by column chromatography 
(section (iv) above), were quantitated by a fluorimetric 
assay according to the method of Kisic and Rapport (1974). 
Fluorescamine is a reagent used for the detection of 
primary amines in the estimation of amino acids, peptides 
and proteins in the picomole range. It reacts with primary
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amines with a half life of 500 m seconds to form a 
fluorophor (Udenfriend et al., 1972), which can be detected 
at 410 nm excitation and 490 nm emission. Kisic and Rapport 
have extended this technique to measure glycosphingolipids. 
These lipids when acid hydrolysed yield sphingosine which 
has a primary amine group detectable, and thus quantitively 
assayed using fluorescamine.
Reagents used were as follows:
3N HCl
O.IM sodium acetate buffer, pH 3.7
6 mg fluorescamine in 25 ml acetone
ethyl acetate.
Samples of the dried glycosylceramides were hydrolysed 
with 0.3 ml of 3N HCl for 2 h in a boiling water bath in 
glass stoppered tubes, and the HCl removed jji vacuo in a 
dessicator over NaOH pellets overnight. To the dry residue, 
4 ml of ethyl acetate and 2.5 ml of buffer were added, the 
mixture shaken and then centrifuged at low speed for 2 min. 
0.5 ml of the fluorescamine solution was added, and the 
mixture immediately shaken vigorously by hand. The tubes 
were centrifuged at low speed and the fluorescamine in the 
ethyl acetate layer was determined at an axcitation 
wavelength of 410 nm and an emission wavelength of 490 nm.
f .' Assay of radioactivity.
3 3H-glucocerebroside and H-CBE.
Counting vials containing 1 ml aqueous aliquots of the 
material to be counted were mixed with 10 ml triton toluene 
scintillant and dark adapted for several hours to allow any
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chemlluminescence present to decay. These samples as well 
as tissue samples processed for radioactive estimation were 
counted in a LKB Rack Beta liquid scintillation counter.
An external standard source incorporated into the machine 
measures the amount of quenching produced by substances in 
the sample. Pre-calculated quench coefficients fed into the 
attached Multi 20 mini computer then allow it to compensate 
automatically for quenching.
Appropriate quench correction curves were used with
be r
3.
3
th adioactive estimation of H-glucocerebroside and
H-CBE.
(viii) Gas liquid chromatography (glc).
a. Processing lipid.
The glycosyl ceramide content of mouse liver was 
estimated by glc using a partially purified liver lipid 
extract as follows. 3 ml of 0.5N methanolic HCl were added 
to the dried lipid extract and hydrolysed at 80° C for 
18-24 h in sealed thick-walled pyrex tubes. After cooling, 
the tubes were opened and 0.15 pMoles of mannitol (stock 
solution, 2 ^Moles/ml in 99^ McOH) were added. The methyl 
esters of the fatty acids present after the hydrolysis were 
removed into hexane by three extractions with equal volumes 
of hexane. The preparation was neutralised by adding silver 
carbonate until all the effervescence had stopped. The 
samples were then centrifuged, the supernatant transferred 
to 10 ml stoppered tubes and taken to dryness by rotary 
evaporation under reduced pressure at 35° C and flushed 
with N^.
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The final step in the preparation of carbohydrates for 
glc was the formation of volatile derivatives by 
trimethylsilylation. This was accomplished by adding 0,J+ ml 
of hexamethyldisilazane (HMDS), trimethyl chlorosilane (TMCS) 
and pyridine in a ratio of 2:2:5 by volume. The solution 
became cloudy on addition of TMCS owing to precipitation 
presumably of NH^Cl. The formation of the corresponding
0-trimethylsilyl (TMSi) sugars, is complete after a few 
minutes at room temperature. After about 15 min the samples 
were centrifuged and the supernatants pipetted out and 
sealed in small glass vials ready for estimation of glc.
b .' glc estimation.
Glucose was estimated by glc, with a flame ionisation 
detector on a Hewlett Packard 5750 gas chromatograph. The 
derivatised sample was injected into a column (2 m x 2 mm) 
packed with Ufo SE30 on chromosab ¥-HP. The column 
temperature was run from 120-210° 0 at 2° per min and then 
raised to 10° per min up to 300° 0. The carrier gas was .
£.' Conditions for combined gas chromatography-mass spectrometry
The identity of the peaks obtained by glc were verified 
using mass spectrometry. This was accomplished by combined 
GC-mass spectrometry.
The gas chromatography coupled to the varian MAT 731 
mass spectrometer contained a column (2 m x 2 mm) packed with 
3% OV-1 on gas chrom Q. The column temperature during 
repetitive scan analysis was programmed from 150-250° C 
at 2° per min. The injector temperature was 250° C and 
helium used as the carrier gas at 20 ml min ^ . Mass 
spectrometer settings were:
7C
ionising voltage : 70 eV
accelerating voltage ; 8 kV 
During the automatic scanning operation the magnetic field 
is varied to cover the mass range (usually 50-1000) every 
10 s at 2 s/decade. Each scan is assigned a spectrum 
number as the data is acquired by the computer auto magnetic 
tape. The ion current of the beam passing from the source 
into the analyser is monitored and can be recorded 
directly using a pen recorder. This TIC (total ion current) 
is comparable with the chromatogram obtained using gas 
chromatographic analysis with a flame ionisation detector.
d. Estimation of molar adjustment factor and final 
glucose content.
Quantitative analysis by glc is usually achieved by 
means of "internal standardisation". A known weight of an 
internal standard is added at the beginning of the 
procedure and the ratio of the peak area for each component 
compared to that of internal standard is then a direct 
estimate of the amount of that component present. With 
monosaccharides, the internal standard commonly used is 
mannitol. However, it is not possible to quantitate the 
TMSi methyl glycoside directly with the TMSi mannitol 
because these compounds produce slightly different responses 
to the glc flame ionisation detection system, and therefore 
an "adjustment factor" for each monosaccharide must be 
calculated.
A constant amount of internal standard (mannitol) was 
mixed with varying quantities of glucose to produce a range 
of mole ratios of glucose to mannitol as shown in Table 2(iii),
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Table 2 (ill). Internal standard to monosaccharide ratios used to 
determine the molar adjustment factor
Sample
No.
Internal 
standard 
solution (yl)
Monosacchari de 
solution (yl)
Mole ratio of 
glucose to the 
internal standards
1 50 10 0.2
2 50 25 . 0.5
3 50 • 35 0.7
4 • 50 • 50 1.0
5 50 60 1.2
6 50 75 1.5
7 50 85 1.7
8 50 100 2.0
Internal standard solution: 9.1 mg of mannitol in 50 ml of water
(i.e. 1 yMole/ml solution).
Monosaccharide solution: 9 mg of glucose in 50 ml of water
(i.e. 1 ]iMole/ml solution).
and the mixtures dried vacuo in a dessicator over 
phosphoric oxide. Methanolysis of the dry residue was 
carried out in 0.5 ml of IN methanolic HCl at 100° 0 
for 24. h. The samples were neutralised with silver carbonate 
as above, and acetic anhydride (0.05 ml) was added. The 
contents were mixed thoroughly and left to stand for at 
least 6 h at room temperature. The sample was mixed again 
and centrifuged, and the supernatant collected. The 
residual precipitate was washed by further additions of 
methanol (3 x 25 ml) and the supernatants combined. These 
supernatants were taken to dryness by rotary evaporation 
and the dry residue silylated as described previously.
The final TMSi ethers were injected onto a column and 
processed as before (2.2. (vii) b).
The adjustment factor was calculated by establishing 
a standard curve by plotting the total peak area ratio (the
total peak area of glucose to the peak area of mannitol)
against the mole ratio of glucose to mannitol (Fig. 2(iii) ) .
The molar ratio adjustment factor was given by the slope of 
the graph and was calculated to be a value of 1.1. This 
factor was used in the calculation of glucose levels from 
the glc data according to the following formula.
pMoles glucose = area of glucose peaks x 1.1 x jjmole mannitol addec
area of mannitol peak
(ix) General Histology.
The general morphology of mouse liver and spleen were 
examined on fresh frozen, snap frozen and paraffin sections 
of these tissues. Each tissue was cut into 4- pieces and 
processed by the following techniques.
Fig. 2 (iii). Standard curve for estimation of molar adjustment 
factor.
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a.' Blocks of fresh tissue up to 3 mm thick were fresh 
frozen by mounting the piece of tissue on the chuck of a 
cryostat and the tissue frozen immediately by spraying 
liquid CO^ onto it. The chuck with the frozen tissue was 
transferred to the freezing chamber of the microtome which 
was maintained at -15° to -20° C. The sections were cut 
immediately and picked up from the surface of the knife 
onto glass slides. These sections were stored at -70° C 
until required.
b .' Tissue sections were snap frozen as follows.
Approximately 50 ml of isopentane in a small beaker
were lowered into a container of liquid until solid 
white globules began to form. The beaker was then lifted 
out and fixed just above the level of the liquid . The 
animal was killed, the tissue removed rapidly and small 
sections (3 mm) mounted on pieces of cork. These were 
dropped inverted into the freezing isopentane for about 15 s 
and transferred to pre-cooled snap top bags on solid CO^.
The frozen sections were stored at -70° C until required for 
sectioning.
It was essential that the samples were frozen as 
rapidly as possible in order to prevent the formation of 
ice crystal artefacts.
_c. Tissue blocks were fixed in formal calcium for 24- h 
at 4-° C and transferred to 0.88 M sucrose containing gum 
acacia at 4-° 0 for at least 24- h . The blocks were 
sectioned in a cryostat.
81
d. The remainder of the tissue was fixed in 10^ formal 
saline and used for paraffin wax embedding. The tissue 
blocks which were between 3 and 5 mm thick were washed in 
water to remove fixative. They were then dehydrated using 
a range of dehydrating solutions. Starting with 70^ 
alcohol for 3-8 h , the blocks were transferred to 90% 
alcohol and left overnight. The dehydration was completed 
in three changes of absolute alcohol (3 h each). The 
tissue samples were incubated in toluene overnight, and 
finally after three changes in paraffin wax (l h) the 
blocks were embedded in fresh wax. Embedding was done 
using a tissue TCK embedding centre, and the processed 
blocks were sectioned using a microtome.
(x) Staining techniques.
The paraffin wax was removed from paraffin sections 
before any staining process was undertaken.
a.' Haematoxylin-Eosin stain (H & E).
This stain is used to visualise the general morphology 
of cells. Haematoxylin is a nuclear stain and eosin stains 
the cystoplasm and connective tissue.
The slides containing the tissue sections were immersed 
in haematoxylin for 20-30 s and washed in tap water. They 
were then dipped in an acid/alcohol solution (0.5-1% HCl 
in 70% alcohol) for 1 s, washed in running water and viewed. 
This wash was repeated until all background staining was 
eliminated and only the cell nuclei were stained blue.
These sections were then stained in 1% aqueous eosin for
1-3 min. The excess stain was washed and the sections
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dehydrated in absolute alcohol and xylene and finally 
covered with a cover slip using apathy resin.
b. Periodic acid-Schiff (PAS) and PAS/diastase reaction.
This is a general histochemical technique used for 
the demonstration of carbohydrates. It is based on the 
ability of periodic acid to oxidise adjacent 1:2 glycol 
groups (CHOH-CHOH) present in all sugar aldehydes, which 
in turn reacts with the colourless Schiff reagent to give 
a red colour. PAS positive materials therefore stain 
magenta. The PAS reaction was used in conjunction with a 
diastase control for the demonstration of glycogen.
Diastase digestion was accomplished by covering the sections 
with human saliva (a source of diastase) for 30 min and 
washed in water for 15 min. The PAS/diastase and PAS 
sections were covered in periodic acid for 7 min, rinsed in 
distilled water and covered in Schiff's reagent for a 
minimum of 10 min.
The sections were then rinsed in distilled H^O and 
washed extensively in tap water for 30 min. They were 
stained in Cole's haematoxylin for 2 min to stain for 
nuclei and were finally dehydrated in alcohol, cleared in 
xylene and mounted as before.
PAS positive material present in the untreated section 
and absent in the diastase digested section was assumed to 
be glycogen.
£. Oil red 0 stain.
This is a stain used for detecting the presence of lipid 
and may only be used on frozen sections.
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The sections were rinsed thoroughly in 60% triethyl 
phosphate and then .immersed in oil red 0 staining solution 
for 10-15 min. Excess dye was washed off with 60% triethyl 
phosphate and the sections rinsed in distilled H^O. The 
nuclei were counter-stained in Cole’s haematoxylin rinsed 
until blue in tap water and covered wit^ a coverslip as 
before. Any lipid present stains red by this method.
d. Acid phosphatase.
The method of Pearse (1972), was followed to detect 
acid phosphotase activity, a-naphthyl phosphate used as a 
substrate is hydrolysed by this enzyme to form #-naphthol 
which couples with a diazonium salt to form a coloured azo 
dye. Cryostat sections from snap frozen tissue as well as 
formal calcium fixed tissue which were impregnated with gum 
sucrose mounted on glass slides, were used. Freshly 
prepared or-naphthyl phosphate substrate mixture was 
filtered onto the sections at 37° C and incubated for 4-5 
and 90 min. The slides were washed in running water and 
counter-stained in Mayer’s haemalum for 1-2 min. Excess 
stain was washed in running water for 30 min and the sections 
mounted in glyceral jelly.
_ e N o n - s p e c i f i c  esterase stain.
The method of Horwitz (1977), was followed for the 
demonstration of non-specific esterases. Fresh frozen and 
formal calcium fixed tissues were used.
Reagents for incubation medium:
A. phosphate buffer 8.9 ml
(0.15 M pH 7.6)
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B. naphthyl acetate 4. mg
C. ethylene glycol monomethyl ether 0.5 ml
D. pararosanilin solution 0.6 ml
The final pH of the incubating medium was adjusted to 
pH 6.1 with NaOH. This medium was prepared just before use.
9 jjm thick sections were picked up onto coverslips 
which had been pre-treated with gelatine-formaldehyde and 
dried. The sections were allowed to dry for at least 1 h at 
room temperature before incubating with the substrate 
medium for 4-5 min.
After washing and counter-staining with 2% methyl green, 
the sections were washed, dehydrated through alcohols to 
xylene and mounted in Ralmount.
(xi) Electron microscopy.
Tissues were prepared for transmission electron 
microscopy (TEM) as follows.
The tissue blocks were fixed in 3% glutaraldehyde in 
0.1 M sodium cacodylate buffer pH 7.4- with 5% sucrose, for 
a minimum of 1 h . After three rinses in this buffer (over 
24- h), the blocks were post fixed in 1% osmium tetroxide in 
this buffer at 4-° C for 1 h and then rinsed in water.
After staining the blocks overnight in 1% aq. uranyl acetate 
they were dehydrated by rinsing in 70% and 95% acetone, two 
15 min rinses in 100% acetone and two 15 min rinses in 
propylene oxide. They were then incubated for 3 h in 
propylene oxide/spurrs resin (1 :1, v/v), left overnight in 
the resin and then incubated for several more hours in fresh
8resin. The tissue blocks were finally embedded in fresh 
resin and polymerised overnight at 60° G.
Blocks of liposomal preparations were processed for TEM 
by fixing in glutaraldehyde and rinsing in buffer as above. 
The liposomes were pelleted by low speed centrifugation 
between the buffer changes. They were then osmicated as 
above and finally embedded in 1% aqueous agar at 60° C.
The agar was allowed to set, cut into blocks and sectioned.
Sectioning was done on a LKB III microtome, on a 
diamond knife at 0.1 mm s”^. The cut sections were picked 
up on new 200 mesh Athene copper grids, stained in Reynolds 
lead citrate for 1 min, and carbon coated in an Edwards 
E306A carbon coater. The processed sections were examined 
on a Philips 300 microscope.
Enzyme Definitions.
a. In this study glucocerebrosidase activity is 
defined as that enzyme which hydrolyses the 
glycosphingolipid glucocerebroside to glucose 
and ceramide.
b. Glucocerebroside:p-glucosidase describes the 
hydrolysis of the artificial substrate 
4--methylumbelliferyl-^-D-glucopyranoside by the 
’acid’ p-glucosidase enzyme.
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CHAPTER 3 
DEVELOPMENT OF AN ASSAY FOR THE 
QUANTITATIVE DETERMINATION OF 
GLUCOCEREBROSIDE:B-GLUC0SIDASE ACTIVITY
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3 .1 . Introduction.
The mammalian enzyme glucocerebrosidase (EC 3.2.1.4-5) 
is a tightly membrane-bound enzyme which catalyses the 
hydrolysis of the glycolipid glucosylceramide (glucocerebroside) 
to glucose and ceramide (Brady et al., 1965b, Gatt, 1966)
(Fig. 3(i)). Its deficiency results in the lysosomal 
storage disorder Gaucher’s disease (Brady et al., 1965a; 
Patrick, 1965). This is manifested by an accumulation of 
glucosykeramide in the liver and spleen (Halliday et al.,
194-0; Rosenberg and Chargaff, 1958; see also Chapter 1 ).
This deficiency of glucocerebrosidase in adult 
Gaucher’s disease is accompanied by a parallel decrease in 
the activity of p-glucosidase (EC3.2.1.21) in the tissues 
(Patrick, 1965; Ockerman and Ktthlin, 1968). It was 
demonstrated by Ho (1973) that both of these hydrolytic 
activities were present in one enzyme protein. The 
p-glucosidase activity is assayed much more conveniently 
than the glucocerebrosidase activity, using artificial 
substrates such as p-nitrophenyl: f-D-glucoside (PNP) or 
4--methylumbelliferyl:p-D-glucopyranoside (4-MUGlc) (Fig. 3(i)). 
The product of the latter hydrolysis ( 4--methylumbellif erone ) , 
is easily measured fluorimetrically and that of the former, 
spectrophotometrically (Beutler and Kuhl, 1970). Indeed 
the estimation of p-glucosidase activity using 4-MUGlc, and 
to a lesser extent PNP, form the basis of the routine 
clinical diagnosis of Gaucher’s disease. However, the 
existence of several different forms of mammalian 
p-glucosidase is evident (Stephens et al., 1979).
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As well as hydrolysing these artificial substrates and 
glucocerebroside (GC), p-glucosidase has been shown to 
hydrolyse p-D-galactoside, p-D-fucoside, a-L-arabinoside 
and p-D-xyloside. Two isoenzymes of p-glucosidase, a 
high molecular weight membrane bound form, and a low 
molecular weight cytosolic form are believed to be 
responsible for this somewhat indiscriminate substrate 
specificity. It is the former isoenzyme that is deficient 
in Gaucher's disease and believed to be identical with 
glucocerebrosidase (Ho et al., 1973.). It has an acid pH 
optimum whilst the cytosolic isoenzyme shows maximal 
activity at neutral pH. This latter neutral form is 
believed to be responsible for the other hydrolyses 
mentioned above and its activity remains unchanged in 
Gaucher's disease.
Thus, since both forms of the enzyme hydrolyse 4-MUGlc 
equally, when p-glucosidase activity is used to estimate 
the status of Gaucher's disease in tissue, differentiation 
between the two isoenzymes to reflect preferentially the 
'acid' p-glucosidase activity, is essential for reliable 
diagnosis .
In human liver and spleen the two isoenzymes may be 
distinguished by their different subcellular locations.
The 'acid' form is tightly membrane-bound in the lysosomes 
and is also known as the particulate p-glucosidase while 
the 'neutral' form is the soluble p-glucosidase, and is 
located in the cell cytosol. When considering the enzyme
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activity in a total tissue homogenate with 4-MUGlc as 
substrate, the apparent pH for optimum activity of the 
system does not reflect the true properties of either 
enzyme. For example, it was demonstrated by Beutler and 
Kuhl (1970), that leukocyte preparations, whether from 
normal or Gaucher patients, showed an optimum pH for 
activity between 5.0 and 5.5. However, on considering the 
profile as a whole it was apparent that the best 
differentiation between the leukocytes was obtained at pH 
4-.0, far below the pH optimum shown by this non-specific 
system.
Various factors such as detergents, have been shown 
to affect the two isoenzymes differently. These, and 
parameters such as pH of the system, have been manipulated 
by several workers to render the otherwise non-specific 
4-MUGlc assay specific for 'acid' p-glucosidase in total 
tissue homogenate, and thus reflect more closely 
glucocerebrosidase activity. However there is considerable 
divergence in assay conditions recommended for measuring 
this enzyme. It appears that the enzyme is tissue 
specific as well as species specific. For example, 
fibroblasts of patients with Gaucher's disease are 
deficient in p-glucosidase activity, but they do not 
display a pH activity profile similar to that shown by the 
leukocytes. Instead there is a single peak at 
approximately pH 4-.5 (Beutler et al,, 1971). Human liver 
'acid' p-glucosidase is assayed using 4-MUGlc as substrate
9 1
at pH 5.2 (Ockerman, 1968) and requires 1.2% sodium 
taurocholate (Tc) for optimum activity, while the human 
spleen enzyme has optimal activity at pH 4-.0-4-.3 and is 
stimulated by 0.02% triton X-100 (Ho and O'Brien, 1971). 
Yaqoob and Carroll (1980) assay Spleen 'acid'
P-glucosidase at pH 5.8 with no added factors. Braidman 
and Gregoriadis (1977) assay partially purified human 
placental enzyme at pH 4-.8 with 0.02% triton X-100.
Highly purified human placental enzyme is assayed at pH
6.0 with 0.1 mM phosphatidylserine and 0.25% Tc with the 
artificial substrate by Dale and Beutler (1976). Mouse 
liver p-glucosidase is assayed at pH 4-. 5 with 0.5% Tc 
(Stephens et al., 1978), while the rat liver enzyme is 
assayed at pH 5.2 (Patel and Tappel, 1969). This lack of 
coherence between the assay systems adopted by different 
workers for measuring 'acid' p-glucosidase, indicated a 
considerable degree of confusion regarding the properties 
of this enzyme.
Studies into the^  feasibility of creating a durable 
animal model of Gaucher's disease in the mouse were a major 
part of this project. Deficiency in glucocerebrosidase 
activity was the main parameter to be considered and thus, 
the need for an efficient and accurate assay for this 
enzyme was evident. In view of the differences that exist 
in the assay conditions used with this enzyme it was 
obvious that none of these systems could be reliably 
extended for use with mouse liver and spleen.
9The following studies were carried out to establish 
the best conditions for estimating the level of 
glucocerebrosidase in mouse tissue as reflected by 'acid* 
p-glucosidase activity, which was assayed using the 
artificial substrate 4-MUGlc, 1a  assaying for 
glucocerebroside:p-glucosidase. In this study, hydrolytic 
activity on glucocerebroside by any enzyme source is 
described by the enzyme glucocerebrosidase. The activity 
of the 'acid' p-glucosidase enzyme with 4-MUGlc as substrate 
is described by glucocerebroside:p-glucosidase and the 
'neutral' p-glucosidase activity on this substrate, by 
soluble p-glucosidase.
3.2. The P-Glucosidase Enzymes.
(i) 'Acid' P-glucosidase.
Much evidence exists in support of the theory that 
'acid' p-glucosidase and glucocerebrosidase activities are 
due to one enzyme protein (Kanfer et al., 1974-, 1977;
Ho, 1973; Peters et al., 1976). Ho (1973), provided 
convincing evidence in support of this theory by 
demonstrating that 'acid' p-glucosidase ànd glucocerebrosidase 
activities were reconstituted simultaneously jji vitro from 
two inactive macromolecular factors, P and C from human 
spleen. In bovine spleen extract, acid p-glucosidase, 
glucocerebrosidase and glucosylsphingosine:p-glucosidase 
co-purified by affinity chromatography (Kanfer et al.,
1974-). In rat kidney the pH versus activity curves of 
the particle bound enzyme assayed with both 4-MUGlc and GC
as substrates were superimposable, with a pH optimum of 
5.0, a Km of 1.1 x 10.^ M with artificial substrate and 
2 X 10 ^ M with GC (Kanfer et al., 1977). Although the 
accepted activity of glucocerebrosidase is in the hydrolysis 
of glucocerebroside, purified glucocerebrosidase from calf 
brain and spleen have been shown to catalyse the formation 
of glucosylceramide with ^^C-ceramide as the acceptor and 
various p-glucosides such as 4-MUGlc as the glucose donor 
in a transglucosylation reaction (Mumford et al., 1976;
Kanfer et al., 1975a).
eg 4-Me-Umb-glucose 4-Me-umbellif er one
glucocerebrosidase
----------------
& &
(^^C)-ceramide glucos e -ceramide
The crude particulate f-glucosidase from rat kidney also 
catalysed this reaction, while transglucolytic activity by 
soluble enzyme was not detectable under these conditions.
Thus, it is apparent that the ’acid’ p-glucosidase and 
glucocerebrosidase enzymes share several common properties.
The activity of the glucocerebrosidase is assayed using 
radiolabelled glucocerebroside ( H-glucose-cerebroside). 
Problems arise when trying to measure glucocerebrosidase 
by an vitro assay system because the natural substrate 
of this enzyme is an amphipathic glycolipid normally 
associated with a membrane. Consequently, this is poorly 
soluble in aqueous solution where it tends to exist as a 
multimolecular aggregate or micelle with the oligosaccharide 
chains projected into the aqueous phase. Such micelle
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formation must decrease the chances of fruitful enzyme- 
substrate interactions by several orders of magnitude, 
partly because of the decrease in effective substrate 
concentration, but mostly because of the steric hindrance 
to enzyme recognition of the glycosidic bond. Anionic 
detergents such as Tc are used to overcome this problem 
of enzyme-substrate approach. These facilitate the lipid- 
protein interactions required for the hydrolysis, by 
solubilising the lipid substrate to form lipid-detergent 
micelles. Electrostatic attractions between the oppositely 
charged groups on the detergent and the enzyme-protein 
molecule enables initial interactions between the enzyme 
and its substrate. Since glucocerebrosidase is a strongly 
hydrophobic molecule it can then interact with the core of 
the micelle.
This mechanism follows closely the current views of 
how enzyme-substrate interactions occur in the membrane 
bilayer vivo, where initial attraction between charged 
groups on the protein and the polar lipid head groups is 
followed by hydrophobic interactions of the protein with 
the bulk bilayer lipid (Razin, 1972).
Peters et al. (1976) reported that the optimum 
conditions for the assay of glucocerebrosidase in human 
leukocytes, kidney, liver and spleen involved a pH of 
between 5.0 and 6.0 and the presence of 0.9-1.2% Tc.
They also reported that when the relatively non-specific 
artificial substrate 4-MUGlc was used under assay conditions
9 t'
optimal for glucocerebroside hydrolysis, it effectively 
measured glucocerebroside:Ç-glucosidase activity.
Inclusion of sodium taurocholate with 4-MUGlc, decreased 
the activity of non-specific soluble p-glucosidase and 
stimulated the particulate ’acid’ f-glucosidase 
(glucocerebroside:p-glucosidase). Thus the use of sodium 
taurocholate with the artificial substrate 4-MUGlc causes 
the non-specific p-glucosidase assay to reflect more 
closely the p-glucocerebrosidase activity of a given tissue 
It is this property of sodium taurocholate which is applied 
when 4-MUGlc is used in the routine diagnosis of Gaucher *s 
disease. A crude homogenate when assayed with IMUGlc in 
the absence of Tc is thus believed to represent total 
p-glucosidase, and in the presence of Tc, the particulate 
glucocerebroside:p-glucosidase.
Small amounts of phosphatidylserine (5 p-g per assay) 
have been shown to stimulate hepatic glucocerebroside: 
p-glucosidase 17 fold when assayed with MÏÏGlc as substrate 
(Peters et al., 1976). It also inhibits soluble hepatic 
p-glucosidase (Ho and Light, 1973). Thus it is apparent 
that assay procedures employing artificial substrates are 
only useful if the conditions for assay can 1 
such that a non-specific substrate under one 
conditions becomes a specific substrate under another,
(ii) Soluble P-glucosidase.
soluble p-
a number of investigators in a variety of species
8 6
including rat, pig and human (Patel and Tappel, 1969; 
Abrahams and Robinson, 1969; Dance et al., 1969). It 
occurs predominantly in the kidney. A high speed
supernatant fraction of rat kidney has 700-fold greater
activity than the same fraction of heart, skeletal muscle, 
lung, spleen, brain or liver (Glew et al., 1976). It has 
a high pH optimum near neutrality (pH 6-7.0), exists in 
the cytosol of the cell and appears to be a single enzyme
with rather broad substrate specificity. p-glucosidase
co-chromatographs with p-galactosidase, p-D-fucosidase, 
Of-L-arabinosidase and p-D-xylosidase and exhibits activity 
towards the PNP and MUGlc derivatives of their respective 
substrates (Glew et al., 1976). The soluble p-glucosidase 
has an isoelectric point of 4.9 and is inhibited by 
triton X-100 (Kanfer et al., 1977). The Km for the 
purified enzyme is 130 ^M. The partially purified enzyme 
has a broad pH range for optimum activity (5.5-7.0).
Although the rat kidney enzyme is not affected by 
sodium taurocholate, the human tissue soluble p-glucosidase 
is inhibited by it. A physiological or a natural substrate 
for this neutral soluble p-glucosidase has not yet been 
identified and so the function of this enzyme remains 
obscure. Histochemical techniques have shown this enzyme 
in kidney to be associated largely with the proximal 
convoluted tubule which carries out monosaccharide 
reabsorption. This and other evidence has prompted the 
tentative suggestion that neutral p-glucosidase plays a
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role in the active transport of glucose in the kidney 
(Rutenberg et al., 1958; Semenza et al., 1964; Abrahams 
and Robinson, 1969). Clinical interest in this particular 
p-glucosidase stems from the observation that its concen­
tration in the urine of laboratory animals with experimentally 
induced renal disease is elevated long before proteinuria 
is apparent (Robinson et al., 1967). However, the function 
of this enzyme in other tissues is not known. Thus it is 
this enzyme activity which has to be suppressed in order to 
render the 4MUGlc assay specific for glucocerebroside: 
p-glucosidase in tissues.
Since a reliable assay for ’acid’ P-glucosidase 
(glucocerebroside:p-glucosidase) in crude mouse tissue was 
required, an assay system which maximised the expression of 
this enzyme whilst suppressing the expression of the non­
specific soluble p-glucosidase was investigated. A 
typical pattern of behaviour for glucocerebrosidase with 
its natural substrate (GC) was established using highly 
purified enzyme from human placenta. This preparation is 
believed to be mainly composed of glucocerebrosidase (’acid’ 
p-glucosidase) with only trace amounts of the soluble 
non-specific p-glucosidase (Pentchev et al., 1973). On 
the basis of the activity profiles obtained here, assay 
conditions using the synthetic substrate 4MUGlc, with 
this enzyme preparation were manipulated in order to 
optimise the extent of glucocerebrosidase activity 
reflected by the glucocerebroside:p-glucosidase assay.
9 0
The behaviour of the human placental enzyme was compared 
with that of the mouse liver enzyme with both artificial and 
natural substrates and an appropriate assay system to render 
the non-specific XMUGlc assay specific for glucocerebroside: 
p-glucosidase in total mouse liver homogenate was developed 
in the following studies.
3.3. Preparation of Enzyme Fractions.
(i) In experiments using whole mouse liver homogenate as the 
source of unpurified enzyme, the homogenates were prepared 
as described in Section 2.2.(iii). When particulate 
versus cytosolic p-glucosidase activity was studied, 25% 
liver homogenates were centrifuged at 600 x g for ten 
minutes in order to remove nuclear and cell debris and 
the resultant supernatant was then centrifuged at
100,000 X g for one hour. The pellet so formed contains 
the lysosomal and microsomal fractions of the cell. This 
was used as the source of particulate P-glucosidase, and 
the resultant supernatant, of cytosolic soluble p-glucosidase
It was necessary to establish the integrity of the 
separated fractions as sources of particulate and soluble 
enzyme. This was done by assaying for the lysosomal marker 
enzyme N-acetyl-glucosaminidase (NAG) by the method of 
Mead et al. (1955). This enzyme is unique to lysosomes, 
and so any NAG activity found in the soluble- fraction must 
be due to lysis of lysosomes during preparation of the two 
fractions. Between 86 and 90% of the total NAG activity 
was found in the particulate fraction. A 10-14% breakdown
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of lysosomes by this method is generally accepted (Peters, 
1981), and thus using the supernatant and pellet as sources 
of soluble and particulate enzyme respectively was 
considered a valid approach.
(ii) When this study was commenced, pure glucocerebrosidase 
was not easily available and since this was one of the main 
problems hampering enzyme replacement therapy trials, 
methods of preparing this enzyme from human placenta were 
investigated. Published methods for purification of this 
enzyme follow conventional protein extraction procedures, 
but differ in detail. The method of Braidman and 
Gregoriadis (1977), with some modifications was tried first. 
A general scheme for the procedure is shown in Scheme 3(i). 
Enzyme activity was assayed using the artificial substrate 
as described in Section 2.2.(vii)b at pH 4.5. No 
significant yields of enzyme were obtained by this method, 
and on further investigation it appeared that the detergent 
triton WR 1339 was ineffective in solubilising the membrane 
bound enzyme. This was established by dividing the first 
citrate buffer homogenate (from step I ) into two equal 
parts. One half was re-homogenised in 0.15% triton WR 1339 
according to step 2 in the scheme, and the other half 
re-homogenised using 1% sodium cholate as the detergent in 
citrate buffer. Of the total units of enzyme activity 
obtained from these two homogenates, only 5.5% was due to 
the triton WR 1339 solubilised fraction. It was therefore 
decided to try sodium cholate as the detergent to solubilise
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Scheme 3 (i). A Procedure for the Preparation of Glucocerebrosidase 
from Human Placenta (Braidman and Gregoriadis, 1977).
1. Fresh human placentae \iere freed of cords and membranes, 
va shed with distilled K2 O and homogenised in 50 mM sodium 
citrate buffer pH 6.0 at 4 °C.
2. The homogenate vas centrifuged at low speed and the resultant 
pellet re-homogenised in the same buffer containing 0.15% (v/v) 
triton V/R1339 (buffer A), and re-centrifuged at 12,000 rpm.
The clear detergent extract thus obtained in the supernatant 
vas made 5 mî-î with respect to CaCl^ and MnCl^.
3. The detergent extract vas mixed with 200 ml of Con-A Sepharose 
at room temperature for 30 mins and then filtered through
a Buchner funnel. The Sepharose vas washed in 300 ml of 
buffer A and filtered three times, after which it vas stirred 
in 250 ml of 0,1 M a-methyl mannoside in buffer A at room 
temperature for 30 min. This vas then passed through a 
Buchner funnel and the filtrate collected on ice.
4. The Con-A Sepharose eluate was then precipitated in 4 volumes
of ethanol/chloroform (9:1, v/v), at 4°C for two hours. The 
resultant protein mixture vas centrifuged at 18,000 rpm for 
30 min and the pellet flushed in a stream of N2  to eliminate 
excess solvent.
5 . The precipitate vas then re-dissolved in 20 ml of citrate
f Duffer, and the solution dialysed overnight against citrate
buffer at 4°C.
6 . The dialysed solution vas centrifuged at 18,000 rpm and the
supernatant rich in glucocerebrosidase was further purified 
and concentrated by ultrafiltration on an Amicon XT^ I-50 membrane
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the membrane bound enzyme. The procedure was identical to 
the previous scheme except that buffer A contained 1% 
sodium cholate. The results of a typical preparation are 
given in Table 3(i).
It was apparent from these results that most (92%) of 
the enzyme is lost in the early stages of the procedure at 
the affinity chromatographic step on concavalin-A-sepharose 
(con-A), This loss may have been due to inefficient binding 
of enzyme by con-A, or alternatively by lack of efficient 
elution by the methyl-mannoside solution. On assaying 
con-A sepharose for residual enzyme activity after elution 
with Me-mannoside, when in theory all the adsorbed enzyme 
should have been removed, approximately 25^ of the activity 
was found still associated with the con-A sepharose. Even 
after regeneration of the con-A by successive washes in high 
and low pH buffers, enzyme was still found associated with 
the con-A sepharose beads. Several approaches were tried 
in order to displace bound enzyme from the con-A, with no 
significant success.
Thus it was decided to try the method of Dale et al. 
(1976) for purifying placental glucocerebrosidase. A 
general scheme for the procedure is given in Scheme 3(ii), 
and the results of a typical extraction in Table 3(ii).
This procedure differs from the others using crude sodium 
taurocholate as detergent. Con-A sepharose is used in a 
conventional column, and acetone is used instead of ethanol/ 
chloroform as the organic solvent. Enzyme activity for
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Scheme 3 (ii). A Procedure for the Purification of Glucocerebrosidase 
from Human Placenta (Dale et al., 1976),
1. Procedure as in Scheme 3 (i) but using distilled water to 
homogenise the placenta (25%, w/v).
2. Detergent extraction in 0.5% taurocholic acid (40%, w/v) in
50 mî-î sodium citrate buffer, pH 6.0 (buffer A). The resultant 
extract v/as treated as in Scheme 3 (i) prior to affinity 
chromatography on Con-A Sepharose.
3. The taurocholate extract was applied to a column containing
50 ml Con-A Sepharose and washed with 500 ml buffer A. Enzyme 
was eluted off the column with 500 ml a-methyl mannoside and 
concentrated to 250 ml by ultrafiltration.
4 . The enzyme solution was precipitated in acetone (10 vol per 
ml protein solution) at -15°C and the solid protein residue 
was collected by filtration under pressure.
5 . Steps 5 and 6  of Scheme 3 (i) v/ere followed to obtain the 
final enzyme preparation.
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this method was assayed using the artificial substrate 
/-methylumbelliferyl-^-D-glucopyranoside at pH 6.0.
The final yield of enzyme by this method was 13^. The 
loss of enzyme at the con-A sepharose chromatography step 
by the conventional column method of Dale et al. (Method 2), 
was only l6? in contrast with the 92% lost by the Braidman 
method. However, these methods are not directly comparable 
as Dale et al. reported an increase in activity due to a 
shift in pH optimum of glucocerebrosidase from /.5 to 6.0 
during the purification and thus assay at pH 6.0. When 
enzyme produced by this method is assayed at pH 4.. 5 (in 
order to compare directly with Method l), there was a loss 
of of enzyme activity which, although not as good as
l6%, is still considerably better than losing 92% of the 
initial activity. When the con-A sepharose eluate from 
the Method 1 was assayed at pH 6.0, the apparent loss of 
enzyme was still fairly high (about 4-0^ ) (see Table 3(i)).
The larger losses of enzyme by Method 1 may be due to the 
batchwise use of con-A sepharose rather than using it in a 
conventional column. The organic solvent used in the protein 
precipitation step also affects the pH optimum of the 
glucocerebrosidase. In Method 2, when the acetone 
precipitate was redissolved, it had a higher activity at 
pH 6.0 than at pH 4-.5. When the mannoside eluate from this 
method was alternatively precipitated in ethanol/chloroform, 
the enzyme activity was now higher at pH 4-. 5 than at 6.0. 
There was little to choose between the two methods as the
l O G
final yield of enzyme activity by either method was 
approximately the same (124-8 units and 1339 units by 
Methods 1 and 2 respectively). The procedures were very 
unreliable as far as yields were concerned, time consuming 
and the final preparation unstable. Dale et al. have 
recently developed a large scale procedure for the 
purification of this enzyme thus making it more readily 
available. In view of the difficulties encountered with 
the laboratory scale preparation of this enzyme, it was 
therefore decided to use this pure glucocerebrosidase 
prepared by the large scale procedure in the remainder of 
these studies.
3.4-. Glucocerebrosidase and Glucocerebroside ;B-Glucosidase 
Activities in the Pure Human Placental Enzyme 
Preparation and in Mouse Liver.
(i) Factors influencing human placental glucocerebrosidase
and glucocerebroside:B-glucosidase activities.
a. The effect of pH on human placental p-glucocerebrosidase 
activity was determined using the general assay procedure 
for natural substrate described in Section 2.2.(vii)a, 
over a range of pH from 3.0-7.5 as shown in Fig. 3(ii).
The optimum pH for activity was at 4-.0 with activity 
falling sharply at 3.5 due to protein precipitation, and 
more gradually from pH 4- .5 upwards. The effect of varying 
concentrations of the detergent (sodium taurocholate (Tc)) 
and phospholipid (phosphatidylserine (PS)), on this enzyme 
were studied. It appeared that the best condition for 
assay of this enzyme was in the presence of 0.5 mg of Tc
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Fig. 3 (ii). The effect of pK on human placental glucocerebrosidase 
activity.
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as the only added factor. PS, alone or in conjunction 
with Tc, had a marked inhibitory effect (Fig. 3(iii)).
Thus all further assays using this system contained 
0.5 mg Tc per assay.
b. The subsequent study was carried out in order to 
determine the validity of using the artificial substrate 
(4-MUGlc), with sodium taurocholate and/or phosphatidylserine, 
to assay the placental glucocerebrosidase activity.
The effect of pH, sodium taurocholate and phosphatidyl­
serine of placental enzyme was investigated with /MUGlc 
as substrate, according to the assay system described in 
Section 2.2.(vii)b. In the absence of either factor 
there was a rather broad profile with a slight peak at 
pH 6.0. The profile with PS as the added component (B) 
had a well-defined peak at pH 5.5 with a small increase in 
activity in comparison with the activity in profile A at 
the same pH. Tc as the added component also showed a small 
activation about above that of profile A, but with a
less well defined peak than profiles A or B. The presence 
of both factors together made the most significant 
difference to the enzyme activity. There was a marked 
increase in activity throughout the entire pH range in 
comparison with the activity shown in profiles A, B and C. 
The mean percentage activation was 100% at each point.
Optimum activity was between pH 5.0 and 5.5 with the 
highest activation of 150% at pH 5.0. Results are shown in 
Fig. 3(iv).
Fig. 3 (iv). The effect of pH, phosphatidylserine and sodium 
taurocholate on pure placental glucocerebroside:B-glucosidase 
activity.
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A in the absence of added factors (0— 0).
B in the presence of phosphatidylserine (15 yg per assay; ■---■).
C in the presence of sodium taurocholate (0.5 mg per assay ;^  ' ^).
D in the presence of both phosphatidylserine and sodium taurocholate
The results (mean ±-S.E.) are from a single experiment where the assays were 
performed in triplicate.
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(ii) Glucocerebrosidase and glucocerebroside :
glucosidase activities in normal and 'Gaucher* 
mouse liver.
a. When glucocerebrosidase activiiy ; of total mouse liver 
homogenate in normal and ’Gaucher’ (CBE treated) mouse was 
followed over a pH range from 3.0-7.5, the major peak of 
activity was at pH 4-. 0 in the normal liver. In the 
’Gaucher’ liver this peak was depressed by 84-^  compared 
with the normal. Since the natural substrate is specific 
for glucocerebrosidase alone, this profile was taken to 
represent mouse liver glucocerebrosidase activity, which as 
expected ms inhibited in the ’Gaucher’ liver (Fig. 3(v)). 
However, there was a second unexpected peak at pH 6.5-7.0 
with equal activity in both samples.
In order to study the properties of mouse liver 
glucocerebrosidase further, the behaviour of this enzyme in 
the separated particulate and soluble fractions of normal 
mouse liver was investigated. A pH versus activity profile 
of glucocerebrosidase in the two fractions showed that the 
major well-defined peak of activity for this enzyme in the 
particulate fraction was between 4.0 and 4.5, with a second 
peak of equal magnitude at pH 7.0. The activity profile 
for the soluble fraction although similar in shape to the 
particulate profile had its major peak at pH 7.0 with a much 
smaller peak at pH 4.5 of less than half the magnitude of 
the peak at 7.0. Therefore the additional hydrolytic 
activity at pH 7.0 was apparently present in both tissue
1 1 2
Fig. 3 (y). pH-activity profiles of normal and 'Gaucher' mouse 
hepatic glucocerebrosidase.
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The effect of pH on glucocerebrosidase activity meas’ured in normal 
mouse liver ( # ) and conduritol-B-enoxide-treated mouse liver
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i’he results are mean values (— S.E,) from two separate experiments where the assays 
were performed in duplicate.
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fractions and could not be differentiated on the basis of 
subcellular localisation. Glucocerebrosidase activity 
(at pH 4-.5) in the soluble fraction was only 10^ of the 
total activity present in the two fractions, and could be 
accounted for by the leakage of enzyme into this fraction 
from lysed lysosomes during the fractionation process 
(Fig. 3(vi)). The possibility that the second peak (at 
pH 7.0) was due to spontaneous hydrolysis of 
glucocerebroside (GO) at this pH was investigated by 
carrying out control incubations of the natural substrate 
at high and low pH for varying lengths of time, in the 
absence of enzyme. The incubations were stopped, the 
phases clarified and radioactivity estimated according to 
the usual procedure. If any hydrolysis had occurred this 
would have appeared in the aqueous upper phase, and been 
detected as radiolabelled glucose. No evidence for 
spontaneous hydrolysis of glucocerebroside under these 
conditions was found, and the identity of the second peak 
(at pH 7.0) remained unresolved.
b. Phosphatidylserine and sodium taurocholate are both 
factors which are thought to activate ’acid’ p-glucosidase 
and inhibit the ’neutral’ p-glucosidase (see above). These 
parameters were manipulated to achieve the best conditions 
for assaying glucocerebroside:p-glucosidase in whole mouse 
liver homogenate with the artificial substrate 
4--methylumbelliferyl-p-D-glucopyranoside (4-MUGlc) .
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Firr. 3 (vi). Glucocerebrosidase activity in the particulate and 
cytosolic fractions of mouse liver homogenates.
2-5
c
1*5
0*5
3 54 6 7
pH
A  A  the particulate (1 0 0 , 0 0 0  x g) fraction
^  A  the cytosolic (1 0 0 , 0 0 0  x g) supernatant
The results are from two experiments (mean i S.E.) where the assays were performed
in triplicate.
11
The effect of the added factors on the separated tissue 
fractions were investigated. First, particulate and soluble 
enzyme fractions were prepared as described in Section
3.3.(i) and used with the artificial substrate assay system 
(Section 2.2. (vii)b) .in a pH range from 4-.0 to 6.5 in the 
presence and absence of Tc and PS (Fig. 3(vii)). With no 
added components (A), broad pH profiles were obtained from 
both fractions. However the pH for optimum activity in the 
particulate fraction was between 4-.5 and 5.5 with a slight 
peak at 5.0, while the soluble fraction had a sharper peak 
at pH 5.5. When PS was the only additional component, 
contrary to other reports (see Section 3.2. (i)), no 
inhibition of the soluble enzyme or stimulation of the 
particulate enzyme was observed. Tc as the added component 
caused a noticeable inhibition of the soluble enzyme 
(approximately 4-3^  less activity than in the other two 
cases). It also had a pronounced effect on the activity 
in the particulate fraction. There was a significant 
change in the pH optimum to an extremely well defined peak 
at the more acidic pH of 4-.5 together with a small increase 
in activity. In the presence of both factors this shift in 
the pH optimum of the 'acid' p-glucosidase became more 
pronounced. The change in the pH optimum of the system was 
brought about by the marked inhibition of p-glucosidase 
activity at pH values above 4-.5. For example the 
particulate enzyme activity at pH 5.0 in profile D (+Tc 
+PS) in comparison with the activity present in profiles A 
and B was considerably inhibited (approximately 33#).
Results are shown in Fig. 3(vii).
l i e
Fig. 3 (vii). pH-activity profiles of glucocerebrosidase:B-glucosidase 
in the particulate and soluble fractions of mouse liver homogenate.
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The effect of added factors on glucocerebroside:3-glucosidase activity 
in the particulate ( ▲  ) and cytosolic ( A  ) fractions of mouse
liver.
A in the absence of other factors 
B in the presence of phosphatidylserine (15 yg)
C in the presence of taurocholate (1.5 mg)
D in the presence of phosphatidylserine and taurocholate.
The results (mean ± S.E.) are from one experiment where the estimations were
performed in triplicate.
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When the ratios of the ^-glucosidase activities in the 
two fractions at pH U,5 were considered, while in the 
absence of added factors the value was 1.6 (particulate to 
soluble), in the presence of Tc alone it had increased to 
2.17 (by a small increase in activity of the particulate 
enzyme and a considerable decrease in activity of the 
soluble enzyme), and with PS and Tc present the 
p-glucosidase activity in the particulate fraction was 2.4- 
fold greater than that of the f-glucosidase in the soluble 
fraction at the same pH. Thus the differentiation between 
the two isoenzymes appeared greatest in the presence of 
PS and Tc at pH 4-.5, when the particulate 'acid’ 
p-glucosidase activity was expressed preferentially. The 
relative distribution of p-glucosidase in the two mouse 
liver fractions is compared in Table 3(iii). Considering 
the p-glucosidase activity in the particulate and soluble 
fractions, it is apparent from these results that the 
distribution of p-glucosidase between the two fractions 
changes from 58.7% in the particulate fraction and 4-1.2% 
in the soluble fraction when assayed in the absence of any 
factors (Le. under non-specific conditions), to 70% and 29% 
(particulate and soluble respectively) in the presence of 
PS and Tc. Therefore it appears that the presence of these 
factors and the appropriate choice of pH for the system, 
enables the otherwise non-specific assay to be used to 
measure the 'acid' B-glucosidase enzyme preferentially.
When these parameters were applied to the whole mouse 
liver homogenate, the results obtained were less well
1 1 8
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defined (Fig. 3(viii)). All the profiles were similar in 
shape with a well defined peak at pH 5.0 except in the 
absence of PS and Tc where there was a broad optimum 
between 1.5 and 5.5. There was also a fairly well defined 
shoulder of activity between pH 5.5 and 6.0 in all cases. 
The presence of PS alone had the effect of generally 
inhibiting the activity of the entire profile. Tc alone, 
as well as inhibiting the overall activity rather more 
than PS alone, had a pronounced inhibitory effect of the 
shoulder of activity between pH 5.5-6.0, thus making the 
pH optimum well defined at 5.0. However, in the presence 
of both Tc and PS, the activity was inhibited throughout 
the pH range. Thus it was apparent that differentiation 
between the isoenzymes and preferential expression of 
glucocerebroside:^ -glucosidase in a crude tissue homogenate 
could not be achieved by extending the criteria found to be 
effective with the separated fractions. The pH optimum was 
at 5.0 instead of 1.5 and the effect of the added factors 
less obvious than before. It appeared that the inclusion 
of sodium taurocholate as the only added factor in the 
assay for glucocerebroside:p-glucosidase in total mouse 
tissue homogenate was the most suitable. It defined the 
pH optimum at a more acid pH (pH 5.0) by inhibiting 
p-glucosidase activity expressed at higher pHs (the soluble 
neutral p-glucosidase). Since this was similar to its 
effect on the separated fractions (inhibiting activity 
expressed in the soluble fraction and accentuating
120
Fig. 3 (viii). The effect of pH, phosphatidylserine and sodium 
taurocholate on glucocerebroside:B-glucosidase activity in mouse 
liver homogenate,
CD
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pH
O  in the absence of added factors
■  in the presence of phosphatidylserine (15 yg per assay)
4  in the presence of sodium taurocholate (0.5 mg per assay)
0  in the presence of both factors.
The results (mean t. S.E.) are from separate experiments where the assays v/eie 
perfoimed in triplicate. _
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the activity at acid pH in the particulate fraction), 
glucocerebroside:p“glucosidase in a crude tissue homogenate 
appeared to be best expressed at pH 5.0 with 0.5 mg sodium 
taurocholate when using the artificial substrate, 4-MUGlc.
3.5. Discussion.
One of the main objectives of the studies described 
here, was to differentiate from other enzyme activities in 
mouse liver that enzyme which is specifically responsible
f
for hydrolysing and thus preventing the accumulation of 
glucocerebroside, and to establish optimum conditions for 
measuring the activity of this enzyme. Human placental 
glucocerebrosidase is obtainable in high purity and using 
the assay conditions developed here characteristics of 
this pure enzyme compared well with those of a 
glucocerebrosidase in whole and partially purified mouse 
liver homogenate. The sharp peak at pH 4-.0 for optimal 
activity of pure placental enzyme was also present in the 
liver homogenate, from a normal mouse. The liver enzyme 
activity was inhibited by 84-^  after treatment of the mouse 
with CBE, in agreement with the large inhibitory effect of 
CBE on placental enzyme Jm  vitro. Since mouse liver was 
shown to be capable of hydrolysing the glucocerebroside of 
human Gaucher spleen there seems to be no species 
specificity of the mouse enzyme for this human substrate. 
The acid pH optimum for the liver enzyme was expected since 
this enzyme is associated with the acid milieu of lysosomes 
However, this is in contrast to the conditions used by
2  2
PentcheV et al. (1973), and Dale and Beutler (1976), where 
pure human placental glucocerebrosidase is assayed at pH 
6.4- and 6.0 respectively.
An unexpected finding in both normal and ’Gaucher’ 
mouse livers was the presence of a second major peak of 
glucocerebrosidase activity at pH 7.0, not found with the 
pure placental enzyme. Soluble ’neutral’ p-glucosidase is 
believed to be unable to hydrolyse glucocerebroside, and 
there is no known enzyme other than ^-glucocerebrosidase 
which can hydroi^se this substrate. The possibility of 
spontaneous hydrolysis of the glucocerebroside at this pH 
was eliminated (see above). The fact that the peak from 
the ’Gaucher’ liver fraction was equal in magnitude to 
that of normal liver, indicated that the component 
responsible for this hydrolysis was not affected by the 
administered CBE. In order to investigate the possible 
location of this second ”enzyme” capable of hydrolysing 
glucocerebroside, glucocerebrosidase activity in the 
separated particulate and soluble fractions was determined. 
In the 100,000 x g supernatant (ie the soluble fraction), 
the second peak was the major peak; in the particulate 
fraction, the peaks at 4-.5 and 7.0 were of equal magnitude.
This raises the problem of establishing the identities 
of the two enzymes capable of hydrolysing glucocerebroside 
in mouse liver. Since the hydrolysis at pH 4-. 0 corresponds 
with the pH optimum obtained with the pure placental
2 3
glucocerebrosidase preparation and the activity of this peak 
was inhibited in the ’Gaucher’ mouse liver, it appears that 
the GC hydrolysis at this pH in mouse liver is due to the 
glucocerebrosidase enzyme involved in Gaucher’s disease.
A further point in favour of this theory is its cellular 
location (ie predominantly in the particulate fraction).
The activity in the soluble fraction at the acid pH 
represents only 11.4-^ of the total activity in both 
fractions at this pH. This corresponds well with the value 
obtained for lysosomal lysis during fractionation (10-14%), 
so that this small peak of activity in the soluble fraction 
at pH 4.5 could well be due to leakage of lysosomal enzyme 
into the cytosol. This suggests that the hydrolysis at 
pH 4.0 in mouse liver is by an enzyme which is membrane 
bound and possibly lysosomal in location. However the 
second peak of activity at pH 7.0 is nearly 30^ of the total 
activity at this pH (in both fractions) and cannot be 
wholly accounted for by lysosomal leakage.
The identity of the hydrolytic activity represented by 
the second peak remains obscure. It is apparently present 
in both soluble and particulate fractions and if enzymatic 
in origin is unaffected by CBE. Since separation of these 
fractions is only partial it is possible that this peak 
represents glucocerebrosidase activity from another cell 
compartment which is active under nearly neutral conditions, 
and not fully removed by this fractionation procedure. 
Microfractionation and enzyme analysis of cells by the
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sucrose density gradient of Peters (l98l) which achieves 
very complete fractionation of subcellular organelles may 
help to resolve this point.
Peters et al. (1976) found similar pH optima for 
glucocerebroside:^ -glucosidase and glucocerebrosidase 
activities in human leukocytes liver and spleen 
respectively in the presence of sodium taurocholate.
However, in this study a comparison of these enzymes in 
human placenta showed no similarity in terms of pH.
Whilst glucocerebrosidase had a pH optimum of 4.0, the 
glucocerebroside:p-glucosidase pH optimum was between 5.0 
and 5.5. The activities of the glucocerebrosidase and 
glucocerebroside:p-glucosidase in the particulate fraction 
of mouse liver on the other hand were quite comparable in 
terms of their pH optima, both enzymes being most active in 
the range of pH 4.0-4.5.
Both mouse liver and human placenta had a similar pH 
for optimal activity of the glucocerebrosidase involved in 
Gaucher*s disease. Glucocerebroside:p-glucosidase 
activities in the two tissues also showed similar pH 
optima at pH 5.0 (between pH 5.0 and 5.5 in the case of 
placental enzyme). However, the responses of ’acid’ 
p-glucosidase activity in mouse liver and human placenta to 
PS and Tc were totally different, the placental enzyme being 
markedly activated and the liver enzyme inhibited. The 
activation on placental enzyme by the added factors can be
readily explained. It is quite likely that the highly 
purified human placental enzyme is lacking in co-factors 
normally present in the intact tissue and thus addition of 
factors such as PS and Tc which mimic the natural factors 
(Ho and O ’Brien, 1971), results in the marked observed 
activation.
Phosphatidylserine has been found to stimulate 
glucocerebroside:p-glucosidase activity in partially 
purified human liver extract (Peters et al., 1976), but 
in this study it had very little effect on the particulate 
mouse liver enzyme. Sodium taurocholate has been reported 
to markedly inhibit soluble p-glucosidase and activate 
particulate p-glucosidase activity. While the soluble 
p-glucosidase was found here to be inhibited, activation of 
the particulate enzyme was not seen. However in the 
presence of taurocholate, pronounced shifts in the pH for 
optimal activity of the particulate enzyme were observed 
enabling better differentiation between the particulate and 
soluble p-glucosidase isoenzymes. Therefore in contrast to 
other reports (Ho and Light, 1973; Peters et al., 1976) 
the usefulness of sodium taurocholate in assays using 
IMUGlc to evaluate glucocerebrosidase activity is in its 
ability to inhibit non-specific B-glucosidase rather than 
in the activation of ’acid’ If-glucosidase. However, sodium 
taurocholate stimulates the natural glucocerebrosidase 
activity.
Thus, the inclusion of sodium taurocholate in assays 
using 4--methylumbelliferyl-p-D-glucopyranoside as substrate
12G
permits the specific measurement of glucocerebroside: 
p-glucosidase activity because it inhibits the f-glucosidase 
not involved in Gaucher’s disease and stimulates the 
relevant glucocerebrosidase activity.
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CHAPTER U
EVALUATION OF A SUITABLE LIPOSOME CARRIER
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1.1. IntT'oductlon. '
Stephens et al. (1978), showed that chronic administration 
of conduritol-B-epoxide (CBE) into mice led to the inhibition 
of glucocerebroside:p-glucosidase activity in a variety of 
tissues. However, accumulation of the substrate, 
glucocerebroside, in these tissues was only modest and there 
was none of the enlargement of organs such as the liver and 
spleen that is usually associated with Gaucher’s disease.
This lack of success can be attributed to the loss of 
significant amounts of the administered inhibitor due to 
excretion into the urine or, to its inability to enter 
tissue cells efficiently. Therefore, it was reasoned that 
injection of CBE incorporated inside liposomes might help 
to direct most of the inhibitor to tie liver and spleen, the 
tissues mainly responsible for the removal of this carrier 
from the circulation (see Chapter 1).
As discussed in Chapter 1, parameters such as liposomal 
lipid composition and size can be manipulated to suit the 
particular requirements of the system. In this case, large 
MLVs were the obvious choice since direct targeting of the 
inhibitor to the liver and spleen was desired. However, 
only low entrapment values have been obtained with these 
preparations, due to the relatively low volume of entrapped 
aqueous phase per mole of lipid. This is because in MLVs 
most of the lipid participates in the internal lamellae 
and the close apposition of the adjacent concentric 
bilayers restricts the volume of the internal water space.
It was demonstrated by Sessa and Weissmann (1970), that
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increasing the net charge on the lipids, increased the 
volume of the aqueous -spaces and hence the level of 
entrapment of material within them. The principle is 
that similarly charged phospholipid polar head groups of 
the adjacent lipid layers repel each other, thereby 
increasing the volume of the aqueous spaces. In small 
unilamellar vesicles (SUV), which have a single compartment, 
the ratio of the surface area to encapsulated volume is so 
large that only a small aqueous volume per mole of lipid 
can be incorporated.
Several techniques have been developed to circumvent 
the problems of low entrapment. An ether infusion technique 
reported by Deamer and Bangham (1976), produced large 
unilamellar vesicles with high captured volume per mole of 
lipid. Other techniques for preparing large volume vesicles 
either in the presence (Deamer and Bangham, 1976) or 
absence (Papahadjapoulos et al., 1975) of organic solvent 
have used specialised conditions or were restricted to a 
single phospholipid type. However, the entrapment values 
were still relatively low. More recently, Szoka and 
Papahadjapoulos (1978) reported the development of a 
reverse phase evaporation technique for making large 
unilamellar and oligolamellar vesicles which appears to 
overcome this limitation. These liposomes have large 
internal aquous spaces and enable high entrapment of water 
soluble materials.
A number of methods are available for separation of 
liposomes and their contents from the non-entapped solutes.
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The physical characteristics of both liposomes and solute 
must be taken into consideration when deciding on a 
suitable method. Small sonicated liposomes may be separated 
by gel filtration (Huang, 1969) or by ultracentrifugation 
(Barenholtz et al., 1977). Larger liposomes may not 
penetrate a gel column, but MLVs sediment with high speed 
centrifugation and REVs can often be separated from 
unentrapped material by bench centrifugation (600 x g ).
Small liposomes tend to be lost to the supernatant when an 
MLV preparation is centrifuged and gel filtration has the 
inherent disadvantage that some dilution of the liposomes 
will invariably occur. When the solute has a low molecular 
weight, dialysis may be used, but for macromolecules such 
as proteins, this is not possible. Thus all of these 
methods have their limitations.
4-.2. Liposome Entrapment' of Conduritol-B-Epoxide and Glucose.
(i) Conventional multilamellar vesicles (MLV).
Negatively charged MLVs composed of egg phosphatidylcholine 
(PC):cholesterol(Choi)rdicetyl phosphate (DP) (molar ratio, 
7:7:2) and egg phosphatidylcholine : cholesterol:phosphatidic 
acid (p a ) (7:7:2), were prepared according to the 
conventional technique described in Section 2.2.(i).
The aqueous phase contained 10 mg CBE and 0.5 x 10^ dpm 
of ^H-labelled CBE (^H-CBE) in 2 ml of PBS. Entrapment was 
calculated by estimation of radioactivity (by the method 
described in Section 2.2.(vii)f) associated with the 
liposome fractions and expressed as a percentage of the 
total used. A sepharose CL-6B column (l cm x 25 cm) was
3 1
prepared and equilibrated with PBS, The liposome 
preparations containing CBE were added to the columns 
and eluted with PBS. 1 ml fractions were collected and 
assayed for radioactivity. The elution profiles are shown 
in Fig. 4(i). Entrapments of 12.9^ and 7.83^ were 
obtained for PC:Chol:DP and PC:Chol:PA respectively.
For a passively entrapped water soluble molecule these 
values were high, however, there was extensive trailing of 
the liposomes from fraction 1-10 so that dilution of the 
liposomes was a problem. Although entrapment values 
obtained with PC:Chol:PA liposomes were good, the preparation 
precipitated and so only MLVs composed of PC:Chol:DP (7:7:2) 
were used in subsequent studies. In an attempt to 
increase the concentration of the liposome preparation, 
the fractions collected from the column were pooled and 
centrifuged at 92,000 x g for one hour. A final entrapment 
of 1.11^ was achieved by this method. Due to the 
inadequacy of the overall level of entrapment by this 
procedure it was decided to omit the gel filtration stage 
and try direct centrifugation. A liposome preparation 
(PC:Chol:DP) prepared as above was centrifuged directly at
92,000 X g for one hour. The pelleted liposomes were 
resuspended in PBS and then re-centrifuged in order to 
ensure complete removal of unentrapped material.
While 11.2% of the original counts were associated with 
the first pellet, after the second centrifugation a final 
entrapment of 2.53% was obtained. The high initial 
entrapment value was probably due mainly to incomplete
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Fig. 4 (i). Separation of liposomes (MLV) containing CEE from 
unentrapped CBE by gel filtration on Sepharose CL-6 E columns.
A phosphatidylcholine : cholesterol : phosphatidic acid
B phosphatidylcholine : cholesterol : dicetyl phosphate
The results are derived from a single experiment
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removal of free material associated with the liposomes, 
but breakdown of liposomes was probably a contributory 
factor since ultracentrifuging is a relatively harsh 
procedure.
In order to avoid a second centrifugation but still 
remove most of the unentrapped material, the re-suspended 
liposomes were dialysed overnight against 1 1 PBS at 4-° C. 
Final entrapment with this method was 2,1%, Direct 
dialysis of the liposome preparation was also tried with 
several changes of dialysis buffer (over 2 days). The 
entrapment of the inhibitor in the final preparation was 
2,55%, Thus, while the technique of gel filtration gave 
high apparent entrapment values, dilution was a problem. 
Direct centrifugation gave incomplete separation and a 
second centrifugation resulted in very low entrapment. 
However, the much milder method of dialysis did not improve 
the entrapment values. A level of encapsulation of 2.0% 
for a small water soluble molecule such as CBE was not 
unreasonable for conventional liposomes.
(ii) Reverse evaporation vesicles (REV).
The reverse phase evaporation technique of Szoka and 
Papahadjapoulos (1978) was used according to the method 
described in Section 2.2.(i)b in an attempt to increase 
the entrapment values of CBE. This technique is a 
relatively new development in the liposome field, and 
factors which affect the nature of the final REVs are not 
yet fully understood. Liposomal lipid compositions were
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varied and conditions of preparation manipulated in an 
attempt to maximise entrapment and stability. In order 
to conserve CBE for animal work, glucose was used instead 
of CBE in the preliminary entrapment studies as it was 
similar in structure and size to CBE (see Chapter 5).
Glucose was assayed according to the method of Bernt and 
Lachenicht (1974-) described in Section 2.2.(vii)c. 1%
triton X-100 was used to dissolve the liposomal membrane 
in order to release the contents and make it available for 
assay.
REV liposomes composed of PCiChol (l:l) containing 
25 mg glucose in 10 fold dilution of PBS were made and 
dialysed overnight against PBS. Entrapment was l6% with 
a latency of 76,5%. It was possible that the low latency 
value was due to unentrapped solute being adsorbed to the 
outside of the liposomes rather than due to entrapped
leaking out. When a control incubation of 'empty' 
liposomes (buffer loaded) were incubated with free glucose, 
even after extensive dialysis over 2 days, 5% of the glucose 
remained associated with the liposomes. When the liposomes 
containing entrapped glucose were centrifuged directly at
92,000 X g for one hour, the apparent entrapment was 15%, 
with only 6l% latency. It has been reported that that 
formation of REVs is influenced by the ionic strength of 
the aqueous phase and optimum entrapment requires a low 
ionic strength. In an attempt to improve the efficiency 
of encapsulation a 15 fold dilution of PBS was used with 
glucose as solute and the same lipid composition as before. 
The average entrapment (for 2 preparations) was 22%, with
13 r;
92% latency after extensive dialysis. Since solute 
encapsulation was improved substantially in this case 
this dilution of PBS was used as the aqueous medium for 
all further work with REVs, together with extensive 
dialysis as the method of separating free material. The 
lipid composition was manipulated in an attempt to improve 
entrapment further. Negatively charged liposomes were 
made using various lipid compositions and phosphatidic 
acid. As the results in Table 4-(i) show, introduction of 
a negative charge to the liposomes gave higher levels of 
glucose incorporation. 33.2% entrapment was obtained with 
PC:Chol:PA (4:5:l) liposomes. Latency values were also 
improved. Since the reverse phase evaporation technique 
gave such a substantial improvement in terms of entrapment 
of solute, entrapment of CBE in REVs was investigated.
PCrChol (l:l) liposomes were prepared containing 10 mg 
CBE and 0.5 x 10^ dpm ^H-CBE in 15 fold diluted PBS and 
dialysed extensively for 24- h at 4-*^ C against the same 
buffer. Average entrapment was 14-^ . When the preparation 
was centrifuged at 100,000 x g for 30 min approximately 
90% of the CBE remained entrapped, indicating that these 
liposomes were stable to centrifugation. Entrapment of 
CBE by neutral SMrChol (l:l) REVs and negatively charged 
REVs composed of PC:Chol:PA and SM:Chol:PA (4-:5:l) was 
also investigated. Results were given in Table 4-(i)«
From these results it appeared that the presence of a 
negative charge improved the entrapment considerably for
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both PC and SM containing liposomes. Levels of entrapment 
in REVs were substantially higher than in MLVs of similar 
lipid composition.
4-.3. Stability of Conduritol-B-Epoxide' Containing Liposomes
in' V'itr o .'
The concept of stability of liposomes may be considered 
either in ferms of reduced permeability and therefore less 
leakage of entrapped material from the liposomal membrane, 
or in terms of increased resistance to breakdown of the 
liposomal membrane and thus its enhanced integrity. Both 
of these aspects of liposome stability were considered in 
the following investigations. There is virtually no 
information available concerning the relative stability of 
REVs in body fluids, therefore, the ability of REVs and MLVs 
to retain their entrapped CBE during incubation was 
investigated and compared.
(i) Stability of MLVs.
Fresh mouse plasma was obtained by exsanguination of 
TO mice via the brachial vein. The blood was collected in 
heparinised tubes and centrifuged at 600 x g for 5 min.
The pelleted red blood cells were discarded and the plasma 
used.
In a typical experiment, 0.3 ml MLVs composed of 
PC:Chol:DP (7:7:2) and containing labelled and unlabelled 
CBE were incubated with 0.7 ml of plasma or PBS. A 0.5 ml 
aliquot was taken at the time of mixing (0 min), and after
4-5 min of incubation at 37° C and fractionated on a column
138
of sepharose CL-6B (l cm x 25 cm). This separated the 
intact liposomes from any free material. 1 ml fractions 
of column eluate were collected and taken for radioactive 
analysis. Results are shown in Fig. 4-(ii). When MLVs 
were incubated with PBS, intact liposomes were eluted in 
the first two fractions and the free CBE in fractions
5-8. However, in the MLV/plasma incubation, a third peak 
was present between the liposome peak and the free peak.
It has been shown that plasma protein factors such as 
HDLs and albumin are eluted in the region of this extra 
peak, and it appears that free CBE associates with these 
proteins, thus accounting for the presence of the third 
peak. When calculating entrapment the counts making up 
this extra peak were considered as free, released CBE, and 
added to the true free CBE peak.
(ii) Stability of REVs.
Investigation of the stability of REVs using the 
above system presented problems since the REVs would not 
penetrate the sepharose columns. Therefore, dialysis was 
used as the method of separating released CBE from CBE 
entrapped in liposomes. The following procedure was used 
in a typical experiment. 0.5 ml of fresh mouse plasma or 
0.5 ml of PBS was mixed with 0.1 ml of liposomes containing 
labelled and unlabelled CBE and incubated at 37° C.
Aliquots (0.1 ml) were removed from the incubation mixtures 
at time intervals, diluted with 0.3 ml PBS and dialysed 
exhaustively (for 24- h ) against 5 1- of PBS at 4-° C. After
3
dialysis the contents of the bag were assayed for H.
139
rao
B
Üi
oc
c
•H
Oo
(H
c
c0
•H
1
-püu
■p
c0
1
aeu
O
ü
a«HH
Cû
00
O
CN
CD
C
o
o
CD
U_
(N
CN 00
W
•H
(383-Hg) Ludo AjjAipBojpBy
W
C
C «H
•H 0
E ü
LO enCD
1
A PI
O o(H
0
O m
2CO 0
P:
■p ex
cd 0en
G c
— o
cd •c
E 0CQ p:Cfl exiH 0
&
fe
0 oCOp»D 0O EE OA
A P0 ü
03
_< C0
en
fpCL
C ••H
•a
ü C
•p •HCS E
3 LO
ü V
C•H 03
d
0 0A
g)
CL
C o
iH
O
e:O •H
Eo
CL O
«H
0 0
TJ d0 0copcex4SE
O 0
ü A0œ
0
E WO 0m rH
o P.ex E
•H 0P! en
-P
<D
a
•H
u
0
&
0
0 
I—I
Ü
•H
CO
cd
a
o
p
«H
Tl
0
>
•H
A
0
ij
0
A
0
CQ
-P
I—I
en
0
A
0
X!
54
140
Control mixtures consisting of 0.5 ml plasma or PBS with 
0.1 ml free labelled and unlabelled CBE (unentrapped), or 
0.1 ml 'empty' (buffer loaded liposomes with free H-CBE and 
unlabelled CBE were also treated as above. The results of 
these incubations are shown in Figs. l(iii) and l(iv).
Neutral liposomes composed of PCrChol (l:l) and SMrChol (l:l) 
and negatively charged liposomes of PC:Chol:PA (1:5:1) and 
SM:Chol:PA (1:5:1) were used.
These experiments were designed to indicate the type 
of liposome (in terms of lipid composition) which retained 
its encapsulated CBE most effectively in the presence of 
plasma. From these results it appeared that liposomes 
composed of SM showed better retention of entrapped drug 
compared to PC liposomes, and the neutral SMrChol (irl) 
were less permeable than the negatively charged SM 
liposomes. Almost 50^ of the entrapped CBE remained 
encapsulated after incubation with plasma for 1 h. The REV 
liposomes were also considerably more stable under these 
in' 'Vitro 'conditions than the MLV liposomes after 15 min 
incubation. In view of this and the low entrapment of CBE 
obtained with MLV liposomes, they were considered 
unsuitable for use in this system and all further work was 
directed towards the use of REVs with CBE.
1.1. Liposomal Retention of Conduritol-B-Epoxide jni vivo
The purpose of these experiments was to establish the 
type of liposome most stable in the circulation and 
therefore most capable of transporting liposomally 
entrapped CBE to the liver and spleen. The advantage (if
14 1
Fig, 4 (iii). CBE retention by liposomes in mouse plasma,
40
o
CD
O
Incubation time (min)
'^ K-CBE containing liposomes composed of pC;Choi;PA (A) or SI'i:Chol:?A (p) 
were incubated in the presence of mouse plasma ( O ) or PBS ( A  ). 
The results presented are mean values from two experiments.
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Fiq. 4 (iv). CBE retention by liposomes in mouse plasma.
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200
^H-CBE containing liposomes composed of PC: Choi (A) or Su : Choi (.■ ) 
were incubated in the presence of mouse plasma ( O ) or PBS ( A ). 
The results presented are mean values from two experiments.
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any) of administering liposomal CBE rather than free CBE 
was also investigated.
Balb/c mice were injected intravenously (0.2-0.25 ml) 
via the tail vein or intraperitoneally (0.3-0.35 ml) with 
free or liposomally entrapped CBE (0.15-0.25 mg and
c o
1.3 X 10 dpm H-CBE per mouse). Blood samples were 
collected in heparinised capillary tubes (25-50 pi) from 
the tail vein at time intervals, mixed with 1 ml PBS and 
centrifuged at 600 x g for 5 min. This sedimented the blood 
cells and the supernatant containing the plasma was then 
assayed for radioactivity by the method described in 
Section 2.2.(vii). Free CBE and CBE entrapped in liposomes 
composed of PCiChol (l:l) and SMiChol (l:l) were used in 
these experiments.
From these results (FigSjl(v) and l(vi)), it was 
apparent that liposomally administered CBE remained longer in 
the circulation than the free CBE. When entrapped in SM 
liposomes and given i.v., 35^ of the CBE was retained in the 
circulation and 15^ and G% respectively when entrapped in PC 
liposomes or given in the free form, one hour after injection 
Intraperitoneal (i.p.) administration of these liposomes 
(SMrChol) also showed an extended half life of liposomal 
CBE in the circulation in comparison with free (Fig. 4(vi)). 
Liposomes administered i.p., reached their highest levels 
in the circulation approximately 2 h after injection with 
a slow rate of clearance from the circulation thereafter.
Localisation of CBE in the liver and spleen and 
kidneys at the time of termination (5 h after injection)
was also examined. The tissues were processed for radio-
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Fig. 4 (y). Clearance of CBE from the circulation after i.v, injection.
Level of CBE in blood after i .v . in jection
5 0 -
3 52 40 6
Tim e after in je c tio n (tio u rs )
Mice (5 in each group) were injected intravenously vrith free H-CBE 
( O  )i free CBE mixed with 'empty' SM;Chol liposomes ( @ ),
^H-CBE entrapped in liposomes composed of SM;Chol ( □  ) or PC:Choi
( A  ), Results (mean ± S.S.) are % of the dose recovered in total 
mouse blood , and are from five replicates vrithin the same experiment in each 
group.
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Fig. 4 (vi). Appearance and clearance of CBE from the mouse 
circulation after i.p. injection.
Level of CBE in blood after i.p. injection
20 n
10-
>
o03O
■O
03
O
CD
c
o
0.5 -J
0 1 2 3 4
Time after injection (hours
• Mice were injected with H-CBE free ( O  ), entrapped in liposomes 
composed of PCiChol ( A  ) or SM;Chol ( □  ). Results (mean t S.E.)
are % of the dose recovered in total mouse blood ( 2  ml).
Six replicates were used in each group within the same experiment.
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active estimation by the method of Lindsay et al. (1969) 
as described in Section 2.2.(iv). Table 4(ii) shows the 
extent of tissue localisation of CBE administered free and 
liposomally entrapped, 5 h after i.v. and i.p. injection.
The amount of radioactivity detectable in the tissues of 
animals injected with free CBE was negligible. These 
oligolamellar vesicles appeared to localise very 
efficiently in the liver and spleen, with those composed 
of SM:Chol (l:l) showing the best localisation in these 
organs.
4-. 5. in Vitro Studies on Liposomal Glucocerebroside : pj^Glucosidase
(i) Entrapment.
Glucocerebroside : ;p-glucosidase which _in situ is tightly 
bound to the lysosomal membrane, is a largely hydrophobic 
glycoprotein composed of four subunits, each with a molecular 
weight of about 60,000 Daltons. This enzyme is used in 
replacement therapy trials of Gaucher’s disease (Beutler 
et al., 1977; Brady et al., 1974-; Belchetz et al., 1977).
In order to protect the enzyme from the deleterious effects 
of circulating hydrolases it has been entrapped in a
variety of carriers prior to its vivo administration in
these trials (see Chapter 1). MLVs were used by
Gregoriadis et al. (1979) to entrap this enzyme in a
long-term clinical trial of Gaucher*s disease. Criteria 
for the entrapment of large macromolecules such as proteins, 
are governed largely by the physical properties of the 
protein. Due to its hydrophobicity, association with the 
lipid phase of liposomes instead of entrapment within the 
internal aqueous spaces would be expected as a dominant
14
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feature. Liposomes of varying lipid compositions were used 
to investigate entrapment of pure placental glucocerebroside: 
Ç-glucosidase.
Enzyme activity was assayed using k mM 4-MUGlc 
according to the conditions for assay established in 
Chapter 3. The liposomal membranes were broken down in 
order to release the entrapped enzyme within, using 1% 
triton X-100 in the assay system. Since detergents are 
known to variously activate or inhibit this enzyme (see 
Chapter 3), the effect of triton X-100 on the activity of 
glucocerebroside:p-glucosidase was studied. Triton 
concentrations in a range from 0.1-1.0% appeared to increase 
enzyme activity by approximately 22^ compared to the activity 
present in the absence of detergent. At a concentration 
of \% triton X-100 activation was 20^ (tl.2^) and this 
effect was taken into account when assaying for p-glucosidase 
activity in the presence of detergent.
MLVs and REVs composed of PCrChol (l:l), PCrCholrPA 
(4:5:1), and REVs of SMrChol (l:l) and SMrCholrPA (4:5:1) 
were used to study enzyme entrapment. Ultrasonic radiation 
has been shown to break down labile molecules such as 
enzymes, therefore, in order to minimise any degradative 
effects of sonication on the enzyme the MLV preparation was 
vigorously hand shaken until all the lipid was in suspension. 
After the preparation was left at room temperature for one 
hour, the liposomes were separated from non-entrapped 
enzyme by centrifuging at 97,000 x g for 30 min at 4° C.
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The liposome pellet was re-suspended in PBS and assayed 
for entrapment and latency. REVs composed of PC were 
prepared at 1° C and left to anneal at room temperature.
SM liposomes were made at 4-0° C and left to anneal at 
room temperature. Unentrapped protein was removed by 
bench centrifuging for 5 min at 600 x g . Substantially 
higher entrapment values were obtained with REVs than MLVs 
as the results in Table 4-(iii) show. SM liposomes were 
unsuitable for entrapment of enzyme as the high temperature 
required deactivated the enzyme. The latency values 
obtained with all the preparations were low suggesting the 
possibility of enzyme association with the lipid phase.
(ii) Stability.
The stability of the enzyme both entrapped and free in 
the presence of plasma was investigated. In a typical 
experiment 0.1 ml liposomes or 0.1 ml free enzyme plus
0.5 ml plasma or PBS were incubated at 37° C and a 50 jul 
aliquot taken for assay of ^-glucosidase in the presence 
and absence of triton X-100 at various time intervals. 
Control reaction mixtures of 0.1ml*empty’ (buffer loaded) 
liposomes with free enzyme in 0.5 ml plasma or buffer and 
free enzyme alone in plasma or buffer, were also incubated 
and assayed for p-glucosidase as above. The results of 
the behaviour of the free enzyme under the above conditions 
are shown in Fig. 4(vii). The enzyme on its own was very 
labile with over inactivation after only 15 min
incubation in PBS. However, plasma appeared to stabilise 
the enzyme substantially with over 10% of the activity 
still present after 2 h of incubation. At the final time
151
Fig, 4 (vil). Effect of plasma on free glucocerebroside:B-glucosidase,
100
90
o
>
o
CD
N
c  30
90 120 u
Incubation time (min)
6030 150 210180
Free incubated in mouse plasma or PBS, and free enz\nr.e mixed
with 'empty' liposomes (PC;Chol, 1:1), incubated in plasma or PBS,
A
□
0
o
enzyme in plasma
enzyme with 'empty' liposomes in plasma 
enz}TTie with 'empty' liposomes in PBS
enzyme in PBS
The results are mean values (t S.E.) from a single experiment in v/hich enzyme activity 
was assayed in triplicate at each time point.
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point (3è h), of the enzyme activity was detectable in
the enzyme/buffer incubation. The presence of lipid in 
the form of 'empty' liposomes appeared to protect the 
enzyme, since the rate of loss of activity with 'empty' 
liposomes, and buffer was less than seen with enzyme and 
buffer alone. In contrast, the stabilising effect of plasma 
on the enzyme observed above, was greatly reduced in the 
presence of 'empty' liposomes.
The results of liposome entrapped enzyme in plasma and 
buffer are shown in Fig. 4-(viii). It was apparent that the 
low latency values obtained in the preliminary entrapment 
studies was due to unentrapped enzyme associating with the 
outside of the liposomes as the profiles for inactivation 
of enzyme in these incubations showed two separate patterns 
in the presence and absence of triton. The activity 
assayed without triton (due to the unentrapped enzyme on the 
outside of the liposomes) showed a profile similar to that 
obtained with 'empty' liposomes and free enzyme seen above. 
It was apparent from these studies that enzyme entrapped 
within liposomes remained very stable (with only 20% 
breakdown after 4- h incubation in plasma).
Thus liposome entrapped enzyme used in enzyme 
replacement therapy would appear to be a considerable 
improvement on free enzyme administration on the basis of 
these results as the chances for an active enzyme reaching 
the relevant organs appear greatly increased.
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Fig. 4 (viii). Effect of plasma on liposome-entrapped glucocerebroside 
B-?lucosidase.
100
fO
o
O)
N
c
LU20
6030 90 150 180 210120
Incubation time (min)
Pure clucocerel'-rosido : p-glucosidase containing liposomes composed of 
pCrChol (1:1) incubated in the presence of mouse plasma or PBS.
▲  liposome-entrapped enz^ nme in plasma
# liposome-entrapped enzyme in PBS
■  liposome-associated enzyme in plasma
^  liposome-associated enz^ mie in PBS.
The results are mean values U  S.E.)from a single experinent in which enzyme activity 
was assayed in triplicate at each time point in the presence and absence of 
triton X-IQO.
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4-.6. in: fvivo Clearance of Liposomal and Free Enzyme.
Liposome preparations containing entrapped enzyme 
were prepared as above and an average dose of 4-0 units 
(nM.min ^ ) free or entrapped was injected via the tail 
vein into Balb/c mice. Blood samples were collected at 
time intervals in heparinised haematocrit tubes 
(approximately 25 ^l), plugged and centrifuged in a MSE 
haematocrit centrifuge for 2 min. The plasma separated in 
this way was assayed for glucocerebroside:p-glucosidase 
activity in the presence of triton X-100. Activity was 
calculated per ml of plasma after background endogenous 
plasma p-glucosidase activity had been subtracted.
Clearance profiles obtained shoiA^ d a slower rate of 
clearance of the liposomal enzyme compared with the free 
(Fig. 4-(ix)). No increased activity due to tissue 
localisation of administered enzyme was seen in either the 
liver or spleen. In order to investigate tissue localisation 
of administered enzyme, the endogenous tissue enzyme activity 
was inhibited by administering 0.4- mg free CBE per mouse 
24- h prior to the liposomal enzyme clearance and 
localisation study. The clearance profiles obtained were 
identical to those established above, however, no significant 
difference in the levels of tissue p-glucosidase was 
detected.
4-.7. Discussion.
When considering the efficacy of liposomes as carriers 
of useful molecules, high entrapment of solute and stability 
to circulating agents vivo, as well as efficient
Fig, 4 (ix)
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Mice were injected intras/e.i1ou$jy / vdth pure placental glucocerebroside: 
3-glucosidase free ( () ) or entrapped in liposomes composed of PC:Choi
( ® ) (molar ratio, 1:1),
The results (mean t S.E.)are presented as ^ of the dose recovered in total mouse 
blood(2ml). Four replicates were used per group in two separate experiments.
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localisation in the desired organs are fundamental 
considerations. These experiments were designed in order 
to find the liposomal lipid composition which optimised 
the above parameters with both conduritol-B-epoxide, a 
small molecular weight solute, and the enzyme
glucocerebroside:p-glucosidase which is a lacge macromolecule. 
The reverse phase evaporation vesicles (REV) of Szoka and 
Papahadjapoulos were clearly the liposomes of choice for 
entrapment of both materials. Although the entrapments 
obtained with these molecules were a great improvement 
on their entrapment with conventional MLVs, they were only 
modest in comparison with the entrapment values obtained 
by Szoka et al. for molecules with similar physical 
properties.
The presence of a negative charge improved the 
entrapment values of CBE considerably in both PC and SM 
liposomes. The use of glucose as a substitute for CBE 
enabled the latency of these liposome preparations to be 
evaluated and in agreement with other reports (Kirby et 
al., 1980a; Kirby and Gregoriadis, 1980), it appeared that 
the presence of cholesterol greatly decreased the 
permeability of these preparations. An important criterion 
with the liposome approach is that of lasting liposomal 
stability ^  vivo. A number of different factors can be 
envisaged to influence liposomal integrity after their 
introduction into the circulation.
Scherphof et al. (1978), have demonstrated that 
lecithin made liposomes are susceptible to deleterious
1 57
attack by a variety of plasma constituents. Albumin and 
high density lipoproteins (HDL) have been shown to take 
up and bind sufficient proportions of liposomal lecithins 
to cause severe damage to the liposomal integrity.
Although the loss of liposomal lecithin can be greatly 
reduced by incorporating cholesterol into these vesicles 
(Kirby et al., 1980b), it appeared that liposomes composed 
of sphingomyelin : cholesterol were considerably more stable 
under vitro conditions to deleterious effects by plasma 
factors than the lecithin preparations. The presence of 
a negative charge made both types of liposome less stable 
in plasma than the corresponding neutral preparations.
Studies on the retention time of liposomal CBE in the 
circulation showed that the use of liposomes composed of 
sphingomyelin : cholesterol (l:l) greatly increased the half 
life of the CBE vivo. This is in agreement with 
Gregoriadis and Senior (1980), where SUVs composed of 
sphingomyelin were shown to prolong the half life of 
circulating material up to l6 h. As observed with the 
in vitro studies, the liposomal lipid did not affect the 
clearance of CBE from the circulation since CBE mixed with 
'empty' SM liposomes had identical clearance profiles to 
that of free CBE alone.
Intraperitoneal administration of CBE in the respective 
liposomes showed SMiChol liposomes were maintained at a 
steady level (10# of injected dose) in the circulation 
over 5 h . While PCrChol liposomal CBE, and free CBE were
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ahost undetectable within the same period of time. On 
studying the effect of tissue localisation of administered 
inhibitor at 5 h, it was apparent that sphingomyelin 
liposomes were more efficient at delivering liposomal 
contents to the target organs than PC liposomes and that 
using a carrier was markedly better than free inhibitor 
in terms of tissue localisation.
A large glycoprotein such as glucocerebroside:p- 
glucosidase would be expected to associate with the 
hydrophobic regions of the liposomal membrane. The low 
latency values obtained with these liposome preparations 
were due to enzyme association on the outside of the 
liposomes and therefore, this appeared to confirm the 
predicted behaviour for the enzyme.
It was further substantiated in the vitro studies 
with liposomal enzyme where two distinct enzyme activity 
profiles were obtained in the absence and presence of 
triton. The stabilising effect of plasma on the free enzyme 
was most probably due to enzyme associating with plasma 
factors such as albumin or other plasma protein. Indeed, 
human serum albumin (HSA) is added to the pure placental 
glucocerebrosidase preparations in order to confer 
stability on the otherwise labile protein. It was likely 
that a similar protective effect was occuring in vivo, 
however, the mechanism of action by HSA on the enzyme is 
not known.
On the basis of the results obtained with the vitro 
incubation of free enzyme with plasma, it was likely that
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the apparent rapid clearance from the circulation of free 
enzyme observed after its administration vivo was due to 
breakdown of enzyme rather than due to clearance and 
localisation in the organs of the RES. The exogenous 
liposomal or free enzyme dose was only 25# with respect to 
normal liver p-glucosidase levels, but 60# with respect to 
CBE treated mouse liver enzyme levels. Whilst the lack of 
detectable exogenous enzyme after its injection in the 
livers of normal mice was to be expected, its absence in 
the CBE mice may be due to inhibition ^  situ due to the 
presence of uncatabolised active inhibitor in the tissue. 
Therefore, while the vitro work with the liposome 
entrapped enzyme was encouraging a more detailed 
investigation of its vivo effect is needed for proper 
evaluation of the efficacy of this approach in enzyme 
replacement therapy.
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CHAPTER 5 
STUDIES IN THE DEVELOPMENT 
OF A ’CAUCHER MOUSE’
1 6
5.1. Introduction'.^
As discussed in Chapter I, the physiological and 
biochemical basis of Caucher’s disease is still largely a 
matter of speculation. This and the limited understanding 
of how the cells and tissues of the RES respond to 
extraneous agents such as drugs, has been manifested in 
singularly disappointing results for the innumerable 
techniques and agents used in therapy for this and other 
related disorders. The development of an animal model of 
a sphingolipidosis should provide the opportunity to study 
the pathogenesis of lysosomal storage diseases in general. 
Several compounds have been found to inhibit calf brain 
and spleen Ç-glucosidase ^  vitro (Kanfer et al., 1975b ; 
Mumford et al., 1976). These include CBE, which had been 
shown to be a site specific, competitive inhibitor of 
non-mammalian p-glucosidase (Legler, 1966). This is a 
small (molecular weight 162), water soluble molecule 
structurally related to inositol, and due to its resemblance 
to glucose, behaves as a substrate analogue of p-glucosidase
Fig. 5(i)
Glucose CBE
Kanfer et al. (I975b)demonstrated the feasibility of 
producing an animal model of Caucher’s disease 
pharmacologically by jji vivo administration of CBE.
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The currently accepted biochemical features of the 
disease are elevated levels of tissue glucosylceramide 
(Suomi and Agranoff, 1965) in concert with decreased 
activity of the associated hydrolytic enzyme, 
glucocerebroside:B-glucosidase. By repeated intraperitoneal 
(i.p.) injection of the inhibitor into mice over a period of 
3-4- weeks, Kanfer et al. (I975b% were able to reproduce 
these symptoms in several organs. Stephens et al. (1978), 
found the response of brain tissue to the inhibitor to be 
rather more marked than that of liver or spleen, in terms 
of both substrate accumulation and enzyme depression.
Indeed it appeared that considerably larger doses of 
inhibitor were required to produce an equivalent response 
in the liver and spleen. All tissues reverted to normal 
within a short time, whereas in order to observe in full 
the changes characteristic of Gaucher’s disease, it would be 
necessary to maintain the Ç-glucosidase activity at a 
depressed level for several weeks.
In contrast to this, Stephens et al. (1981), reported 
that the localisation of CBE in brain and its concomittant 
enzyme inhibition was very low, whilst inhibition in liver 
was considerably higher than before. In view of these 
conflicting reports, the relative distribution of 
administered CBE in the relevant tissues was still in doubt. 
Since Gaucher’s disease type 1 is by far the most prevalent 
form of the disease, creation of an animal model without 
CNS involvement was considered more desirable than one with.
. 163
Large liposomes are known to localise preferentially 
in the tissues of the RES, especially the liver and spleen. 
They are also unable to cross the blood/brain barrier. 
Therefore, the inhibitor was administered entrapped in 
liposomes in an attempt to localise it specifically in the 
liver and spleen. This had the added advantage of reducing 
rapid renal clearance of administered drug. Results of 
preliminary investigations using liposome-entrapped 
inhibitor are given in Chapter 4-. Since reasonable 
entrapment levels of this material were achieved and 
preferential localisation of the liposomal inhibitor in 
the liver and spleen was demonstrated, attempts were made to 
produce a more durable animal model of Gaucher’s disease 
using liposome-entrapped rather than free CBE.
Since monitoring of the levels of glucocerebroside in 
mouse liver and spleen was an important aspect of this 
study, a reliable and reproducible method for its 
quantitative estimation was essential. Glucocerebroside 
is a neutral glycosylceramide, i,e. a glycolipid composed 
of N-acyl sphingosine and a single glucose unit (Fig. 5(ii)). 
Crude total lipid extracted from animal tissue according 
to the technique of Folch et al. (1957), generally contains 
all of the main classes of lipid including phospholipids, 
neutral lipids, glycolipids and steroids. Although several 
systems are available which permit the qualitative and 
quantitative analysis of these major classes from different 
animal tissues, the systematic analysis of the main types 
of glycolipid still presents problems. The methods are
164
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1 6
time consuming and unreliable, often requiring solvent 
extraction and partitioning, column chromatography, 
alkaline methanolysis, preparative TLC and subsequent 
measurement by either cOlorimetric, fluorimetric or glc 
methods. The measurement of total glycosylceramides was 
considered adequate for the present study since this would 
indicate any changes in concentration of glucocerebroside. 
Therefore various methods of achieving this end were 
explored.
5.2. Evaluation of a Suitable Method for Quantitative
Estimation of Glycosylceramide.
The initial approach involved TLC to isolate the 
glycosylceramides from the total tissue lipid, as a single 
spot which was then scraped from the plate and the amount 
of associated lipid determined by an acid dichromate 
reduction technique (Amenta, 196^). (See Chapter 2 for 
details.) Total crude Folch lipid extract of mouse liver 
homogenate (see Section 2.2.(iii)), was applied to silica 
gel plates and several TLC systems were investigated in an 
attempt to improve separation of the appropriate lipid 
classes (Amenta, 1964-; Svennerholm and Svennerholm, 1963; 
Skipski et al., 1967), but none enabled adequate resolution 
of the glycolipid from the other lipids present. In 
particular many phospholipids tend to move with the 
glycolipid and interfere with the separation of the 
latter (Skipski et al., 1967). Since glycosylceramide 
accounts for only a small proportion of total tissue lipid, 
overloading of the TLC plates was an inherent problem.
16C
Moreover the acid dichromate method used to quantitate the 
lipid was not sufficiently sensitive at the low glycolipid 
concentrations involved.
Suomi and Agranoff (1965), described a method which 
effectively separated phospholipids and neutral lipids from 
glycolipids, by column chromatography. A modification of 
this procedure was used to purify glycolipid from a crude 
tissue lipid extract. The lipid extract was first 
fractionated on a florisil column to remove phospholipids 
(Radin et al., 1955) and then on a silicic acid column to 
separate total glycosylceramides from the remaining lipids 
(see Section 2.2.(vi)). The resultant glycosylceramides 
were quantitatively determined using a fluorimetric assay 
which had been adapted to measure glycosphingolipids 
(Kisic and Rapport, 1974).
Whilst this fractionation procedure did not give complete 
recovery when pure glucocerebroside was used (between 70^ 
and 75% of the total lipid applied being recovered) the 
results were very reproducible. However when crude lipid 
extracts were fractionated the results were much less 
consistent and the method was eventually abandoned.
The final method investigated involved lipid 
fractionation by silicic acid chromatography followed by 
quantitative estimation by gas liquid chromatography (glc)
(see Section 2.2.(vii)). This was a modification of the 
method of Vance and Sweeley (1967). The crude lipid 
extract was applied to a silicic acid column as a chloroform
1 6 7
solution and neutral lipids were eluted from the column with 
chloroform. Total glycosylceramides were then eluted with 
acetone/methanol (9:1, v/v), any phospholipids present 
remaining adsorbed to the column (Section 2.2.(vi)).
Quantitative estimation of the isolated glycosyl­
ceramides was based on the determination of their carbohydrate 
contents, in particular, their glucose content. The 
olLgosaccaride portions of these compounds were cleaved 
into their individual monosaccharide units by methanolysis, 
and the resulting methyl glycosides were in turn converted 
to volatile trimethylsilyl derivatives in which form they 
were measured by glc. The resulting glucose content was 
quantitated using mannitol as the internal standard (see 
Section 2.2.(vii)d). Since no attempt was made to 
differentiate between glucocerebroside (glucosylceramide) 
and other glycosylceramides, which might have one or more 
glucose moieties, results were expressed here as glucose 
equivalents rather than as absolute units of glycolipid.
This was considered valid since the only glycosylceramide 
expected to be affected in these studies was glucocerebroside. 
The results obtained with the pure GC were very reproducible, 
with a standard error of -5%. Glucose gave two peaks 
( Ct & p isomers) adjacent to the mannitol peak (Fig. 5(iii)).
The identity of the peaks obtained by glc were 
verified by mass spectrometry. The conditions used for 
combined gas chromatography/mass spectrometry are given in 
Section 2.2.(viii)c. A reconstructed total ion current
168
Fig. 5 (iii).. Gas chromatogram of glucose present in glucocerebroside.
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chromatograph is shown in Fig. 5(iv). ^The two peaks for 
the glucose isomers were at scan numbers 33 and 36. The 
mass spectra obtained at these points are shown in 
Fig. 5(v). These compared well with published spectra for 
glucose (Golding et al., 1964).
When crude total lipid from mouse liver was purified 
on the silicic acid column alone, 90.4# (-2#) of the glycolipid 
applied was recovered. This recovery was determined by
3
mixing H-GC with the total liver lipid and estimating its 
recovery in the acetone/methanol column eluate. TLC of 
the column eluate developed on silica gel G plates 
(Section 2.2.(v)) showed the overriding presence of 
glucosyl ceramide. Successive fractionation and measurement 
of aliquots of the same total liver extract, and of total 
liver lipids from different untreated mice, gave a mean 
value of 0.078 (i.002 ) pmoles of glucose equivalents per g 
of tissue. This was considered suitably consistent and so 
this protocol was followed for all subsequent studies.
5.3. Inhibition of Tissue Glu'cocerebro.side : B-Glucosidase
Actdvity hy GDEv
(i) The' effect of' non-entrapped QBE.
The results of the preceding chapter indicated that
the liposomally entrapped QBE when administered to mice
became more extensively localised in the liver and spleen
than did free CBE. However, it was not known whether this
localised CBE was in an active form. The effect of the 
«
administered CBE on the activity of endogenous tissue 
glucocerebroside:p“glucosidase was therefore investigated.
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Mice were injected with 0.2 mg of free CBE and its 
effect on the activity of a range of lysosomal enzymes was 
investigated. Subcellular fractionation of the tissues 
was carried out according to the procedure described in 
Section 2.2.(ii). The various cellular components isolated 
were assayed for glucocerebroside:p-glucosidase, 
p-galactosidase and p-glucosaminidase activities.
Fig. 5(vi), compares the enzyme activities in CBE treated 
mice with those of untreated controls. The results 
suggested that the inhibitor was active and was specific 
for glucocerebroside:p-glucosidase, since none of the 
other enzymes were affected. Furthermore, the lysosomal 
localisation of the inhibitor was indicated by the fact 
that glucocerebroside:p-glucosidase activity in this 
fraction was preferentially inhibited.
A range of doses of free CBE were injected i.v. into 
groups of mice in order to assess relative degrees of 
enzyme inhibition and general levels of toxicity of the 
inhibitor. Endogenous liver glucocerebroside:p-glucosidase 
was estimated 4-8 h after administration. The tissues were 
removed and aqueous homogenates prepared at 4-° C according 
to the method described in Section 2.2.(iii) and enzyme 
activity assayed according to the conditions established 
in Chapter 3 for glucocerebroside:p-glucosidase (see 
Section 2.2,(vii)b).
No significant difference in the degree of inhibition 
of the enzyme was observed throughout the range of CBE 
doses used. This implied the possibility that only a
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Fig, 5(vi). Subcellular distribution of B-glucosidase, B-galactosidase 
and G-glucosaminidase in mouse liver after a single injection of CBE.
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Mice v^ ere injected with 0.2 mg CBE (i.p.) and killed 24h later.
The levels of glucocerebroside : 3-glucosidase (A), B-galactosidase (B) 
and B-glucosaminidase (C) in the separated subcellular fractions of 
liver were compared with those in normal untreated mice.
The results (mean t S.E.) are from two separate experiments in which three mice were 
used per group and the respective enzyme activities asss^ /ed in triplicate.
finite amount of the particulate enzyme was accessible 
to the inhibitor (approximately 55%)• Therefore it 
appeared that inhibition was not dosage dependent in any 
significant way. However, this was contrary to reports by 
Stephens et al. (1978), who describe a definite dose 
related effect with greater inhibition of the enzyme given 
by large doses of CBE than by small doses.
(ii) The effect of CBE entrapped within liposomes.
3
Since the tissue localisation of H-CBE was much more 
extensive with the liposome entrapped preparation than 
with the free inhibitor (see Chapter l), the degree of 
inhibition obtained with liposomally entrapped CBE 
preparations would be expected to be greater than that 
obtained with the free CBE alone. These effects were 
compared.
a. Short-term effect of a single dose of inhibitor.
A preliminary study was carried out on the effect of 
a single dose of CBE on endogenous glucocerebroside:p- 
glucosidase activity 4-8 h after administration. CBE 
containing MLV liposomes composed of PC:Chol:PA (7:7:2, 
molar ratio) and REV liposomes composed of PC:Chol (1:1, 
molar ratio) and SM:Chol (1:1, molar ratio) were prepared 
as described in Section 2.2.(i). The MLV preparation was 
injected intravenously, whilst the REV preparations were 
injected both intravenously (0.2 mg CBE in 0.2 ml 
liposomes) via the tail vein and intraperitoneally 
(0.2 mg in 0.35 ml liposomes) into adult Balb/c mice
7 5
(average weight 25 g). The effects of similar doses of 
free CBE (0.2 mg per dose), ’empty' (buffer loaded)
SMiChol REV (0.2 ml liposomes) mixed with free CBE and 
'empty' liposomes alone were also examined. The mice were 
killed J+S h after the injection and the level of liver 
glucocerebroside:p-glucosidase activity estimated.
Results are presented in Table 5(i). Although the 
entrapment and latency values obtained with the MLV 
preparations (Chapter A) were very poor, these liposomes 
appeared to transport CBE very effectively to the liver 
since the endogenous glucocerebroside:p-glucosidase 
activity was inhibited by 58%. The highest inhibition 
in both liver and spleen was obtained with CBE entrapped 
in SMrChol REVs.
This preparation has consistently been the most 
effective in terms of stability (in vivo and iui vitro) , 
latency and entrapment of the inhibitor,when compared with 
liposomes of other lipid compositions (see Chapter 1). Hence, 
the importance of these paramàers is vindicated by the fact 
that this preparation produced maximum inhibition in liver 
and spleen when administered i.v. or i.p. Somewhat 
surprisingly, no difference was observed in the level of 
inhibition obtained with tie PC:Choi REV preparation 
compared with the free CBE when both were administered i.v. 
This may be due to the poor retention of entrapped material 
within these liposomes in the presence of plasma (see 
Section 4.3.(ii)). However free CBE was considerably less
176
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effective than CBE in PC:Choi liposomes when administered 
i.p., suggesting either that the integrity of these liposomes 
was maintained better when administered by this route or 
that the uptake of free drug from the peritoneal cavity 
was inefficient.
The inhibition of enzyme activity in the spleen was 
always less than that seen in the liver. Empty liposomes 
had no effect on enzyme activity and neither were they 
found to have any effect on the level of enzyme inhibition 
produced by the CBE.
b D e t e r m i n a t i o n  of the rate of recovery of tissue
glucocerebroside:p-glucosidase activity after a single
dose of inhibitor.
A sustained inhibition of glucocerebroside:p-glucosidase 
activity is needed to allow the substrate to accumulate to 
measurable levels in the tissues of the RES as seen in 
Gaucher*s disease. It was envisaged that repeated 
injections of the inhibitor, whether entrapped in liposomes 
or in the free form, would be required to render the endogenous 
enzyme inactive for a sufficient period of time. In order 
to establish the frequency of administration of inhibitor 
that would achieve this, the rate of recovery of the 
p-glucosidase in liver and spleen after i.v. or i.p. 
administration of a single dose of free or entrapped 
inhibitor was monitored. In view of the substantially 
better results obtained with the SM:Chol liposomes in the 
short-term experiment above, these liposomes were used in 
the following studies.
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Adult Balb/c mice were injected intravenously (0.2 ml) 
or intraperitoneally (0.3 ml) with CBE (0.2 mg of unlabelled
c o
and 1.3 x 10 dpm H-CBE), either free or entrapped
(0.2-0.3 ml liposomes containing 2 mg SM) and the level of
glucocerebroside:p-glucosidase activity in liver and spleen
was determined at a range of time intervals up to a
maximum of I64 h after administration. In a typical
experiment between 3 and 6 mice per group (free or
entrapped, i.v. or i.p.) were killed at each time point,
tissues removed rapidly and processed for enzyme estimation.
The extent of tissue localisation of the inhibitor was also
established at these time points by radioactive estimation 
3
of H-CBE. Results of these studies are given in 
Figs. 5(vii) and (viii).
Intravenous administration of liposome-entrapped CBE
was accompanied by rapid localisation of the inhibitor in
both liver and spleen (Fig. 5(vii)). Although the uptake
by the liver was relatively low {9% of the dose per g
tissue) at 5 h while more than 250% of the injected dose
(per g tissue) was recovered in the spleen, the percentage
inhibition of the endogenous glucocerebroside:p-glucosidase
relative to untreated controls was similar in both tissues
(66# in liver and 60# in spleen). Whilst tissue
localisation of inhibitor as established by radioactive 
3
estimation of H was undetectable in either tissue 75 h 
after injection, the level of enzyme inhibition was 
maintained at around 60# in liver, and a fall to 40# in
Fig. 5 (vii). Levels of CBE and glucocerebroside:B-glucosidase in 
mouse tissues after intravenous injection with free and liposome- 
entrapped CBE.
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Fig. 5 (viii). Levels of CBE and B-glucosidase in mouse tissue after 
intraperitonea1 injection with free and liposome-entrapped CBE.
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the spleen. In agreement with the short-term study 
(see Section 5.3. (ii)a), inhibition in the liver was more 
effective than in the spleen since liver glucocerebroside: 
^-glucosidase activity was still decreased by over 4-0^  
while spleen enzyme activity had returned to normal 
levels after 7 days.
Although inhibition of hepatic and splenic enzyme 
activity was more effective when liposomal CBE (SM:Chol) 
was injected i.v. than i.p. in the short-term study, in the 
current experiment inhibition and subsequent recovery of 
enzyme activity in both organs after i.p. administration 
of entrapped inhibitor followed a similar pattern to that 
of the i.v. profiles (Fig. 5(viii)). The extent of hepatic 
enzyme inhibition by day 7 by i.p. route was down to 4-0^  
but this recovery of endogenous enzyme activity was somewhat 
slower than that observed with i.v. administered inhibitor. 
Again no correlation was apparent between tissue localisation 
and degree of enzyme inhibition. Although the initial 
degree of inhibition of spleen enzyme after i.p. 
administration of entrapped CBE was not as great as after
i.v. administration {iO% and 65% respectively), the former 
was maintained at a fairly constant level (4-0-50^) over a 
longer period of time than the latter, and even after 
l60 h was 15^ of normal (Fig. 5(viii)B).
Although CBE administered i.v. or i.p. in the free form 
was undetectable in either tissue by radioactive estimation, 
its effect on hepatic enzyme activity followed a similar 
pattern to that of the entrapped inhibitor albeit with a
1 8
slightly lower (approximately 10%) inhibitory effect.
Thus by day 7, hepatic glucocerebroside:p-glucosidase 
activity was 70% of the normal level (i.v. and i.p.). The 
differences in the splenic glucocerebroside:p-glucosidase 
activity after i.v. administration of free and entrapped 
CBE was rather more pronounced. Maximum inhibition with 
free CBE (after 5 h) was only 4-2% compared with 56% for the 
liposome group, and enzyme activity of the former group 
had recovered completely by 3 days, whilst the latter was 
still at 70% of normal at day 4-. The considerable 
inhibition observed with free inhibitor in spite of its 
lack of detection in the tissues by estimation of 
radioactivity can only be explained by the apparent ability 
of very small amounts of inhibitor in the liver and spleen 
to partially inhibit the endogenous enzyme for prolonged 
periods of time.
From these results it was apparent that the use of 
liposomes to administer CBE was markedly more effective 
than free CBE especially in terms of maintenance of 
inhibition. The effect on hepatic glucocerebroside: 
Ç-glucosidase was rather more pronounced than the splenic 
enzyme, but i.p. administration of liposomal CBE increased 
the level of inhibition of the latter. In terms of hepatic 
enzyme inhibition, no advantage was apparent with either 
route of administration. However, in view of the improved 
effect on spleen glucocerebroside:p-glucosidase and since 
in the mouse, repeated intravenous injections are difficult
183
to perform, the i.p. route appeared preferable for the 
subsequent studies.
(iii) Ti'S'Sue glucocerebroside : B-glucosidase activity and 
glucocerebroside levels after chronic treatment 
with- CBE ■
In an attempt to reproduce the main symptoms of human 
Gaucher*s disease (decreased glucocerebroside:p-glucosidase 
and increased tissue glucocerebroside) in the mouse, adult 
Balb/c mice were subjected to chronic treatment with free 
or liposomally entrapped (SMrChol, 1:1) CBE. Each animal 
was injected with 10 doses of 0.35 mg CBE (2.0 mg SM in 
the liposome-treated group) at 4-8 h intervals and the 
animals killed 1, 5, 10 and 14- days after the last 
injection (3 mice per time point from each group).
Homogenates of the livers and spleens were prepared and 
assayed for glucocerebroside:p-glucosidase activity as 
before. The remainder of the homogenates were used for 
the estimation of tissue glucocerebroside as described in 
Section 2.2.(vii). Results of the enzyme assay are shown 
in Fig. 5(ix).
In contrast to the recovery pattern observed after a 
single i.p. injection (Fig 5(viii)), the recovery profiles 
for the endogenous liver enzyme after chronic treatment with 
both entrapped and free CBE were virtually identical. Whilst 
initial inhibition (24- h after last injection) was 66% 
relative to normal controls, the hepatic enzyme activity 
recovered gradually so that only 35.5% inhibition was
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Fig. 5 (ix). Levels of.glucocerebrosidase;B-glucosidase in mouse 
tissue after chronic treatment with free or liposome-entrapped CBE.
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Mice v/ere injected with ten doses of free CBE ( O  ) or liposome- 
entrapped CBS ( @ ) in liposom.es composed of SMrChol (molar ratio,
1:1), The asterisk on the ordinate denotes the level of 3-glucosidase 
activity in control mice.
The results (mean t S.E.) expressed as the level of B-Glucosidase activity ifi the 
respective tissues are from a single experiment in which three mice were used per 
time point and enzyme activity assayed in triplicate.
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observed on the 10th day. By the 15th day, activity was 
about 85% (he. 15% inhibition) of the control values.
Since the extent of inhibition was similar in both 
entrapped and non-entrapped groups, it would appear that, 
with chronic treatment, liposome-entrapped CBE had no 
advantage over free CBE in terms of its ability to inhibit 
glucocerebroside:p-glucosidase.
A more pronounced difference between the free and the 
entrapped treated groups was seen when spleen 
glucocerebroside:p-glucosidase was considered. The rate 
of recovery was rather slower with the entrapped group, 
although both groups had the same level of residual 
activity initially. By day 5, the free CBE-treated group 
was back to approximately 90% of the control activity value, 
whilst the entrapped CBE-treated group still showed about 
4-5% inhibition of the splenic enzyme (Fig. 5(ix)). In 
agreement with the preliminary studies using a single 
dose of CBE (see Sections 5.3.(ii) a & b), the long-term 
administration of inhibitor was also less effective in 
the spleen than in the liver. By day 10, both entrapped 
CBE and free CBE-treated groups were back to normal levels 
of activity, ^
Despite the similarity in enzyme recovery patterns 
after treatment with free and liposomal CBE, pronounced 
differences were observed in the levels of glucocerebroside 
accumulated in the tissues of the two groups during the 
course of treatment (Fig. 5(x)). The glycosylceramide
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Fig. 5 (x). Levels of glycosylceramide .in mouse tissue after chronic 
treatment with free or liposome-entrapped CBE,
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content one day after termination of injections was over 
three-fold greater in the liver and five-fold greater in 
spleen of animals treated with liposomal CBE when compared 
to control levels. In the free CBE-treated group, hepatic 
and splenic glycosylceramide content was essentially the 
same as that measured in untreated control animals. The 
enhanced glycolipid levels of the entrapped CBE-treated 
group however, declined rapidly in both tissues to reach 
normal levels within 5 days of termination of treatment.
An interesting aspect of this study was the significant 
increase in the size of the spleens in mice treated with 
liposomal CBE (Table 5(ii) and Fig. 5( xi )). The average 
wèight of a normal mouse spleen is around 0.15 g , whereas 
the spleens of the entrapped CBE-treated group the day 
after cessation of injections,had increased 2.5 fold to a 
mean weight of 0.37 g . The recovery to normal size was 
only gradual. By day 5, a two-fold increase in spleen 
weight was still present, and this decreased to normal 
levels by day 10. There was no change in liver size 
apparent in either group and no change in the spleens of 
free CBE-treated mice.
The increase in size of the spleens did not correlate 
directly with the other parameters measured, namely enzyme 
inhibition and glucocerebroside accumulation. By day 5, 
the spleen glycolipid content was reduced dramatically 
whilst a considerable increase in size was still apparent.
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Table 5 (ii). Tissue weight after chronic treatment of mice with free,
liposomal CBE or 'empty' sphingomyelin;cho1esterol liposomes
Tissue
Days after Tissue weight (g ± S.E.)
last injection
Free CBE Liposomal CBE 'Empty'
SM: Choi:liposomes
1 1.3 1 0.08 1.6 t 0.08 2.06 t 0.11
Liver 5
10
1.3 t 0.07
1.4 1 0.03
1.4 1 0.03
1.5 t 0.06
14 1.2 + 0.13 1.4 t 0.03
1 0.14 t 0.00 0.37 i 0.01 0.44 t 0.04
Spleen
5
10
0,13 t 0.00 
0.11 t 0.00
0.29 t 0.08
0.16 t 0.01
14 0.12 t 0.00 0.14 t 0.01
Values are means 1 S.E. from 3 mice in the CBE experiment.
The SMrChol values are means t S.E. from 12 mice.
Tissues of untreated (control) mice (n=lO) weighed 1.34 g 1 0.03 (liver) 
and 0.15 g - 0.007 (spleen).
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Yxp, 5 (xi). Mouse spleen after long-term treatment v/ith free or 
liposomal CBE.
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Spleens of control untreated mice (C) compared with spleens from the 
free CBE treated (F) and liposome-entrapped CBE treated (L) mice.
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It appeared therefore that glycolipid accumulation alone 
could not account for the differences in size observed.
A control study using ’empty’ buffer loaded SMiChol 
liposomes was set up in order to investigate this 
phenomenon of splenomegaly. Mice were injected with 10 
doses of the ’empty’ liposomes (2 mg SM per dose) at 4-8 h 
intervals and tissues weighed at termination. Table 5(ii) 
shows that a similar increase in spleen size was obtained 
as seen in the previous study. Some enlargement in the 
liver size was also seen. This effect of SMiChol liposomes 
is further investigated in Chapter 6.
Since the short-term inhibitory effect of CBE 
entrapped in liposomes composed of PCtChol (1:1, molar 
ratio) and injected intraperitoneally, compared well with 
that obtained with SM:Chol (l:l) liposomes (see Table 5(i)), 
the above study of chronic administration of CBE was 
repeated using PC:Chol (l:l) liposomes. Animals were 
injected i.p. with a mean dose of 0.2 mg of CBE (free or 
entrapped), and killed 1, 4- and 8 days after the last 
injection. Tissue glucocerebroside:B-glucosidase and 
glycosylceramide levels were measured as before.
The increase in hepatic glycosylceramide was slightly 
less than that obtained with SM:Chol liposomes (2.8 fold 
over the control values). It reached a peak on day 5 
after cessation of treatment and was reasonably well 
maintained at day 8. As before there was no significant
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increase in the free treated group tissue glycolipid 
(Fig. 5(xii). Although the increase in spleen 
glycosylceramide after treatment with PCrChol liposomal 
CBE was rather more modest than when the inhibitor was 
entrapped in SMrChol liposomes, the increased levels 
were better maintained with this lipid composition. These 
results were encouraging especially in view of the fact 
that PCrChol liposomes did not have the effect of enlarging 
the tissues as observed after repeated administration of 
liposomes composed of sphingomyelin.
As seen with the first chronic study using SMrChol 
liposomal CBE, the hepatic glucocerebrosiderp-glucosidase 
recovery profiles of the PCrChol liposome-entrapped and 
free CBE-treated animals in this long-term study were also 
very similar (Fig. 5(xiii)). However it was apparent that 
the SMrChol liposomes were more effective since enzyme 
inhibition was 4-0%.. 8 days after the last injection with 
these liposomes, while inhibition was only 20% using CBE 
in PCrChol liposomes in the same period of time.
Also in agreement with the SMrChol long-term study 
was the fact that in the liposome treated (PCrChol) group, 
spleen enzyme activity recovered more slowly than in the 
free CBE-treated group, although both groups showed the 
same levels of inhibition initially (62% and 64-%). By 
day 4,while the liposome treated group still showed 
approximately 50% inhibition, the free-treated group was
1 9
Fig. 5(xii), Levels of glycosylceramide in mouse tissue after chronic 
treatment with liposome-entrapped or free CEE,
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Fig, 5(xiii). Recovery profiles of mouse tissue glucocerebroside: 
B-glucosidase after chronic treatment v/ith free or linosome-entranped 
CBE.
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The tissues of mice used in the experiment described in the legend 
to Fig, 5(xii) were assayed for hepatic (A) and splenic (E) 
glucocerebroside:B-glucosidase activity.
The results (mean 1 S.E.)are expressed as percentage of B-Glucosidase inhibition 
relative to nonrial levels and. are from one experiment in which three mice were 
u^ed per point.
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down to only 25% inhibition. The recovery profiles of the 
spleen glucocerebroside:p-glucosidase with the PC:Chol 
liposome-treated group and the SM:Chol-treated group were 
very similar. Both groups showed approximately k5% 
inhibition of enzyme after 5 days and were down to 38% 
eight days after the cessation of treatment.
5.4-. Di's c^ussion'.f
Studies on p-glucosidase from plant and bacterial 
sources by Legler (1973) showed that CBE was an active 
site specific irreversible competitive inhibitor of the 
enzyme. The fact that the inhibitor was equally active 
towards mammalian p-glucosidase suggested that all these 
enzymes share at least one common mechanism of action at 
their active sites. The specificity of CBE for p-glucosidase 
alone in spite of the fact that several mammalian 
glycohydrolases appear to be closely related,was demonstrated 
well in these studies. While p-glucosidase activity in the 
subcellular fractions of liver was substantially reduced, 
no decrease was apparent in p-galactosidase or p-glucosaminidase.
The studies on the toxicity of CBE administered in 
serial dilution doses showed no short-term side effects.
However, the absence of dose-related inhibition was surprising. 
There are two possible explanations for this apparently 
limiting degree of inhibition. The loss of enzyme might 
stimulate the synthesis of new enzyme by feed-back control, 
the extent of renewed synthesis being proportional to the
IS r y
degree of inhibition present. Thus the rate of synthesis 
of new enzyme would be slower with low doses than with high 
doses, resulting in the apparent limiting degree of 
inhibition after 4-8 h. Alternatively there may be 
incomplete access to the enzyme by the inhibitor, 
accessibility being restricted either at the extracellular 
or subcellular levels. For example the fact that 
glucocerebroside:p-glucosidase is a membrane bound enzyme 
might point to the possibility of subcellular control 
with the membrane bilayer restricting the availability of 
the active group of the enzyme for covalent bond formation 
with CBE.
The differential effect of the inhibition of 
endogenous p-glucosidase seen in liver and spleen with all 
of the preparations after a single dose of inhibitor was 
interesting. In agreement with other investigators the 
effect on the spleen of inhibitor administered free or 
entrapped,intravenously or intraperitoneally, was always 
less pronounced than that obtained with liver (Kanfer et al., 
1975b; Stephens et al., 1981). Although a possible 
explanation for this was that the liver cells were more 
effective in taking up extraneous material, this was 
refuted on the basis of the observed tissue localisation 
of administered inhibitor. While approximately 70% of 
the injected dose (entrapped) was recovered in the spleen, 
only 10% was recovered in the liver.
The reason for this lack of correlation between tissue 
localisation of inhibitor and the subsequent level of
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inhibition obtained is unclear. The enzyme present in the 
liver is possibly more susceptible to inhibition than that 
present in the spleen.. On the other hand, the spleen is 
the primary site for the assimilation of red blood cell 
breakdown products which include a high proportion of 
glycolipids. It is possible that the rate of turnover of 
the p-glucosidase is more rapid in this tissue than in 
liver, hence the rather more rapid recovery of tissue 
p-glucosidase observed in spleen. Another, explanation is 
suggested by the fact that while vesicle uptake by liver 
is believed to be mediated mainly by the Kupffer cells 
with efficient intériorisation in lysosomes, a recent 
report (van Rooyen and van Nieuwmegen, 1979) demonstrated 
that in spleen, many liposomes were adsorbed onto cells 
without significant intracellular uptake, thus possibly 
accounting for the high tissue localisation of CBE without 
correspondingly high enzyme inhibition.
This study assumes that the reappearance of activity 
was not due to reactivation of the inhibited enzyme. In 
the case of Ç-glucosidases which undergo reaction with 
CBE to form an ester with aspartic acid at the active site 
(Legler, 1966), reactivation would require either 
spontaneous or enzymatic hydrolysis of the ester linkage. 
Whilst this is unlikely, the validity of the technique 
requires independent confirmation by another method.
Using a range of lipid compositions as well as 
different types (oligolamellar and multilamellar) of
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liposomes, it was established that administering liposomally- 
entrapped CBE was always more effective than the free 
inhibitor in terms of endogenous enzyme inhibition.
Although the entrapment of CBE in multilamellar vesicles 
was poor, they were very effectively localised in the liver 
as the inhibition values show.
Liposomes composed of SMrChol (irl) combined the 
criteria of high entrapment and stability vitro, with 
efficient localisation and expression of entrapped agent 
in' viV'O'.' CBE in these liposomes was markedly more effective 
than the free inhibitor and considerably better than when 
entrapped in liposomes of other lipid compositions. This 
was demonstrated in the short-term study using a single 
dose of inhibitor and determining tissue levels of enzyme 
activity 4.8 h after administration. These preliminary 
results were borne out by the more long-term study of 
enzyme recovery after a single dose of free or entrapped 
CBE. Enzyme inhibition by the liposomal CBE was always 
more effective than the free inhibitor and in the case of 
spleen, the inhibition was maintained much more 
effectively with the entrapped CBE than with the free.
The differences between the liposomal and free CBE were 
more marked when given by the i.p. route than when given 
i.v. Since i.p. injection is much more convenient for 
the long-term administration of the inhibitor, the use of 
liposomes to deliver CBE to the appropriate organs was 
obviously an improvement over the free CBE. In view of
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the dissimilar inhibitory effects produced by a single dose 
of free or entrapped CBE, the identical patterns of 
recovery of the liver enzyme after chronic treatment with 
free and SM liposome-entrapped inhibitor were somewhat 
surprising. It was obvious however, that the inhibitor 
was most effective in the entrapped form from the 
significantly greater accumulation of glucocerebroside 
that resulted. These apparently conflicting effects might 
be explained if the time course of recovery of enzyme from 
inhibition by the two types of CBE pynestntaKon is 
examined (Fig. 5(viii)). Whilst inhibition by the 
liposomal CBE was maintained at a constant level for a 
4-8 h period (60% and 55% in liver and spleen respectively), 
during the same period of time there was a recovery of 
enzyme activity after administering non-entrapped CBE 
(inhibition falling from 55% to 45% in liver and 45% to 
30% in spleen). It seems likely that in the intervening 
time period between consecutive injections of free CBE 
enzyme activity was restored to a sufficient extent to 
prevent any significant accumulation of stored substrate, 
while the sustained inhibition produced by the liposomal 
CBE did allow glucocerebroside accumulation.
The increased level of tissue glycosylceramide caused 
by the PCiChol liposomes was rather more modest than that 
obtained with the SMiChol liposomes. However, it was 
maintained at the higher levels for considerably longer 
(up to day 8 in liver and day 5 in spleen). The very
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abrupt fall in the levels of stored glycolipid after 
cessation of treatment with SMrChol liposomes may be due 
to an increase of synthesis of new enzyme as a result of a 
positive feedback effect initiated by the high levels of 
glucocerebroside present. However, estimation of tissue 
Ç-glucosidase showed only a gradual return to normal 
enzyme activity. Interpretation of results from this study 
were complicated by the unanticipated tissue enlargement 
which appeared to be due to the liposomal lipids 
sphingomyelin and cholesterol (see Chapter 6). It 
appeared therefore, that while entrapping small molecules 
such as CBE in liposomes, greatly increased their 
localisation in the liver and spleen and successfully 
produced the criteria outlined for an effective animal 
model of Gaucher’s disease, more work needs to be done to 
find a way of sustaining the symptoms created.
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CHAPTER 6 
INVESTIGATION OF THE TOXICITY 
OF SPHINGOMYELIN:CHOLESTEROL
LIPOSOMES
2 0 1
6.1. Introduction.'
The reason for the tissue enlargement, particularly in 
spleen^produced by repeated administration of liposomes 
composed of SM:Chol, (l:l) is not known. This is the 
first report of this finding.
It is known that senescent red cells, pathological 
red cells, and red cells altered by chemical agents are 
selectively sequestered and destroyed in the spleen. A 
part of this degradative process undoubtedly involves the 
catabolism of several types of lipid present in the 
erythrocyte membrane. Sphingomyelin is one of the main 
components of the erythrocyte membranes. It was shown by 
Kampine et al. (1967) that injection of agents that 
increase the rate of breakdown of erythrocytes 
(erythrocytorhexis), including erythrocyte stroma, 
resulted in the enlargement of liver and spleen with 
concomitant increase in the specific activities of various 
hydrolytic enzymes in these tissues, the activity of spleen 
glucocerebrosidase and sphingomyelinase being particularly 
augmented. Indeed,injection of partially purified stromal 
sphingolipids consisting mainly of globoside and sphingomyelin 
caused a considerable change in the liver enzymes. In view 
of this behaviour of sphingomyelin, it was possible that 
the liposomal lipid composition (SM:Chol, 1:1)) was 
increasing the rate of erythrocytorhexis, thus resulting 
in the tissue enlargement observed.
Another possibility was the development of the 
sphingomyelin storage disorder known as Nieman-Pick disease.
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The biochemical lesion responsible for this disease is the 
lack or malfunction of sphingomyelinase, which results in 
the accumulation of sphingomyelin. Although this was an 
unlikely alternative since sphingomyelin is normally 
metabolised by the body, its repeated administration may 
result in an overload and thus in its accumulation.
Various parameters were investigated in order to 
establish the nature of the tissue enlargement brought 
about by the chronic administration of liposomes composed 
of SM:Chol, (l:l) into mice.
6,2. Measurement of Haematological Parameters.
If sphingomyelin was inducing increased erythrocytorhexis, 
then a decrease in circulating erythrocytes would be 
expected. Mice injected with ten doses of ’empty’ buffer 
loaded SMrChol liposomes (2 mg SM per dose) at 18 h 
intervals, were bled, and the samples taken for estimation 
of red and white cell content. The cells were counted in 
a Coulter cell counter.
No differences were observed in the level of white 
blood cells in the two groups (12.0 x 10^ cells per ml 
whole blood). However, there was a marginal decrease in 
the level of erythrocytes (between 10 & 15%) per ml of 
whole blood in the SM treated group (7.5 x lO^ml), than 
in the untreated controls (8.1 x 10*^ |^|* Although these 
results suggested that red cell breakdown was occurring as 
a result of the SM:Chol liposome injections, they were not 
conclusive.
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6.3. Investigation' of 'Several Biochemica'l Parameters in
Tissues aft'er Long-term Administration of SM:Chol
Li'pos'omes.'
The livers and spleens from mice from Section 6.2. . 
were used for comparison of tissue size, the levels of 
several lysosomal enzymes, general lipid distribution as well 
as glucocerebroside content.
The most pertinent observation from this study using 
’empty’ SM liposomes was the significantly enlarged spleens 
and to a lesser extent, livers obtained after this treatment 
(Table 5(ii)). It therefore appeared that the liposomal 
lipid composition was wholly responsible for the tissue 
enlargement obtained. Since a total of only 20 mg 
sphingomyelin had been injected, this could only account 
for 6.6% of the increase in spleen weight,assuming 100% 
uptake of the liposomes by this tissue and complete 
absence of catabolism of the administered lipid.
Alternatively, if the results from Section 6.2. were 
significant, it would follow that the spleen enlargement 
was due to its loading with erythrocyte membrane lipids.
Crude total lipids extracted from control and treated 
livers and spleens were compared for their respective levels 
of glucocerebroside, sphingomyelin and phosphatidyl choline 
against pure controls by TLC. Since the two I'atter lipids 
are predominant lipids in the red cell membranes, if 
erythrocytorhexis had taken place as a result of the 
repeated treatment with SM:Chol liposomes, these lipids
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would be prominent even at this level of qualitative TLC. 
However, no evidence fbr increased lipid levels was 
apparent. Quantitative estimation of glucocerebroside by 
glc confirmed this observation with respect to 
glycosylceramides as there was no change in the levels 
of tiis lipid detectable.
It was possible that repeated administration of 
SMiChol liposomes resulted in erythrocytorhexis which in 
turn led to an increase in hydrolytic lipases in the 
tissues by some form of positive feedback mechanism.
Since glucocerebroside:p-glucosidase would belong to this 
class of hydrolase, the activity of this enzyme was assayed 
in homogenates of the enlarged tissues. No significant 
change in the level of activity of this enzyme was 
detected. However, the source of the increased tissue 
size could be partially accounted for after estimation of 
total tissue protein by the method described in Section
2.2.(iv).
The total protein in these spleens had increased by 
approximately 2.1 fold when compared with normal mouse 
spleen, and in cases where liver enlargement was also 
evident, a concomitant increase in protein was apparent 
(1.5 fold). Although the final results for glucocerebroside 
^-glucosidase activity in these tissues presented as 
specific activity (nmoles min"^ mg prot"^), showed no 
significant change in the levels of this enzyme in 
comparison with that in the normal tissue, when the enzyme
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activity was presented per total tissue protein (nmoles 
min  ^ per total tissue) instead of per mg protein, the SM 
treated tissue samples showed an increase in Ç-glucosidase 
activity which corresponded with the increase seen in their 
protein levels (see Table 6(i)).
Investigation of the sub-cellular distribution of 
this increased protein as well as various lysosomal enzymes 
including glucocerebroside;p-glucosidase, was undertaken. 
Sub-cellular fractionation of mouse liver was carried out 
according to the method described in section 2.2.(ii).
The fractions obtained were the nuclear (N), mitochondrial 
and lysosomal (M & L), microsomal (ji) , and cytosolic (c). 
The parameters listed above were measured in fractions from 
SM-treated mice and control mice. Fig. 6(i), compares the 
total protein in tissue homogenate as well as in the 
various sub-cellular fractions found in the two groups of 
animals used.
It appeared that the 25% increase in total protein 
found in the SM groups compared with the controls, could be 
accounted for by an increase of similar magnitude found in 
the M & L fraction of these livers. However, this increase 
in content could not be proven to be statistically 
significant as the sample size was too small (three mice 
per group). When the glucocerebroside:p-glucosidase 
activities present in these homogenates as well as 
sub-cellular fractions were investigated, the increase 
observed in total tissue p-glucosidase activity (in 
homogenate) could not be identified by a similar increase
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Fig. 6 (i). Subcellular distribution of protein and B-glucosidase 
activity in mouse liver after chronic treatment with SM:Cholesterol 
liposomes.
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in any of the sub-cellular fractions. However, the 
decrease in p-glucosidase activity (66%) obtained after 
administration of CBE (see Sections 5.3.(i) and Fig. 5(vi)), 
was accompanied by a similar decrease in p-glucosidase 
observed in the M & L fraction (72%). Therefore, while 
this decrease in activity could be readily identified as 
lysosomal in origin, the source of the former increase was 
not so obvious. Estimation of ^-galactosidase and 
p-glucosaminidase showed no differences in these enzyme 
specific activities between any of the groups in all the 
tissue fractions,indicating that the concentration of these 
enzymes had also increased in conjunction with the 
increase in protein levels.
If one compares the tissue protein content with its 
wet weight it becomes apparent that the increase in 
protein levels are approximately proportional to the 
increased tissue weight as the ratio of wet weight to 
total of protein remains relatively unchanged before and 
after SM treatment (Table 6(ii)). Thus if the increase in 
tissue size observed after the repeated treatment with 
SMrChol liposomes may be accounted for by the increase in 
tissue protein, the reason for this increase remains 
unanswered.
6.1. Examination of the Morphology of Mouse Tissue.
Since the results obtained from the biochemical 
parameters examined in the control and sphingomyelin 
treated tissues were inconclusive, histological.
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histochemical and electron microscopic studies of these 
tissues were undertaken.
(i) Light microscopy.
a.. Liver.
The general morphology of liver cells of control and 
(SM) liposome-treated mice were compared after staining 
paraffin embedded tissue sections with haematoxylin and 
eosin (see Section 2.2. (ix,)^ ) for details of method).
Figure 6(ii) is a micrograph of the control mouse liver 
section showing the normal morphology of this tissue.
It is composed of flat anastamosing plates of hepatocytes 
between which can be seen the nuclei of the Kupffer cells 
of the sinusoids. Fig. 6(iii) shows the liver of a 
liposomally treated animal. There is an increase in the 
number of Kupffer cells, which are cells of the monocyte- 
macrophage defence system, and numerous small collections 
of inflammatory cells. Some of these are largely composed 
of polymorphonuclear leucocytes (polymorphs) but there are 
also numerous small granulomas composed of mononuclear 
cells with pink cytoplasm. These areas of granulomatous 
inflammations were also identified on Ip resin embedded 
sections stained with toluidine blue (Fig. 6(iv)).
Some hist ochemical investigations were also carried 
out to further identify the inflammatory cells seen in 
these tissues. Periodic acid Schiff/diastase (PAS/diastase) 
reactions on paraffin sections of control and liposomally 
treated animals (Fig. 6(v)a & b) show the increased
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Fig. 6 (ii). H & E stained section showing the normal morphology of.' 
mouse liver, x63
Fig. 6 (iii). H & E stained section of liposome-treated mouse liver 
showing proliferation of Kupffer cells and a diffuse infiltrate of 
inflammatory cells. x63
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Fig. 6 (v)
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&
PAS/diastase stain on control (a) and liposomal (b) liver sections 
showing Kupffer cells (arrow) in the sinusoids (S), x63
2 14
number of the Kupffer cells in the sinusoids of the latter. 
Further confirmation of the presence of increased numbers 
of cells of the monocyte/macrophage system was obtained by 
positive non-specific esterase and acid phosphatase 
reactions in cells in the sinusoids and areas of granulomatous 
inflammation (see Section 2.2.(ix), for details of methods). 
This granulomatous inflammation appeared to have been 
caused by the repeated injection of liposomes composed of 
sphingomyelin:cholesterol (molar ratio, 1:1).
b .' Spleen.
By light microscopy, the spleens from control animals 
showed the normal morphology of this tissue (Fig. 6(vi)a).
In this micrograph (H & E) rounded malpighian corpuscles 
(or white pulp areas, ¥P) composed of lymphoid tissue are 
seen surrounded by areas of red pulp. An unusual feature 
was the presence of large multinucleated giant cells 
between the malpighian corpuscles (Fig. 6(vi)b). These 
did not appear to be inflammatory giant cells but were 
thought to be megakaryocytes.
On comparing the experimental spleen sections with the 
normal controls, the most prominent feature was the 
expansion of the tissue surrounding the malpighian 
corpuscles due to the presence of a widespread granulomatous 
inflammation (Fig. 6(vii)a). There was also a marked 
increase in the number of giant cells present (Fig. 6(vii)b).
(ii) Electron microscopy (em).
Liver and spleen sections were prepared for em 
according to the method described in Section 2.2.(x).
21 s
Fig. 6 (vi).
m
ii
H & E section of control mouse spleen shovâ.ng the normal 
morphology of this tissue. Malpighian corpuscles or V/.P, 
areas are seen embedded in a vascularised matrix, red pulp (R.P.) 
x25.
b. Giant cells in control mouse spleen (G.C.). x63
SIC
Fig. 6 (vii).
a. Liposome-treated mouse spleen showing diminution in size of 
malpighian corpuscles surrounded by widespread granulomatous 
inflammation. x25
m
b. Liposome-treated spleen showing granulomatous inflammation 
with part of adjacent malpighian corpuscle. x63
%
«
c. Liposome- treated spleen shovdng increased number of giant 
cells or megakaryocytes. x63
M
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The particular blocks taken from the liver for em. did not 
contain any areas of granulomatous inflammation but some 
inflammatory cells were identified in the sinusoids 
(Fig. 6(viii)). Both within the cytoplasm of these 
infiltrating cells, within hepatocyte cytoplasm and lying 
free in the sinusoids were numerous liposome-like myelinoid 
structures (Fig. 6(ix)).
SMiChol liposomes,fixed and stained by the same 
procedure (Section 2.2.(x) for details) as used on the 
tissues,were very similar in structure to the myelinoid 
bodies seen within the liver tissue (Fig. 6(x)). While 
initially these results appeared to be positive 
confirmation of hepatic uptake of liposomes, disappointingly, 
they were rendered invalid by the observation of the 
presence of similar structures in the control sections too 
(Fig. 6(xi)). It appeared therefore, that the procedure 
applied in the preparation of these sections was 
unsuitable for use when investigating the fate of 
administered liposomes in tissue due to the normal 
presence of similar structures in the liver even in 
untreated animals.
However there was no evidence of these myelinoid 
bodies in the spleen sections examined. A prominent 
feature observed at light microscopy level in both control 
and treated spleen sections was the presence of giant 
cells. These were thought to be megakaryocytes (platelet 
precursor cells) at light level, and this was confirmed 
by their ultrastructural features. Some had prominent
218
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Fig. 6 (viii). An inflammatory cell in a sinusoid of liposome- 
treated mouse liver, x5363
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Fig. 6 (ix). Myelinoid bodies in liposome-treated liver sections
a. In a sinusoid. xl9,550
b. Within a hepatocyte. xl9,550
c. In a bile duct, xl9,550
d. In a biliary ductule. xl9,550
a. 220
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Fier, 6 (x). Electron micrograph of a liposome suspension, xl2,/05
Fig. 6 (xi). Myelinoid bodies in control liver sections
2 2 2
%
a. In a hepatocyte. xl9,550
b. Just outside a sinusoid. xl9,550
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granules and demarcation channels in their cytoplasm 
(Fig. 6(xii)). Other cells particularly in the control 
sections did not show such prominent granules but had 
such similar ultrastructural features otherwise, that they 
were also considered to be megakaryocytes, probably at a 
different stage of development. Free lying platelets were 
also identified in a section from a liposome-treated 
animal (Fig. 6(Xiii)).
The extensive granulomatous inflammations seen by 
light microscopy were also evident under em in the spleen 
tissue of liposome-treated mice. Several granulomatous 
areas containing epithelbid cells were identified 
(Fig. 6(xiv)). Numerous active macrophages were also 
observed containing phagocytosed electron dense material 
(Fig. 6(xv)a & b). While this material was most likely 
to be remnants of normal cell debris, occasional 
myelinoid structures were present within such presumed 
lysosomal bodies (Fig. 6(xvi)). Unlike the myelinoid 
artefacts seen in both control and experimental liver, 
these structures were only apparent in the treated spleens 
and not in the controls. However, such membranous structures 
are generally found in phagolysosomes and could not be 
regarded specifically as liposomes.
Therefore, despite the fact that there appeared to be 
a widespread granulomatous (macrophage) inflammation 
identified by light and electron microscopy, no definite
224
Fig. 6 (xii). A megakaryocyte or platelet precursor cell in 
liposome-treated spleen. x5363
mm
m s m* 1
Fig, 6 (xiii). Recently shed platelets in liposome-treated 
spleen. x8,250
225
I
§
Â
'"I#/ >
Fig, 6 (xiv). Epitheloid cells (or granulomas, G) with markedly 
interdigitating microvillus borders in liposome-treated spleen. 
xlO,395.
Fig. 6 (xv). a & Liposome-treated spleen macrophages 
containing electron dense debris, xl9,550.
Fig. 6 (xvi), Myelinoid body in liposome-treated spleen 
macrophage. x28,050.
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liposomes were identified by em. It is possible that the 
cells originally engulfing liposomes had become degenerate 
and have in turn been taken up by macrophages, and that the 
liposomes are catabolysed rapidly so that they are no 
longer recognisable.
6.5. Discussion.
The most salient feature observed in the treated 
tissue at light microscopic level was the presence of a 
diffuse inflammatory reaction elicited as a result of 
administration of SMrChol liposomes. No prior experience 
of toxicity with this liposomal lipid had been reported, 
and both lipids are normally metabolised efficiently by 
mammals.
Although the increased protein present in these 
tissues was not identified as an increase in activity of 
any of the hydrolytic enzymes in particular, it can be 
readily accounted for on the basis of the inflammation 
observed in these tissues. In general, an inflammation 
ensues as a result of injury to a tissue. In this case, 
the injury to the cells would be chemically mediated by 
the liposomes, although as already mentioned, the reason 
for this effect by the liposomal lipid is not known. The 
initial response to such an injury is vasodilatation which 
results in an increased permeability of capillary walls to 
plasma proteins. These plasma proteins which consist 
mainly of fibrinogen, opsonins, and complement as well as
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specific immunoglobulins, form the fluid exudate which 
reaches the inflammatory lesions in the tissue. Therefore, 
if the only effect of chronic administration of these 
liposomes was to elicit an inflammatory response, the 
increased tissue protein observed is readily accounted for 
by the plasma proteins present in the fluid exudate. The 
second phase in an acute inflammatory response is 
infiltration of the tissue by white cells, mainly 
polymorphs and this is generally followed by monocytes.
H & E sections of liver showed the presence of diffuse 
infiltrates as well as numerous small collections of these 
inflammatory cells. The monocytes mature into macrophages 
and the most obvious function of these cells and the 
polymorphs is phagocytosis.
A further source of the increased protein in these 
tissues is within these phagocytotic cells which contain a 
variety of active proteases which in polymorphs include 
acid and neutral proteases. Indeed a variety of proteins 
are known to be involved in eliciting an acute inflammatory 
response and since the inflammation was identified 
histologically, the increased protein content in the 
enlarged tissues is amply accounted for. The tissue 
response to injury follows three phases. The initial stage 
of acute inflammation manifested in the protein-rich fluid 
exudate, is followed by an intensely phagocytotic phase of 
demolition and then, the third and final stage of healing.
It follows that if the agent causing the initial inflammation
is not removed as in this study where SMrChol liposomes 
were injected repeatedly, the final stage of healing 
cannot ensue and this results in a state of chronic 
inflammation.
An inflammatory lesion of this sort has typical 
histological features which are used in their diagnosis 
and descriptive classification. Most notably, these 
include lesions which contain numerous macrophages which 
either infiltrate the tissue diffusely (a diffuse 
granulomatous reaction) or form groups or follicles and 
develop into epithelioid cells (Adams, 1976). Thus, on this 
basis, the inflammatory lesions seen in both liver and 
spleen tissue sections in this study could be classified 
as chronic inflammation, as numerous granulomas were 
identified at light level in both liver and spleen, and 
in the case of spleen, these were confirmed by em.
The precise reason for macrophage cells developing 
into epithelioid cells is not clear. It has been found 
experimentally (Walter and Israel, 1979) that macrophages 
become epithelioid cells when they have not undergone 
phagocytosis or have completely digested phagocytosed 
material. Their formation is inhibited if the phagocytosed 
material is indigestible. Generally, epithelioid cells 
are believed to develop when the influx of macrophages 
exceeds the number required to ingest a non-digestible 
substance or, when the substance is digestible and not
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very toxic to the macrophages, but is constantly available, 
so that new macrophages are involved in the process and do 
not die before they can develop epithelioid features 
(Papadimitrou and Specter, 1971). This latter hypothesis 
is likely to be the one causing the formation of the 
epithelioid cells in the spleens in this study, especially 
in view of the fact that SM was administered repeatedly 
and this lipid is normally digested in the tissues of the 
RES, and not known to be toxic.
Although no direct evidence of the injected liposomes 
was apparent, it is obvious from these studies that they 
do localise in the tissues of the RES. The spleen appears 
to be by far the more active component in this uptake of 
liposomes. The reason for the increased number of 
megakaryocytes in the mouse spleen is difficult to explain. 
Although in normal human, haemopoiesis is exclusive to the 
bone marrow, it is known that the spleen may resume 
haemopoietic activity at any time under pathological 
conditions. In mouse it appears that extramedullary 
haemopoiesis is a normal function of the spleen, which is 
considerably increased with the onset of the inflammatory 
reaction in the SMrChol treated animals. A highly 
speculative explanation may be that the injection of 
liposomes caused an intravascular coagulation syndrome 
with platelet consumption and hence the increased 
production of megakaryocytes as a compensatory process.
Several investigators have used electron microscopy 
to follow the fate of administered liposomes (Rahman and 
Wright, 1975, de Barsy et al., 1976, Segal et al., 1974) 
or liposomes added to cell cultures (Cohen et al., 1976, 
Huang and Pagano, 1975, Batzri and Korn, 1975). In view 
of the liposome-like myelinoid artefacts that were 
demonstrated in this study, results utilising the 
technique of glutaraldehyde fixation of cells and tissues 
to study liposome localisation by em should be regarded 
with some scepticism. The formation of these artefacts 
has been confirmed by Scherphof et al., (1980).
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CHAPTER 7 
GENERAL DISCUSSION
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The aim of this study was to investigate the efficacy 
of using liposomes in the development of an animal model 
of Gaucher's disease. Several aspects of the proposed 
system had to be evaluated when considering this approach. 
These included the complex interrelationship of the enzymes 
involved, the specificity of the inhibitor conduritol-B- 
epoxide, the liposome delivery system, and finally the 
overall effectiveness of the approach. The results of 
these investigations are discussed below.
Since Ho (1973) provided conclusive evidence that 
glucocerebrosidase and ’acid’ p-glucosidase activities were 
associated with a single protein, understanding the system 
of enzymes involved in Gaucher’s disease has been greatly 
facilitated. However, the existence of isoenzymes of 
p-glucosidase becomes a pertinent problem when evaluating 
the status of the disease, making reliable interpretation 
of the results difficult. Although the use of added 
factors such as sodium taurocholate enabled reliable 
differentiation between the non-specific and ’acid’ 
p-glucosidase activities of mouse liver in this study, 
the precise mechanism by which these effects are elicited 
by the detergent is not understood.
Whilst the requirement for a detergent in a hydrolysis 
where the substrate is poorly soluble is apparent (see 
Chapter 3), sodium taurocholate has been shown to play a 
more pertinent role in the case of glucocerebrosidase and
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p-glucosidase activities vitro. Ho (1973) proposed a 
mechanism of action for glucocerebrosidase and 'acid* 
p-glucosidase based on the interactions between two 
macromolecular protein factors P and C. Factor C, which 
is a tightly membrane-bound, heat labile, large molecular 
weight protein, is the catalytic component of the system.
It is inactive in the absence of factor P, which is a heat 
stable, soluble, low molecular weight glycoprotein. The 
combination of these two factors Jjq vitro reconstituted 
both glucocerebrosidase and ^-glucosidase activities. On 
the basis of their investigations. Ho et al. proposed 
that enzyme activity depended on the incorporation of 
factor P into the membrane followed by its irreversible 
association with the membrane-bound factor C to give an 
active enzyme complex. Factor P could thus be envisaged 
as eliciting a conformational change in the membrane-bound 
protein, exposing its active site which is otherwise 
hidden and rendering it catalytically active.
It was found that sodium taurocholate was able to 
activate factor C vitro in the absence of factor P, 
albeit slightly less effectively. Therefore, in addition 
to its capacity to initiate lipid/protein interaction in 
an aqueous milieu with lipid substrates (e.g^ glucocerebroside 
hydrolysis) the presence of Tc during assay of glucocere­
brosidase and p-glucosidase activities had a distinct 
stimulatory effect. However, whilst this effect was seen 
in the present study with placental glucocerebrosidase it 
was not demonstrable with the mouse liver enzymes.
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Nevertheless, the use of sodium taurocholate facilitated 
the development of an assay to distinguish between the 
p-glucosidase isoenzymes enabling reliable estimation of 
glucocerebroside:p-glucosidase activity in a crude mouse 
liver homogenate.
The apparent existence of an additional isoenzyme of 
glucocerebrosidase in mouse liver was an unexpected 
finding. Since 'true* lysosomal glucocerebrosidase 
activity was attributed to the activity at acid pH, this 
second peak of activity found predominantly in the 
particulate fraction (although some activity was present 
in the soluble fraction), could only be attributed to an 
isoenzyme not previously encountered. It was possible 
that this enzyme also hydrolysed the artificial substrate 
4MUGlc, since the jB-glucosidase activity of the separated 
particulate mouse liver fraction expressed at less 
acidic pH (5.5-6.0) responded differently with sodium 
taurocholate to the activity expressed at more acidic pH 
(4.5). Whilst it was possible that the peak at the less 
acid pH was due to contamination by incompletely removed 
soluble 'neutral* p-glucosidase, the extent of taurocholate 
induced inhibition at this pH was much greater for the 
particulate than for the soluble cytosolic enzyme. This 
differential response to detergent with pH suggested the 
possible existence of two distinct isoenzymes of 
p-glucosidase present in the membrane-bound fraction of 
mouse liver.
A general description of this new mouse liver isoenzyme 
on the basis of this preliminary work would be that it is a 
mainly membrane-bound enzyme capable of hydrolysing 
glucocerebroside at pH 7.0, which is not inhibited by QBE.
It also hydrolyses the artificial substrate (4MUGlc) at 
a weakly acid pH and this hydrolytic activity is inhibited 
by sodium taurocholate.
A recent report by Yaqoob and Carroll(1980) suggested 
the existence of two forms of membrane-bound p-glucosidase 
in human spleen, a heat labile form (form A) which was 
affected in Gaucher*s disease and a minor, heat stable 
form (form B) which was not. The residual enzyme activity 
present in Gaucher spleen was attributed to that of the 
minor heat stable fraction not involved in the disease. 
However, in contrast to the present study only one 
isoenzyme, the heat labile form, was capable of hydrolysing 
glucocerebroside. In agreement with this was the fact 
that the form not involved in Gaucher’s disease (form B) 
was inhibited by sodium taurocholate as observed in this 
study. Although the relative positions of the pH optima 
for forms A (pH 5.8) and B (pH 5.0) are the opposite to 
those obtained with mouse liver (pH 4-5 and pH 5.5-6.0 
respectively), recent work by Butterworth and Broadhead 
(1980) reported the presence of two membrane-bound 
p-glucosidases in human leukocytes, one with optimal 
activity at about pH 4.0 and the other at pH 5.0-5.5 
which appear to correlate more closely with the mouse
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hepatic isoenzymes. Carroll (l98l) reports similar pH 
optima for the two membrane-bound isoenzymes in human 
fibroblasts. However, precise agreement in the behaviour 
of any of the forms of enzyme is unlikely due to the 
considerable heterogeneity of the enzymes as discussed 
previously (Chapter 3).
The biological reason for the existence of isoenzymes 
is not always clear. This is especially so in the case of 
the lysosomal enzymes which appear to be present in 
several different forms. For instance, while the 'acid' 
p-glucosidase isoenzyme of the p-glucosidases has been 
correlated with lysosomal glucocerebrosidase activity, 
the biological function of the 'neutral' p-glucosidase has 
not been identified. Isoenzymes such as the 'acid' and 
'neutral' p-glucosidase which are physically separable 
are most likely to be products of separate genes. The 
two forms of the membrane-bound enzyme described above 
have not been successfully separated (Yaqoob and Carroll, 
198C) which suggests they are one gene product related 
possibly by non-enzymic membrane components. The existence 
of these latter isoenzymes helps to reconcile some of the 
conflicting reports in the literature regarding the assay 
characteristics of the enzyme involved in Gaucher's 
disease. The biological function of the second membrane- 
bound p-glucosidase (and glucocerebrosidase, in the case 
of mouse liver) remains obscure. It might be identical 
with the microsomal p-glucosidase involved in the
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transglycolytic activity described before (Chapter 3), 
or it may be a precursor to the prevalent ’acid' 
p-glucosidase.
In the presence of mouse plasma the pure placental 
enzyme preparation was considerably less prone to 
dénaturation than in physiological saline. Since any 
foreign protein would be subjected to deleterious attack 
by circulating proteases and since pure enzyme 
preparation is very labile, this stabilising effect of 
plasma was surprising, suggesting the possibility of a 
protective action by some plasma factor. human serum
albumin (HSA, w/v) is used to stabilise the pure placental 
enzyme preparations. However, the mechanism by which this 
protection is mediated is not understood (Furbish et al., 
1977). Ho et al. (1972) found a distinct inhibitory 
effect by HSA on o(-galactosidase and proposed that this 
was due to preferential electrostatic interaction of HSA 
with sodium taurocholate at the pH of assay, thus preventing 
the detergent from interacting with the enzyme. If this 
observation is extended to the present case it is possible 
that negatively charged HSA (or other plasma protein) 
binds with the enzyme in the absence of sodium taurocholate, 
thereby protecting it from spontaneous breakdown by 
maintaining it in a stable conformation or by rendering it 
unrecognisable to circulating hydrolases.
This protection of free enzyme in plasma was reduced 
in the presence of liposomes. Liposomes are known to
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interact with plasma high density lipoproteins resulting 
in loss of phospholipid to the latter, and their 
consequent destabilisation (Krupp et al., 1976; Scherphof 
et al., 1978). The presence of cholesterol decreases 
this loss, possibly due to tighter packing of the 
phospholipid molecules induced by the sterol (Kirby et 
al., 1980b). Not only is phospholipid transferred to 
HDL but protein is transferred from the latter to the 
liposomes. Interactions between other plasma proteins 
and liposomes also take place (Zborowski et al., 1977). 
Therefore it is conceivable that the loss of stability 
of the free enzyme in plasma in the presence of liposomes 
was due to preferential interaction of some enzyme 
stabilising factor with the liposomes instead of with the 
enzyme.
The proposed interactions between plasma proteins 
and liposomes obviously did not affect the stability of 
the REVs used in this study to any significant extent 
since the entrapped enzyme was protected from breakdown 
and maintained effectively in an active form. It appeared 
from this study that administration of liposomally- 
entrapped enzyme in enzyme replacement therapy of a 
lysosomal storage disease such as Gaucher’s disease would 
be a considerable improvement over that of free enzyme, 
since the chances of delivery of a catalytically active 
enzyme to the target organs would then be optimised.
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The feasibility of using conduritol-B-epoxide to 
create symptoms of humàn Gaucher's disease in mouse was 
vindicated in this study. CBE\-was first used as an active 
site specific, competitive inhibitor of non-mammalian 
p-glucosidases from plant and animal sources (Legler, 1966).
Its ability to inhibit mammalian glucosidases equally 
effectively (see Chapter 3 and 3), suggested a common 
mechanism of action between all these p-glucosidases. Due 
to its structural similarity to glucose (see Chapter 5)
CBE has been used extensively to gain more information on 
the mechanism of action of the ^-glucosidases (Legler,
1973). From these investigations it was established that 
the interaction of substrate with the enzyme was stereospecific 
as only the d-enantiomer of the racemic conduritol-B- 
epoxide was effective as an inhibitor.
On the basis of their experiments, Legler et al. have 
shown the presence of an acid and a carboxylate ion at 
the active site of the enzyme, and the following tentative 
mechanism proposed. The acid group protonates the 
glucosyl oxygen followed by cleavage of the bond between 
Cl and the oxygen to release the aglycoii which in the 
present study would be either 4-methylumbelliferone or 
ceramide. The remaining glucosyl ion might be stabilised 
by the carboxylate ion or it might form a covalent bond 
with this group which would ensure that the subsequent 
reaction with water proceeded stereospecifically to yield 
glucose (see Scheme 7(i)). Thus in view of its specificity
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Scheme (7 (i). Mechanism of action of B-glucosidase (from Legler, 1973).
O'O'xO
CH:;OH + HO-R
11a
CH-OH
AH
11b
+ HO-R
CH-OH
the glucosyl oxygen is protonated followed by cleavage of the 
bond between Cl of glucose and oxygen to release the aglycon 
(HO-R).
Ila the remaining glucosyl ion is stabilised by the carboxyl ion.
lib the remaining glucosyl ion is stabilised by covalent bond
formation with the carboxylate ion.
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towards ^-glucosidases and particularly to glucocerebrosidase, 
the use of CBE in attempting to develop an animal model of 
Gaucher's disease was well justified, and this was borne 
out by the selective inhibition of glucocerebrosidase and 
concomi t ant increase in liver and spleen glucocerebroside 
seen in this study.
Although in theory the validity of using QBE to 
selectively inhibit glucocerebrosidase was apparent, 
drug administration to selective areas jni vivo presents 
a plethora of problems, the most pertinent to the present 
study being the lack of target selectivity and rapid 
renal excretion of small molecules such as CBE from the 
circulation. It was apparent from this work that the use 
of liposomes greatly increased the efficacy of the 
approach by improving selective localisation and reducing 
loss of administered drug through the kidneys. This was 
true for both of the liposomal lipid compositions used 
(pCiChol and SMiChol). It was likely that the observed 
differences in effect of free and liposomally-entrapped 
CBE were determined in part by the respective modes of 
cellular uptake of the material.
Extracellular material can enter cells by passive 
diffusion, by specific transport mechanisms or by 
endocytosis. Many small molecular weight substances such 
as CBE can be taken up by passive diffusion and gain access 
directly to the cell cytoplasm. However CBE is required 
to act within the lysosomes of the cells and its
0 ^ 1
subsequent intériorisation within these organelles would 
normally be wholly dependent on random autophagic events 
which happen to include areas of CBE sequestration in the 
cytoplasm. In view of the better results obtained with 
liposomal CBE in the present study it appeared that these 
vesicles interacted efficiently with lysosomes, their 
intended targets. It is clear that effective use of 
lipid vesicles as carrier vehicles demands at least some 
appreciation of the mechanisms by which they interact 
with cells and some knowledge of the intracellular 
distribution and eventual fate of the various vesicle 
components.
It has been suggested that entire liposomes can 
enter cells by two distinct pathways, fusion and 
endocytosis (see Fig. l(iv)). In addition, exchange or 
net transfer of individual lipid molecules can take 
place between liposomes and cells (Bruckdorfer et al.,
1968a & b). The fusion mechanism involves incorporation 
of the liposomal outer membrane into the plasma membrane 
of the cell (Papahadjopoulos et al., 1971; Pagano and 
Huang, 1975) and consequent transfer of the liposome 
contents into the cell cytoplasm. In the case of a 
unilamellar liposome undergoing fusion the vesicle contents 
will be released unentrapped into the cytoplasm, but where 
the original liposome is multilamellar the contents will 
still be bounded by the internal lamellae. Fusion of 
vesicles with the plasma membrane appears to be confined
to charged vesicles composed of phospholipids which are 
fluid at 37° C (reviewed by Poste, 1980). However 
there is a lack of definite proof of the occurrence of 
liposome/plasma membrane fusion vivo and it seems 
that the phenomenon is of only minor importance in the 
context of the present studies. Evidence is now 
accumulating which suggests that a high proportion of 
liposome uptake is due to adsorption of vesicles to the 
plasma membrane. Indeed much of the evidence originally 
purporting to support the occurrence of fusion may on 
re-examination be interpreted as being due to adsorption 
of liposomes.
Endocytosis on the other hand results in the uptake 
of intact liposomes into the cell (Weissmann et al.,
1975; Batzri and Korn, 1975) and offers a pathway for 
introducing vesicles and their contents directly into 
the lysosomal apparatus by the fusion of endocytotic 
vacuoles with primary lysosomes. Endocytosis in the 
reticuloendothelial system is an extensive process 
especially in the liver, where 10^ of the total serum 
albumin and circulating proteases are internalised each 
day (Waterlow et al., 1978). Since lysosomal localisation 
of CBE was the fundamental requirement in the present 
study, endocytotic uptake of administered liposomes 
appeared ideally suited to the system.
Tissue distribution studies have demonstrated that 
macrophages belonging to the RES, in particular the
‘A «J
hepatic Kupffer cells and the spleen macrophages, are 
predominantly responsible for the uptake of intravenously 
injected liposomes from blood (Segal et al., 1974; Misse 
et al., 1976). In contrast Rahman et al. (1980) have 
presented evidence that small liposomes enter the 
hepatocytes in preference to non-parenchymal cells. Since 
the endothelial cells lining the liver sinusoids are 
interrupted by numerous open fenestrations of 100 nm in 
diameter, free access of non-particulate plasma constituents 
to the hepatocytes is allowed. Thus although large 
liposomes will be excluded from the fenestrations, SUVs 
will be able to pass through and make contact with the 
hepatocytes. However, Roerdink et al. (l98l) concluded 
that uptake of liposomes by hepatocytes was much less 
than Kupffer cell uptake, even for those vesicles small 
enough to penetrate the sinusoids. Whilst rapid inter­
cellular passage of liposome-derived lipid from Kupffer 
cells to hepatocytes was seen, no transfer of actual 
liposome contents took place.
Although liposomes appear to localise preferentially 
in the Kupffer cells regardless of their size, the use of 
large oligolamellar vesicles (REVs) in this study ensured 
their optimal interaction with these cells. The extensive 
interaction of liposomes and Kupffer cells was reflected 
in the high level of localisation of radioactive CBE and 
concurrent enzyme inhibition in the liver obtained with 
the entrapped inhibitor compared to free. Localisation
24C
of radioactive CBE in the spleen was much higher than that 
observed in the liver but this was not coupled with any 
increase in enzyme inhibition. This might be due to 
adsorption of liposomes to cells in the spleen without 
concomittant intériorisation.
Vesicle surface charge and the physical state of the 
phospholipids within the vesicle membrane are of major 
importance in determining vesicle cell interactions 
(Poste and Papahadjapoulos, 1976; Weissmann et al., 1975; 
Stendhal and Tagesson, 1977). By manipulating the liposomal 
membrane composition it should be possible to obtain a 
vesicle which shows maximal rate of endocytotic uptake by 
the RES cells. The presence of high levels of cholesterol 
used in these studies will maintain the PC liposomes in a 
solid state and the SM liposomes in an intermediate fluid 
state. Both of these conditions, together with the 
absence of charged groups, favour the occurrence of 
endocytosis.
Since REVs are a recent development in liposome 
technology, their behaviour under physiological conditions 
has not been fully evaluated. Both SUVs and MLVs of 
similar lipid composition behaved identically in terms of 
cellular uptake (Poste and Papahadjapoulos, 1976) and so 
it appeared reasonable to expect REVs of a similar lipid 
composition to behave in a similar manner. The types of 
liposomes used in the present investigations ^  vivo were
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neutral REVs containing equimolar cholesterol with 
sphingomyelin or egg phosphatidylcholine. Since these 
compositions favoured endocytosis, the agents entrapped 
within these liposomes (CBE or placental enzyme) would be 
delivered directly to their target organelle, the lysosome
In agreement with results obtained with SUVs 
(Cregoriadis and Senior, 1980) a high degree of stability 
of REVs composed of sphingomyelin and cholesterol was 
apparent in the present study. Cholesterol increases the 
stability of liposomes composed of egg phosphatidylcholine 
in the presence of plasma by preventing removal of 
liposomal phospholipid by plasma HDL. Sphingomyelin is 
known to interact even more strongly with cholesterol 
(Demel et al., 1977) and it was possible that this 
interaction prevented removal of sphingomyelin by plasma 
HDL (see Chapter 4) resulting in the improved retention 
of entrapped agent within liposomes composed of SM: 
Cholesterol (1:1).
Profiles obtained for the appearance of entrapped
3
H-CBE in the circulation after i.p. injection was 
indicative of the transport of intact vesicle-entrapped 
CBE from the peritoneal cavity into the blood. This is in 
agreement with a report by Kirby et al. (l980a) using SUVs 
Ellens et al. (1981) confirmed this observation using REVs 
and presented conclusive evidence that following i.p.
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injection, the vesicles were localised mainly in the liver 
and spleen while the unentrapped material was much less 
efficiently localised. The peritoneal cavity appears to 
act as a reservoir of vesicles for some hours, a property 
which would elicit controlled release of inhibitor to the 
circulation rather than a massive overload envisaged with 
direct delivery of liposomes after i.v. administration.
It may be that prolonged exposure of the fixed 
macrophages to the circulating liposomes would increase 
the interaction between the vesicles and these cells.
Leakage of entrapped material from liposomes is 
significantly greater in the presence of serum (Zborowski 
et al., 1977). Therefore retention of the liposomes in 
the peritoneal cavity would be expected to minimise serum- 
induced damage. Thus, after initial saturation of the 
cells of the RES, sustained entry of intact liposomes into 
the blood would optimise the enzyme inhibition required 
in the present study.
Since SM: Cholesterol liposomes satisfied all the 
fundamental parameters specified by this system including 
high levels of entrapment, stability of entrapped drug 
and specific localisation in lysosomes, the toxicity effect 
obtained with this lipid composition was disappointing.
A chronic inflammatory lesion as elicited by these liposomes 
is believed to be due to the continual exposure of affected 
tissue to the inflammatory agent, as was the case in the
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long-term study. The inflammatory response by spleen, 
which was greater than that in liver, may be explained in 
terms of the way in which these two organs metabolise the 
administered sphingomyelin.
It appears that sphingomyelin entering the liver is 
rapidly converted to phosphatidylcholine, while only 
limited metabolism of administered SM is obtained in the 
spleen (Ellens et al., 1981) in the same period of time.
This would result in the persistence of SM in the spleen 
giving rise to the inflammatory lesion observed. The 
reason for the differential behaviour by the two organs 
towards SM may be due to the low levels of splenic 
sphingomyelinase present compared to liver (Schneider and 
Kennedy, 1967) or to the metabolically very active 
hepatocytes in the liver which may contribute to the 
metabolism of lipids following primary uptake by Kupffer 
cells (Scherphof et al., 1981). However, in spite of the 
ability of the liver to metabolise sphingomyelin more 
efficiently than spleen, the amount of the lipid used in 
this study (20 mg total) was obviously toxic to both 
organs, as was evident by the inflammatory lesions 
observed in them.
In view of the toxic effects produced by sphingomyelin' 
containing liposomes, the liposome studies must be 
regarded as preliminary. Whilst the PC:Choi liposomes 
did fulfil the requirements of the proposed model, it was 
obvious by comparison with the sphingomyelin results that
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the system could still be improved. The key factor 
accounting for the advantages of the sphingomyelin 
vesicles was probably their enhanced stability in the 
presence of blood and it is quite feasible that an 
extensive survey of liposomes prepared from physiologically 
’solid’ phospholipids i.e. phospholipids with a transition 
temperature greater than 37° C, might yield a suitable 
carrier with the advantages of sphingomyelin without its 
toxicity.
In conclusion, these studies have indicated that CBE 
entrapped within liposomes can be used as a basis for the 
development of an animal model for Gaucher’s disease.
Such a model would afford the opportunity to study the 
characteristics of the disease within the affected cells 
in situ. It will thus present a much more realistic view 
of the disease than will be given by the more artificial 
conditions associated with tissue culture type model 
systems. Due to the mode of presentation of the inhibitor, 
the cells affected will be precisely the same type as those 
affected in the disease itself, and an additional 
advantage is that the stored substrate is of entirely 
endogenous origin. Accumulation of stored substrate can 
be studied in detail under various conditions to give 
greater understanding of the development of the disease, 
for example to clarify the relationship between the 
severity of the symptoms and the degree of enzyme 
deficiency. It may also be possible to use the model to
251
test and compare the efficacy of the various forms of 
therapy of Gaucher’s disease being attempted, without 
the numerical and ethical limitations associated with 
human trials.
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